Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

114
results for

"Neoplasm"

Article category

Keywords

Publication year

"Neoplasm"

Reply to Correspondence

Editorial

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence to editorial on “Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway”
    Tomoko Aoki, Naoshi Nishida, Masatoshi Kudo
    Clinical and Molecular Hepatology.2026; 32(1): e79.     CrossRef
  • Reply to correspondence on “Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway”
    Eun Ji Jang, Pil Soo Sung
    Clinical and Molecular Hepatology.2026; 32(1): e115.     CrossRef
  • Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography: A Potential Imaging Biomarker for Predicting Response to Combination Immunotherapy in Hepatocellular Carcinoma
    Masatoshi Kudo
    Liver Cancer.2025; 14(5): 511.     CrossRef
  • 2,616 View
  • 31 Download
  • Crossref

Review

Hepatic neoplasm

Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang
Clin Mol Hepatol 2025;31(Suppl):S228-S254.
Published online December 26, 2024
DOI: https://doi.org/10.3350/cmh.2024.0824
Hepatocellular carcinoma (HCC) is a major global burden, ranking as the third leading cause of cancer-related mortality. HCC due to chronic hepatitis B virus (HBV) or C virus (HCV) infection has decreased due to universal vaccination for HBV and effective antiviral therapy for both HBV and HCV, but HCC related to metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease is increasing. Biannual liver ultrasonography and serum α-fetoprotein are the primary surveillance tools for early HCC detection among high-risk patients (e.g., cirrhosis, chronic HBV). Alternative surveillance tools such as blood-based biomarker panels and abbreviated magnetic resonance imaging (MRI) are being investigated. Multiphasic computed tomography or MRI is the standard for HCC diagnosis, but histological confirmation should be considered, especially when inconclusive findings are seen on cross-sectional imaging. Staging and treatment decisions are complex and should be made in multidisciplinary settings, incorporating multiple factors including tumor burden, degree of liver dysfunction, patient performance status, available expertise, and patient preferences. Early-stage HCC is best treated with curative options such as resection, ablation, or transplantation. For intermediate-stage disease, locoregional therapies are primarily recommended although systemic therapies may be preferred for patients with large intrahepatic tumor burden. In advanced-stage disease, immune checkpoint inhibitor-based therapy is the preferred treatment regimen. In this review article, we discuss the recent global epidemiology, risk factors, and HCC care continuum encompassing surveillance, diagnosis, staging, and treatments.

Citations

Citations to this article as recorded by  Crossref logo
  • Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage: Correspondence to editorial on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”
    Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming-Lung Yu
    Clinical and Molecular Hepatology.2026; 32(1): e68.     CrossRef
  • Advancing policy and practice in alcohol-associated liver disease and alcohol-attributable cancer: Correspondence to the editorial on “Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the Unite
    Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang
    Clinical and Molecular Hepatology.2026; 32(1): e96.     CrossRef
  • Transarterial radioembolization versus atezolizumab-bevacizumab for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis
    Youngsu Park, Yuri Cho, Seung Up Kim, Aryoung Kim, Hyunjae Shin, Hyo-Cheol Kim, In Joon Lee, Gyoung Min Kim, Dongho Hyun, Yunmi Ko, Jeayeon Park, Jae Woong Yoon, Gyung Sun Lim, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan
    Diagnostic and Interventional Imaging.2026; 107(1): 25.     CrossRef
  • The diagnostic value of 18 F-FAPI-04 PET/CT in unresectable hepatocellular carcinoma: a head-to-head comparison with 18 F-FDG PET/CT
    Huanyu Gong, Yong Cheng, Qiang Li, Yingjun He, Qijun Cai, Yongjin Tang, Yulong Liu, Lu Kuang, Yingxin Li, Jingjie Shang, Chengzhi Li, Kangshou Liu, Mingrong Cao, Lu Wang, Xueying Ling, Hao Xu
    European Journal of Nuclear Medicine and Molecular Imaging.2026; 53(3): 1700.     CrossRef
  • Gender, Age, Alpha-fetoprotein, and Des-gamma-carboxyprothrombin Score as a Novel Approach to Early Detection of Hepatocellular Carcinoma: A Narrative Review
    Ludovico Abenavoli, Giuseppe G.M. Scarlata, Maria L. Gambardella, Ivo Lopez, Giuseppe Sena, Domenico Laganà, Francesco Luzza, Giuseppe Currò
    Journal of Clinical and Experimental Hepatology.2026; 16(1): 103203.     CrossRef
  • MRI-based Habitat Imaging Enhances the Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma
    Xiaogang Li, Anbin Hu
    Academic Radiology.2026; 33(1): 59.     CrossRef
  • Split biosensor based on nano-enzymatic ferrocene-tyramine deposition reaction for detection of SMP30 antibody
    Yanping Xing, Xixiang Xie, Jiangtao Liu, Tao Zhao, Xiyu Liu, Pan Wu, Faquan Lin, Yong Huang
    Analytica Chimica Acta.2026; 1382: 344834.     CrossRef
  • Ferroptosis modulation by METTL14 in cancers: From molecular insights to therapeutic strategies
    Boran Huang, Chenglin Zhu, Xinyu Zhang, Qi Zhang, Honggang Wang
    Cellular Signalling.2026; 138: 112212.     CrossRef
  • Integrated multi-Omics and network toxicology elucidate the multi-target mechanisms of environmental hormones in driving hepatocellular carcinoma
    Rong Huang, Jinyue Ma, Jiaxin Yao, Jiyu Pang, Min Zhang, Lu Wen, Liang Wang, Yanan Deng, Xiu He, Chunyan Zhao, Bo Mu
    Ecotoxicology and Environmental Safety.2026; 309: 119519.     CrossRef
  • The regulatory role of circGDI2 in hepatocellular carcinoma proliferation and glycolysis with the involvement of m6A modification
    Shiyi Chen, Hongxiang Xia, Shuwei Chen
    Non-coding RNA Research.2026; 17: 21.     CrossRef
  • CTTN overexpression on circulating tumor cells promotes hepatocellular carcinoma recurrence via enhancing the proliferation and clonality of circulating tumor cells
    Yongzhi Liu, Zhidong Fu, Lihui Jiang, Yang Chen, Feng Jiang, Chuanling Zhang, Tieming Zhu
    Cytotechnology.2026;[Epub]     CrossRef
  • Phenylalanine-Coated PLGA Nanoparticles for Targeted Delivery of Silibinin in Hepatocellular Carcinoma
    Claudia Mari, Federica Aliperta, Amadeo Sanz-Pérez, Mario Alonso, Elena González-Burgos, Juan Francisco González, Irene Lozza, Ana Fernández-Carballido, Ana Isabel Fraguas-Sánchez
    Molecular Pharmaceutics.2026; 23(1): 487.     CrossRef
  • Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study
    Jung Sun Kim, Jeffrey Wong, San‐Chi Chen, David Tai, Hannah Yang, Youngun Kim, Beodeul Kang, Ilhwan Kim, Hyeyeong Kim, Chansik An, Su Jin Jang, Masatoshi Kudo, Ho Yeong Lim, Chan Kim, Thomas Yau, Hong Jae Chon
    Liver International.2026;[Epub]     CrossRef
  • Integrative analyses of network pharmacology and bioinformatics reveal the synergistic antitumor effects of cantharidin and ginsenosides Rg3 on hepatocellular carcinoma
    Xianggang Gou, Zhongzheng Zhou, Yuehua Wang, Henye Yuan, Ziyao Wang, Jie Chen, Wei Yan, Haisheng Wang, Jia Yan
    Biochemical Pharmacology.2026; 246: 117700.     CrossRef
  • Risk stratification for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: Editorial on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic
    Ho Soo Chun, Minjong Lee
    Clinical and Molecular Hepatology.2026; 32(1): 368.     CrossRef
  • An Inflammation-Associated Prognostic Model for Hepatocellular Carcinoma Following Radical Resection
    Yanyun Zhai, Biling Gan, Renguo Guan, Ye Lin, Yanxia Lu
    Journal of Hepatocellular Carcinoma.2026; Volume 13: 1.     CrossRef
  • Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale for triplet therapy in hepatocellular carcinoma
    Hideki Iwamoto, Hironori Koga, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2026; 32(1): e38.     CrossRef
  • Landscape of Somatic and Age‐Related Pathogenic Structural Variations in Hepatocellular Carcinoma Revealed by Long‐Read Sequencing
    Zhewen Wei, Yinghao Cao, Hongchao Liu, Mei Liu, Bolun Zhang, Jianming Ying, Jianqiang Cai, Xinyu Bi, Jianjun Zhao, Jianguo Zhou, Zhiyu Li, Zhen Huang, Jianmei Liu, Xueyan Lv, Zhiwen Luo, Zhicheng Wei, Xiaoshi Zhang, Yi Yang, Yiqiao Deng, Yanjiang Yin, Jin
    MedComm.2026;[Epub]     CrossRef
  • Gastrointestinal cancer statistics in 2022 and projection to 2050: GLOBOCAN estimates across 185 countries
    Pojsakorn Danpanichkul, Yanfang Pang, Primrose Tothanarungroj, Disatorn Dejvajara, Donghee Kim, Preenapun Saokhieo, Kanokphong Suparan, Mark D. Muthiah, Kwanjit Duangsonk, Diego Olavarria Bernal, Rashid N. Lui, Karn Wijarnpreecha, Ghassan K. Abou‐Alfa, Mi
    Cancer.2026;[Epub]     CrossRef
  • Integrating CyTOF with scRNA-seq reveals that Cyclovirobuxine D inhibits HCC progression through hepatic immune microenvironment remodeling
    Fuqiang Ma, Lele Zhang, Yitao Fan, Ziyi Xu, Yuhua He, Jiachun Sun, Juan Lu, Xinyu Gu
    Phytomedicine.2026; 150: 157751.     CrossRef
  • A Biomimetic Manganese Complex Synergistically Disables Antioxidant Defenses and Amplifies Oxidative Stress to Potentiate Ferroptosis in Hepatocellular Carcinoma
    Pengchen Ren, Yan Huang, Linhong Zhong, Ranran Luo, Chenxi Zhang, Zening Zhang, Rui Tang, Zhongsheng Xu, Yun Liu
    Advanced Healthcare Materials.2026;[Epub]     CrossRef
  • Effectiveness of Machine Learning in Detecting Vessels Encapsulating Tumor Clusters in Hepatocellular Carcinoma: Systematic Review and Meta-Analysis
    Huili Shui, Wenyu Wu, Zhenming Xie, Bing Yang, Jia Deng, Dongxin Tang
    Journal of Medical Internet Research.2026; 28: e82839.     CrossRef
  • Emerging DNA- and RNA-based therapeutic strategies in hepatocellular carcinoma: A molecular approach to precision medicine
    Zulfa Nooreen, Ankita Wal, Anjali Shukla, A. Venkata Badarinath, Nishant Kumar, Tanmay Sarma, Abida Khan, Amin Gasmi
    Letters in Drug Design & Discovery.2026; : 100268.     CrossRef
  • Stemness CD24 activation promotes hepatocellular carcinoma progression via an immune escape mechanism
    Yin Cai, Lu-Yin Liu, Xiao-Xiao Xia, Hao Tang, Min Xu, Wen-Li Sai, Deng-Fu Yao, Min Yao
    World Journal of Gastroenterology.2026;[Epub]     CrossRef
  • Identification of novel circulating protein biomarkers for hepatocellular carcinoma superior to alpha-fetoprotein through a stemness index and secretome analysis
    Cai Gao, Xuebing Li, Xinwei Liu, Sha Yan, Xiaodan Ran, Jingxian Han
    World Journal of Surgical Oncology.2026;[Epub]     CrossRef
  • NOP56 interacts with Fibrarin to regulate the PI3K/AKT signaling pathway and inhibit apoptosis of hepatocellular carcinoma
    Hongwei Chen, Xinggang Fan, Di Cui
    Frontiers in Oncology.2026;[Epub]     CrossRef
  • Unmet needs in hepatology: The guidance of the Italian association for the study of the liver (AISF)
    Stefano Gitto, Filippo Gabrielli, Giovanni Addolorato, Claudia Tarli, Giacomo Zaccherini, Rosaria Calia, Giacomo Germani, Patrizia Burra, Alberto Zanetto, Francesca Ferri, Roberta D’Ambrosio, Pierluigi Toniutto, Nicola Pugliese, Fiammetta Cosci, Giuseppe
    Digestive and Liver Disease.2026; 58(2): 182.     CrossRef
  • Integrative multiomics dissection of LSM7 as a prognostic biomarker and therapeutic target in hepatocellular carcinoma
    Shanshan Fan, Yifeng He, Peifeng Ke, Jianhong Jiang, Shengming Zhang, Deqin Zeng, Juan Duan, Ming Wu
    Science Progress.2026;[Epub]     CrossRef
  • AEG-1/MTDH Enhances Hepatocellular Carcinoma Radioresistance by Recruiting PTBP1 Via SND1 To Stabilize ATG5 mRNA and Promote Protective Autophagy
    Xiaochun Chen, Yu Wang, Qishuai Guo, Xing Lin, Zhiping Yuan, Wei Liu, Chuan Lin, Yongjun Li, Yongpeng He
    Cell Biochemistry and Biophysics.2026;[Epub]     CrossRef
  • A prognostic signature of ferroptosis and lipid metabolism related genes predicts survival and immunotherapy response in hepatocellular carcinoma
    Hu Chen, Yan Kong, Qian Dong
    Discover Oncology.2026;[Epub]     CrossRef
  • Emerging importance of ALDH2 in liver diseases and its potential therapeutic role
    Sheng Wang, Shiqiang Xu, Guoqing Xia, Xinren Wang, Xiongwen Lv
    Biochemical Pharmacology.2026; 246: 117732.     CrossRef
  • Regulation of Keratin Chemical Modifications: Potential Molecular Mechanisms in Proliferative Diseases
    Xuemei Ma, Xiaoli Jiang, Mengxue Song, Bingbing Bai, Xia Hou, Qingtian Wu
    International Journal of Molecular Sciences.2026; 27(2): 972.     CrossRef
  • Non-Transplantable Recurrence After Initial Liver Resection of Hepatocellular Carcinoma: A Narrative Review
    Dima Malkawi, Ioannis A. Ziogas, Ana L. Gleisner, Richard D. Schulick, Dimitrios P. Moris
    Cancers.2026; 18(2): 317.     CrossRef
  • Postoperative adjuvant TACE combined with lenvatinib and immune checkpoint inhibitors for hepatocellular carcinoma with high recurrence risks: a multicenter retrospective study
    Ziyue Huang, Taifeng Zhu, Xiaokun Chen, Mingjian Piao, Yang Tan, Chengjie Li, Kai Liu, Shanshan Wang, Lei Zhang, Shunda Du, Chengpei Zhu, Kang Zhou, Xiaobo Yang, Daobing Zeng, Haitao Zhao
    BMC Cancer.2026;[Epub]     CrossRef
  • SLC25A39 binds and modulates PRDX1 to suppress ROS-induced necroptosis in hepatocellular carcinoma
    Wenxuan Liu, Tianrui Kuang, Keshuai Dong, Man Li, Wenhong Deng, Jia Yu
    International Immunopharmacology.2026; 172: 116246.     CrossRef
  • RNA splicing dysregulation in hepatocellular carcinoma: Molecular mechanisms, therapeutic targets, and intervention strategies—A comprehensive review
    Shuai Xiong, Lei Hu, Yun-Yang Sun, Wei Huang, Xiao-Yu Hu
    Biomedicine & Pharmacotherapy.2026; 195: 119025.     CrossRef
  • Assessing predictive value of contrast-enhanced ultrasound combined with doppler ultrasound for post-transcatheter arterial chemoembolization prognosis in hepatocellular carcinoma
    Jia-Jiao Qian, Min Xu, Yan-Song Ji
    World Journal of Gastrointestinal Surgery.2026;[Epub]     CrossRef
  • Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: real-world data and 9-year extended follow-up of a randomized controlled trial
    Hyunjae Shin, Youngsu Park, Byeong Geun Song, Won-Mook Choi, Hyung Joon Han, Youngwoo Lee, Tae-Jin Song, Jong-Eun Yeon, Young-Suk Lim, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Joon Hyeok Lee, Jung-Hwan Yoon, Jeong-Hoon Lee
    Cancer Immunology, Immunotherapy.2026;[Epub]     CrossRef
  • First-line systemic therapy for hepatocellular carcinoma: new options
    Rashida V. Orlova, Natalia V. Popova, Svetlana I. Kutukova, Viacheslav A. Chubenko, Rima S. Agbalyan, Michael V. Pugin
    Clinical Case in Oncology.2026; 3(3): 15.     CrossRef
  • Chronic inflammation and immune response in hepatocellular carcinoma: a comprehensive literature review
    Manaf Alsudaney, Mohammed N. Abdulhaleem, Abdelrahman M. Attia, Jessica Liu, Hasmik Adetyan, Osama Khattab, Andrew Hendifar, Alexander Kuo
    Journal of Cancer Metastasis and Treatment.2026;[Epub]     CrossRef
  • Preclinical Evaluation of Rationally Designed Peptide-NIRF Probe for c-Met Positive Liver Cancer Imaging-Guided Surgery
    Xiaohui Wang, Yongjia Tang, Mengmeng Xiao, Jia Huang, Yaxue Dai, Wenjing Huang, Zhihao Han, Yueqing Gu
    Analytical Chemistry.2026; 98(5): 4179.     CrossRef
  • Research Progress on the Biological Function, Disease-Driving Mechanism and Clinical Targeting Strategies of G3BP2
    Yao Chen, Qi Deng, Li-Ling Yang, Ai-Ling Jiang, Rong Zhang, Qi-Bing Yan, Yong-Kang Wu
    Molecules.2026; 31(4): 622.     CrossRef
  • Quality of Gadoxetate-enhanced MRI versus US during Hepatocellular Carcinoma Screening in Participants with Cirrhosis
    Sara Lewis, Benjamin Wildman-Tobriner, Jordan Cuevas, Sergio Calle, Ian Bolger, Katherine Wang, Himanshu Joshi, Lori Mankowski Gettle, Ju Dong Yang, Ji Hye Min, Claude B. Sirlin, Scott B. Reeder, Mustafa R. Bashir, Bachir Taouli
    Radiology.2026;[Epub]     CrossRef
  • KLF1 Exerts Pro‐Tumour Role in Liver Cancer via Inhibiting ACSL4/LPCAT3‐Regulated Ferroptosis
    Zhihui Chen, Changyan Zhang, Jialin Yang, Yong Peng
    Journal of Cellular and Molecular Medicine.2026;[Epub]     CrossRef
  • Endoplasmic reticulum stress-related CLIP4 plays a procarcinogenic role in hepatocellular carcinoma: an integrated analysis
    Anqi Wang, Sitong Yan, Weijia Jiang, Xiang Chen, Yuhan Huang, Xiangyu Zu, Xiao Du, Lulu Fan, Jiatao Liu, Guoping Sun
    BMC Cancer.2025;[Epub]     CrossRef
  • Progress in the Application of Novel Nanomaterials in Targeted Therapy for Liver Cancer
    Xin Wei, Weihua Cao, Shiyu Wang, Yaqin Zhang, Zixuan Gao, Shuojie Wang, Linmei Yao, Ziyu Zhang, Xinxin Li, Wen Deng, Yao Xie, Minghui Li
    International Journal of Nanomedicine.2025; Volume 20: 2623.     CrossRef
  • Rising Incidence of Early-Onset Liver Cancer and Intrahepatic Bile Duct Cancer: Analysis of the National Childhood Cancer Registry Database
    Pojsakorn Danpanichkul, Yanfang Pang, Thanida Auttapracha, Omar Al Ta’ani, Thanathip Suenghataiphorn, Apichat Kaewdech, Mark D. Muthiah, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang
    Cancers.2025; 17(7): 1133.     CrossRef
  • Role of SMYD2 in gastrointestinal cancer progression (Review)
    Kun Xia, Yaoxiang Zhou, Youping Xie, Yinzhong Cai
    Oncology Letters.2025; 29(6): 1.     CrossRef
  • Longitudinal study of factors associated with the anti-cancer efficacy and liver function in HCC patients treated with TACE in combination with percutaneous ablation
    Huhu Ren, Jian Chen, Zhiqun Wu, Chen Li
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • A Review of Risk Prediction Model for Hepatocellular Carcinoma in Chronic Hepatitis B
    Jiwon Yang, Mark D. Muthiah, Won-Mook Choi
    Current Hepatology Reports.2025;[Epub]     CrossRef
  • LPAR6 Inhibits the Progression of Hepatocellular Carcinoma (HCC) by Suppressing the Nuclear Translocation of YAP/TAZ
    Gegentuya Bao, Manjue Zhai, Yali Yan, Yuewu Wang, Alatangaole Damirin
    International Journal of Molecular Sciences.2025; 26(9): 4205.     CrossRef
  • PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma
    Jitong Zhou, Meng Gao, Shikun Zhang, Wing‐Wa Guo, Wenzhi He, Minghe Zhang, Xi Chen, Cairang Dongzhi, Xiaomian Li, Yufeng Yuan, Weijie Ma
    Advanced Science.2025;[Epub]     CrossRef
  • Pathogenesis and Treatment of Hepatocellular Carcinoma Associated with Nonalcoholic Steatohepatitis
    舒惟 梁
    Advances in Clinical Medicine.2025; 15(05): 2063.     CrossRef
  • Engineered E. coli OMVs Carrying the Membrane-Binding hGC33 Fragment Precisely Target Liver Cancer and Effectively Treat Tumor
    Yufei Deng, Bangya Yang, Zelan Yang, Hanyu Xiao, Yan Zou, Cheng Zou, Song Yang, Xi Sun, Yiting Wang, Jin Bai, Liaoqiong Fang, Zhibiao Wang
    International Journal of Nanomedicine.2025; Volume 20: 6573.     CrossRef
  • Peripheral blood inflammatory score using a cytokine multiplex assay predicts clinical outcomes in patients treated with atezolizumab-bevacizumab for unresectable HCC
    Hee Sun Cho, Soon Kyu Lee, Ji Won Han, Jung Hyun Kwon, Soon Woo Nam, Jaejun Lee, Keungmo Yang, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Jong Young Choi
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Adding salt to foods and risk of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases
    Shunming Zhang, Zhenyu Huo, Yan Borné, Emily Sonestedt, Lu Qi
    European Journal of Nutrition.2025;[Epub]     CrossRef
  • Targeting super-enhancers in liver cancer: from pathogenic mechanisms to clinical applications
    Chang-Lei Li, Zhi-Yuan Yao, Ao Sun, Jing-Yu Cao, Zu-Sen Wang
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Molecular mechanisms underlying Fagopyrum dibotrys-derived nanovesicles induced ferroptosis in hepatocellular carcinoma: a dual-pathway analysis of lipid peroxidation and mitochondrial damage
    Ling Wu, Hongyao Chen, Jingting Zhang, Jincheng Tang, Zhibin Wang, Peisen Xue, Wenhui Gao, Renyi Yang, Puhua Zeng
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • An Artificial Intelligence Pipeline for Hepatocellular Carcinoma: From Data to Treatment Recommendations
    Xuebing Zhang, Liuxin Yang, Chengxiang Liu, Xingxing Yuan, Yali Zhang
    International Journal of General Medicine.2025; Volume 18: 3581.     CrossRef
  • Enhancing ultrasonographic detection of hepatocellular carcinoma with artificial intelligence: current applications, challenges and future directions
    Janthakan Wongsuwan, Teeravut Tubtawee, Sitang Nirattisaikul, Pojsakorn Danpanichkul, Wisit Cheungpasitporn, Sitthichok Chaichulee, Apichat Kaewdech
    BMJ Open Gastroenterology.2025; 12(1): e001832.     CrossRef
  • Exploring the impact of sleep duration and sleep disorders on metabolic dysfunction-associated steatotic liver disease in older adults
    Fan Zhang, Yuan Xue, Wenjian Li
    BMC Geriatrics.2025;[Epub]     CrossRef
  • Integrating machine learning and molecular docking to decipher the molecular network of aflatoxin B1-induced hepatocellular carcinoma
    Junjie Gao, Meijun Zhang, Qun Chen, Kai Ye, Jing Wu, Tao Wang, Puhong Zhang, Gang Feng
    International Journal of Surgery.2025; 111(7): 4539.     CrossRef
  • Managing hepatocellular carcinoma recurrence after liver transplantation: emerging role of immune checkpoint inhibitors
    Mohammad Saeid Rezaee-Zavareh, Soo Young Hwang, Naomy Kim, Hasmik Adetyan, Nguyen H. Tran, Ju Dong Yang
    Discover Oncology.2025;[Epub]     CrossRef
  • Addressing Africa's marginalisation in hepatocellular carcinoma clinical trials
    Mohamed El-Kassas, Hend Shousha, Lewis R Roberts
    The Lancet Gastroenterology & Hepatology.2025; 10(11): 966.     CrossRef
  • Response Assessment in Hepatocellular Carcinoma: A Primer for Radiologists
    Nayla Mroueh, Jinjin Cao, Shravya Srinivas Rao, Soumyadeep Ghosh, Ok Kyu Song, Sasiprang Kongboonvijit, Anuradha Shenoy-Bhangle, Avinash Kambadakone
    Journal of Computer Assisted Tomography.2025;[Epub]     CrossRef
  • Targeting tumor-associated macrophages to overcome immune checkpoint inhibitor resistance in hepatocellular carcinoma
    Fen Liu, Xianying Li, Yiming Zhang, Shan Ge, Zhan Shi, Qingbin Liu, Shulong Jiang
    Journal of Experimental & Clinical Cancer Research.2025;[Epub]     CrossRef
  • Hepatocellular carcinoma of non-viral etiology: From theory to real practice
    V. V. Petkau, N. E. Krasilnikova, E. N. Bessonova, A. A. Tarkhanov
    Meditsinskiy sovet = Medical Council.2025; (10): 66.     CrossRef
  • The transcription factor HOXB7 significantly enhances the expression of PIGT through the Wnt/β-catenin signaling pathway, thereby promoting the proliferation and deterioration of HCC
    Jiaxin Huang, Jiaqi Tan, Nanfeng Meng, Junrong Wang, Peng Han, Hang Wang
    Expert Review of Anticancer Therapy.2025; 25(11): 1299.     CrossRef
  • A Clinical-Imaging Nomogram for Predicting Early Recurrence in Patients with Solitary Hepatocellular Carcinoma After Postoperative Adjuvant TACE
    Jiachen Liu, Xiurong Ding, Yanyan Zhang, Hongjun Li
    Journal of Hepatocellular Carcinoma.2025; Volume 12: 1835.     CrossRef
  • Augmenting conventional criteria: a CT-based deep learning radiomics nomogram for early recurrence risk stratification in hepatocellular carcinoma after liver transplantation
    Ziqian Wu, Danyang Liu, Siyu Ouyang, Jingyi Hu, Jie Ding, Qiu Guo, Jidong Gao, Jiawen Luo, Ke Ren
    Insights into Imaging.2025;[Epub]     CrossRef
  • Exploration of the Mechanism of Action of Dendrobium officinale in the Treatment of Liver Cancer Based on Network Pharmacology, Molecular Docking and in vitro Validation
    Shuimeng Zhan, Xinyan Lu, Hongyan Guo, Yang Liu, Zhi Li, Wei Xu, Fang Xia, Huanjun Tang, Yi Tian, Jing Chen, Xuan Lin
    Journal of Hepatocellular Carcinoma.2025; Volume 12: 1973.     CrossRef
  • Direct-acting Antivirals Therapy for Hepatocellular Carcinoma in Hepatitis C Patients
    Seul Ki Han, Soon Koo Baik, Moon Young Kim
    Journal of Digestive Cancer Research.2025; 13(2): 150.     CrossRef
  • Glypican-3: Novel Theranostic Agent for Hepatocellular Carcinoma
    Luca Filippi
    Seminars in Nuclear Medicine.2025; 55(6): 928.     CrossRef
  • Dihydroartemisinin inhibits histone lactylation through YAP1 to act as a ‘hot’ switch for ‘cold’ tumor in hepatocellular carcinoma
    Yuting Gao, Yi Gong, Xiaoyong Song, Yajun Xiong, Junlan Lu, Yanguang Yang, Yanli Gong, Zhimin Du, Shanshan Wang, Ruilong Jia, Peng Gong, Xinli Shi
    Phytomedicine.2025; 148: 157307.     CrossRef
  • ANTIFIBROTIC STRATEGY IN THE TREATMENT OF CHRONIC LIVER DISEASES
    Mariana M. Seliuk, Anatolii M. Pechinka
    Ukrainian educational and scientific medical space.2025; (1): 28.     CrossRef
  • Selective Angiographic Roadmap Analysis (SARA) of Hepatocellular Carcinoma Feeding Arteries for Transarterial Chemoembolization
    Sultan R. Alharbi
    Diagnostics.2025; 15(19): 2533.     CrossRef
  • Binding and ubiquitination-mediated degradation of ACKR3 by the novel Scutellarein derivative TBS6b potently suppresses hepatocellular carcinoma
    Xing Jiang, Ying Liang, Guotao Tang, Haiyan Quan, Lijun Ruan, Mengli Zhang, Zhijun Song, Min Ou, Zhien Tan, Na Lu, Fangfang Wu, Xiaonan Yang
    Bioorganic Chemistry.2025; 166: 109073.     CrossRef
  • Role of ALBI Grade as a Predictive Factor for Long‐Term Mortality in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
    Kyoung A Ko, Hyunwoo Oh, Myung Sub Kim, Hyun Pyo Hong, Yong Kyun Cho, Byung Ik Kim, Won Sohn
    Journal of Gastroenterology and Hepatology.2025; 40(11): 2758.     CrossRef
  • Innovative Approaches to Hepatocellular Carcinoma: Diagnostic Breakthroughs, Biomarker Integration, and Artificial Intelligence
    Evangelos Koustas, Eleni-Myrto Trifylli, Panagiotis Sarantis, Michalis V. Karamouzis
    Biomedicines.2025; 13(10): 2439.     CrossRef
  • Subset of Child-Pugh Score 7 Shows Comparable Survival Outcomes to Child-Pugh Score 6 in Patients with Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab
    Jaejun Lee, Keungmo Yang, Ji Won Han, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Hee Sun Cho, Hyun Yang, Si Hyun Bae, Ji Hoon Kim, Heechul Nam, Chang Wook Kim, Hae Lim Lee, Hee Yeon Kim, Sung Won Lee, Ahlim Lee, Do Seon Song, Myeong Jun Song, Soon Woo
    Clinical Cancer Research.2025; 31(20): 4323.     CrossRef
  • Plasma exosomal lncRNA-related signatures define molecular subtypes and predict survival and treatment response in hepatocellular carcinoma
    Fangmin Zhong, Fangyi Yao, Xin-Lu Wang, Zihao Wang, Bo Huang, Jing Liu, Xiaozhong Wang, Lei Zhang
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Hepatocellular carcinoma: modern aspects of interdisciplinary management. Part 1. Epidemiology, risk factors, diagnosis
    Yu.M. Stepanov, N.Yu. Zavhorodnia, O.M. Vlasova
    GASTROENTEROLOGY.2025; 59(3): 206.     CrossRef
  • Repurposing HIV-Protease Inhibitor Precursors as Anticancer Agents: The Synthetic Molecule RDD-142 Delays Cell Cycle Progression and Induces Autophagy in HepG2 Cells with Enhanced Efficacy via Liposomal Formulation
    Fabiana Crispo, Antonio Vassallo, Immacolata Faraone, Alessandro Santarsiere, Lucia Chiummiento, Mara Martinelli, Nicoletta Cascelli, Xavier Fernàndez-Busquets, Rocchina Miglionico, Ilaria Nigro, Carla Caddeo, Maria Francesca Armentano
    International Journal of Molecular Sciences.2025; 26(21): 10305.     CrossRef
  • The multidimensional role of SLC16A4 in hepatocellular carcinoma in silico analysis: prognostic significance, metabolic pathways, and immune microenvironment regulation
    Lili Jiang, Yi Shen, Zhengyang Feng, Yong Wang, Yaqun Zhu, Yuntian Shen, Qiliang Peng
    European Journal of Medical Research.2025;[Epub]     CrossRef
  • The potential of soluble programmed cell death-ligand 1 and soluble programmed cell death 1 as diagnostic and prognostic biomarkers for hepatocellular carcinoma: a meta-analysis
    Jie Li, Xiangyang He, Tingting Gao, Qingjun Zhang, Xu Han
    Irish Journal of Medical Science (1971 -).2025; 194(6): 2037.     CrossRef
  • Multi-omics analysis reveals the role of tumor-infiltrating CD4+CCR7+ T cells in EGFR antibody resistance and prognosis of hepatocellular carcinoma
    Zizhong Yang, Lupeng Qiu, Guhe Jia, Zhuoya Sun, Yixin Gong, Yin Chen, Yu Wang, Lai Song, Xiao Zhao, Shunchang Jiao
    BMC Cancer.2025;[Epub]     CrossRef
  • Identification and validation of icaritin-associated prognostic genes in hepatocellular carcinoma through network pharmacology, bioinformatics analysis, and cellular experiments
    Yaru Shi, Yanan Bai, Jianglan Wu, Yunfeng Yu, Xinyu Yang, Haobo Yang, Weixiong Jian, Jun Qing
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Enhancing cancer risk awareness and screening management through artificial intelligence: a narrative review
    Jiaxuan Wu, Xiaolong Tang, Qian Zheng, Xinhang Gu, Li Ma, Jinghong Xian, Hui Mao, Jiadi Gan, Guiyi Ji
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • miR-122-5p Regulates Ferroptosis through Targeting the Glutamine Transporter SLC1A5 in Hepatocellular Carcinoma
    Mingxuan Lei, Jiayin Xu, Xiaoying Hu, Lin Feng, Baoping Luo
    BIOCELL.2025; 0: 1.     CrossRef
  • Targeting endoplasmic reticulum stress-induced CLGN resensitizes hepatocellular carcinoma to apoptosis: paeonol synergistically enhances efficacy by dual inhibition of CLGN and NF-κB
    Sitong Yan, Anqi Wang, Xiang Chen, Weijia Jiang, Xiao Du, Yuhan Huang, Xiangyu Zu, Yue Zhu, Jiatao Liu, Lulu Fan, Lingling Zhang, Guoping Sun
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Lactylation in Cancer: Unlocking the Key to Drug Resistance and Therapeutic Breakthroughs
    Xiangnan Feng, Dayong Li, Pingyu Wang, Xinyu Li, Guangyao Li
    Oncology Research.2025; 33(11): 3327.     CrossRef
  • Organokine-Mediated Crosstalk: A Systems Biology Perspective on the Pathogenesis of MASLD—A Narrative Review
    Sandra Maria Barbalho, Lucas Fornari Laurindo, Vitor Engracia Valenti, Nahum Méndez-Sánchez, Mariana M. Ramírez-Mejía, Ricardo de Alvares Goulart
    International Journal of Molecular Sciences.2025; 26(23): 11547.     CrossRef
  • Systematic analysis of the expression profiles and prognostic values of the FAM72 family in liver cancer
    Weihao Kong, Long Teng, Kangjie Zhang, Yajun Zou, Xingyu Wang, Jianlin Zhang
    Biochemistry and Biophysics Reports.2025; 44: 102358.     CrossRef
  • Bioinformatics Analysis Reveals the Role of DLGAP4 in the Development and Progression of Hepatocellular Carcinoma
    Feng Yang, Shoufeng Chang, Ruxia Li, Jing Wei, Hua Zhang, Qiqi Wang, Zhenjun Li, Yamei Dang
    Journal of Gastrointestinal Cancer.2025;[Epub]     CrossRef
  • Early screening for liver cancer must be performed
    Zi-Han Liu, Wen-Jun Wang, Shuang-Suo Dang
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • –A novel peptide SMIM45-107aa promotes HCC progression via MTDH pathways and its anticancer peptide derivative
    Yan An, Xiangyang Shi, Wentao Huang, Mingyi Shang, Guang-Zhi Jin
    Journal of Translational Medicine.2025;[Epub]     CrossRef
  • Liver Transplantation for Hepatocellular Carcinoma: A Comprehensive Review
    Seok-Hwan Kim
    Convergence Hepatology.2025; 1(1): 24.     CrossRef
  • Clinical significance of citrullinated glial fibrillary acidic protein in predicting outcomes in hepatocellular carcinoma
    Yoon Ah Cho, Dong Woo Shin, Mo-Jong Kim, Ji-Won Park, Ji-Young Choe, Jung-Woo Lee, Sung-Hoon Moon, Akihito Ishigami, Eun Kyoung Choi, Sung-Eun Kim
    World Journal of Gastrointestinal Oncology.2025;[Epub]     CrossRef
  • Intra-tumoral microbiota: Key modulators of tumor immunity and therapeutic potential
    Junju He, Hui Tan, Yanru Qiu, Yuchao Dan, Qian Wan, Lan Li, Jie Wu, Qibin Song, Hongbin Chen, Bin Xu
    Genes & Diseases.2025; : 101963.     CrossRef
  • Prognostic nutritional index and the survival of patients with hepatocellular carcinoma on immune checkpoint inhibitors: a meta-analysis
    Jia Fu, Wei Peng, Jinqiong Jiang, Tan Deng, Huaxin Duan, Kanghan Liu
    BMC Cancer.2025;[Epub]     CrossRef
  • Comparative Evaluation of Proprietary and Open-Source Large Language Models for Systematic Multi-source Information Extraction in Interventional Oncology
    Elif Can, Wibke Uller, Elmar Kotter, Katharina Vogt, Michael Doppler, Michael Brönnimann, Raid Alshinibr, Aboelyazid Elkilany, Felix Busch, Avan Kader, Sebastian Gassenmaier, Saif Afat, Marcus R. Makowski, Keno K. Bressem, Lisa C. Adams
    CardioVascular and Interventional Radiology.2025;[Epub]     CrossRef
  • Survival benefits of different immunotherapies for hepatocellular carcinoma: a meta-analysis highlighting age, gender, etiology, and tumor burden
    Ming-Cheng Guan, Na Li, Qian Ding, Di Sun, Hao Li, Mei Yang, Lei Hong, Hong Zhu
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Visit‑to‑visit variability of inflammation–immunity indices and prognosis in hepatocellular carcinoma
    Qiajun Du, Youli Zhao, Jing Yang, Yongxin Yang
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Biomimetic Nanomedicine for Senescence‐Modulated Immune Activation Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma
    Shiji Fang, Liyun Zheng, Bin Lin, Jiale Chen, Dehai Hou, Yiming Ding, Mengzhu Han, Pan Qin, Mengyuan Wang, Xiaoju Guo, Yeyu Zhang, Gaofeng Shu, Fazong Wu, Jianfei Tu, Minjiang Chen, Zhongwei Zhao, Zhuang Liu, Jiansong Ji
    Advanced Science.2025;[Epub]     CrossRef
  • Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma patients with normal serum alpha-fetoprotein levels
    Kuan-Jung Huang, Chun-Ting Ho, Pei-Chang Lee, San-Chi Chen, Chien-An Liu, Shu-Cheng Chou, I-Cheng Lee, Yi-Hsiang Huang, Jiing-Chyuan Luo, Ming-Chih Hou, Jaw-Ching Wu, Chien-Wei Su
    Journal of the Chinese Medical Association.2025; 88(12): 915.     CrossRef
  • CDCA3 Regulates Tumor-Associated Macrophages Polarize to Promote the Malignant Progression of Hepatocellular Carcinoma
    Shanmei Lyu, Enqin Wang, Juan Lyu, Hongkun Xu, Daochang Zhang, Zhijun Fang, Lihong Zhang
    Journal of Hepatocellular Carcinoma.2025; Volume 12: 3029.     CrossRef
  • Combining Transarterial Chemoembolization with Sorafenib Improves Survival in Selected Patients with Hepatocellular Carcinoma and Extrahepatic Spread: A Multicenter Real-World Study
    Yue Yuan, Yu Qiao, Yejing Zhu, Ping Guo, Jiakun Gou, Kai Liu, Linqian Wang, Shoujie Zhao, Yongchao Zhang, Yunjie Liu, Enxin Wang, Lei Liu
    Journal of Hepatocellular Carcinoma.2025; Volume 12: 3049.     CrossRef
  • Biomarker-Based Precision Prediction of Immunotherapy Response in Hepatocellular Carcinoma
    Hsu-Wen Chao, Yi-Mei Joy Lin, Chen-Shiou Wu
    Diagnostics.2025; 16(1): 85.     CrossRef
  • Effect of statin use on prognostic outcomes in hepatocellular carcinoma following liver surgery: a systematic review and meta-analysis
    Diski Saisa, Syifa Mustika, Mochamad Fachrureza, Stevanus Christian Surya, Derren Rampengan, Juan Alessandro Jeremis Maruli Nura Lele, Ammar Nojaid, Michael Owen Hogipranata
    European Journal of Gastroenterology & Hepatology.2025;[Epub]     CrossRef
  • Serum Biomarkers for Hepatocellular Carcinoma: A Comparative Review of Traditional and Emerging Markers
    Min Kyung Park
    Journal of Digestive Cancer Research.2025; 13(3): 242.     CrossRef
  • Patterns and Prognostic Stratification of Recurrence after Thermal Ablation in Patients with Hepatocellular Carcinoma
    Chi-Ping Tan, Teng-Yu Lee, I-Cheng Lee, Kuo-Cheng Wu, Chien-An Liu, Nai-Chi Chiu, Shao-Jung Hsu, Pei-Chang Lee, Chi-Jung Wu, Chen-Ta Chi, Jiing-Chyuan Luo, Ming-Chih Hou, Yi-Hsiang Huang
    Liver Cancer.2025; : 1.     CrossRef
  • 29,858 View
  • 1,148 Download
  • 104 Web of Science
  • Crossref

Original Article

Steatotic liver disease

Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study
Seogsong Jeong, Yun Hwan Oh, Joseph C Ahn, Seulggie Choi, Sun Jae Park, Hye Jun Kim, Gyeongsil Lee, Joung Sik Son, Heejoon Jang, Dong Hyeon Lee, Meng Sha, Lei Chen, Won Kim, Sang Min Park
Clin Mol Hepatol 2024;30(3):487-499.
Published online May 7, 2024
DOI: https://doi.org/10.3350/cmh.2024.0145
Background/Aims
To determine the association between evolutionary changes in metabolic dysfunction-associated steatotic liver disease (MASLD) status and the risk of hepatocellular carcinoma (HCC) in a nationwide population-based cohort.
Methods
Information on study participants was derived from the Korea National Health Insurance Service database. The study population consisted of 5,080,410 participants who underwent two consecutive biennial health screenings between 2009 and 2012. All participants were followed up until HCC, death, or 31 December 2020. The association of evolutionary changes in MASLD status, as assessed by the fatty liver index and cardiometabolic risk factors, including persistent non-MASLD, resolved MASLD, incident MASLD, and persistent MASLD, with HCC risk was evaluated using multivariable-adjusted Cox proportional hazards regression.
Result
s: Among the 5,080,410 participants with 39,910,331 person-years of follow-up, 4,801 participants developed HCC. The incidence of HCC in participants with resolved, incident, and persistent MASLD was approximately 2.2-, 2.3-, and 4.7-fold higher, respectively, than that in those with persistent non-MASLD among the Korean adult population. When stratifying the participants according to the evolutionary change in MASLD status, persistent (adjusted hazard ratio [aHR], 2.94; 95% confidence interval [CI], 2.68–3.21; P<0.001), incident (aHR, 1.85; 95% CI, 1.63–2.10; P<0.001), and resolved MASLD (aHR, 1.33; 95% CI, 1.18–1.50; P<0.001) had an increased risk of HCC compared to persistent non-MASLD.
Conclusions
The evolutionary changes in MASLD were associated with the differential risk of HCC independent of metabolic risk factors and concomitant medications, providing additional information on the risk of HCC stratification in patients with MASLD.

Citations

Citations to this article as recorded by  Crossref logo
  • Risk stratification for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: Editorial on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic
    Ho Soo Chun, Minjong Lee
    Clinical and Molecular Hepatology.2026; 32(1): 368.     CrossRef
  • Liver cancer risk stratification using deep learning on nationwide longitudinal health screening data: a retrospective cohort study
    Yewon Choi, Sungmin Cho, Changdai Gu, Chungho Kim, Bomi Park, Hwiyoung Kim
    BMC Medical Informatics and Decision Making.2026;[Epub]     CrossRef
  • Dietary quality, perceived health, and psychological status as key risk factors for newly developed metabolic dysfunction–associated steatotic liver disease in a longitudinal study
    Xuangao Wu, Ting Zhang, Sunmin Park
    Nutrition.2025; 130: 112604.     CrossRef
  • A Novel Point-of-Care Prediction Model for Steatotic Liver Disease: Expected Role of Mass Screening in the Global Obesity Crisis
    Jeayeon Park, Goh Eun Chung, Yoosoo Chang, So Eun Kim, Won Sohn, Seungho Ryu, Yunmi Ko, Youngsu Park, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
    Gut and Liver.2025; 19(1): 126.     CrossRef
  • Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy
    Jiatong Xu, Yifan Li, Zixuan Feng, Hongping Chen
    Cells.2025; 14(3): 221.     CrossRef
  • KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025
    Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang
    Clinical and Molecular Hepatology.2025; 31(Suppl): S1.     CrossRef
  • Revealing the importance of a multidisciplinary approach to reducing the global burden of SLD through the COVID-19 pandemic: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”
    Jeayeon Park, Su Jong Yu
    Clinical and Molecular Hepatology.2025; 31(2): 625.     CrossRef
  • Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
    Hai Xu, Yong Zhou, Huikun Wu
    Clinical and Molecular Hepatology.2025; 31(2): e125.     CrossRef
  • Correspondence to letter to the editor 2 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
    Seogsong Jeong, Won Kim, Sang Min Park
    Clinical and Molecular Hepatology.2025; 31(2): e210.     CrossRef
  • Correspondence to editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”
    Tom Ryu, Young Chang, Seung Up Kim, Jae Young Jang
    Clinical and Molecular Hepatology.2025; 31(2): e203.     CrossRef
  • Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
    Seogsong Jeong, Won Kim, Sang Min Park
    Clinical and Molecular Hepatology.2025; 31(2): e208.     CrossRef
  • MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort st
    Ying Wang, Shengfeng Wang, Xiude Fan, Jiajun Zhao, Yongfeng Song
    Clinical and Molecular Hepatology.2025; 31(2): e128.     CrossRef
  • Significant hepatic fat loss after metabolic dysfunction-associated steatotic liver disease: Beware of misclassification as absence of disease
    Seogsong Jeong
    Journal of Hepatology.2025; 83(3): e156.     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease in the Korean General Population: Epidemiology, Risk Factors, and Non-Invasive Screening
    Yong Jun Choi, Jooheon Park, Han-Ik Cho, Myung Geun Shin, Eun-Hee Nah
    Metabolites.2025; 15(5): 299.     CrossRef
  • Protective effects of Ginkgo biloba supplementation on clinical outcomes in metabolic dysfunction-associated steatotic liver disease
    Tom Ryu, Beom Sun Chung, Jaejun Lee, Ji Won Han, Hyun Yang, Keungmo Yang
    Phytomedicine.2025; 143: 156889.     CrossRef
  • Proteomic variation underlies the heterogeneous risk of metabolic dysfunction-associated steatotic liver disease for subsequent chronic diseases
    Jialong Wu, Gonghua Wu, Jiawei Li, Bo Yi, Qingyi Jia, Ke Ju, Qingyang Shi, Zixuan Wang, Xiong Xiao, Bing Guo, Huan Xu, Xing Zhao
    European Journal of Endocrinology.2025; 192(5): 691.     CrossRef
  • Association between green space and hepatocellular carcinoma risk: a retrospective cohort study of seven South Korean metropolitan areas
    Dong Hyun Kim, Seulggie Choi, Seogsong Jeong, Jooyoung Chang, Sung Min Kim, Sun Jae Park, Jun Hwan Kim, Joung Sik Son, Gyeongsil Lee, Soo Jung Choi, Yun Hwan Oh, Kyae Hyung Kim, Sang Min Park
    International Journal of Environmental Health Research.2025; 35(12): 4026.     CrossRef
  • Early portal hypertension in metabolic dysfunction-associated steatotic liver disease: a concise review
    Iván López-Méndez, Eva Juárez-Hernández, Juan Pablo Soriano-Márquez, Misael Uribe, Graciela Castro-Narro
    Expert Review of Gastroenterology & Hepatology.2025; 19(7): 755.     CrossRef
  • Identification of potentially effective drugs for metabolic dysfunction-associated steatotic liver disease against liver cirrhosis: In-silico drug repositioning-based retrospective cohort study
    Chae Won Lee, Eun Seok Kang, Seogsong Jeong, Hyun Wook Han, Samuel O. Antwi
    PLOS One.2025; 20(6): e0323880.     CrossRef
  • All-cause and disease-specific mortality in young adults with MASLD: A nationwide cohort study
    Jeayeon Park, Goh Eun Chung, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Eun Ju Cho
    JHEP Reports.2025; 7(9): 101477.     CrossRef
  • Incidence of Hepatocellular Carcinoma in Metabolic Dysfunction-associated Steatotic Liver Disease: A Reconstructed Individual Patient Data Meta-analysis
    Ryan Yanzhe Lim, Faith Xin Ning Tan, Glenn Jun Kit Ho, Ethan Kai Jun Tham, Alfred Kow, Guoyue Lv, Zhong-Qi Fan, Nicholas Syn, Masahito Nakano, Wenhao Li, Karn Wijarnpreecha, Jörn M. Schattenberg, Vincent Chen, Ming-Hua Zheng, Pojsakorn Danpanichkul, Hirok
    Clinical Gastroenterology and Hepatology.2025;[Epub]     CrossRef
  • Even Lower Alcohol Intake Might Be Harmful for East Asian Males With MASLD Spectrum
    Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon
    Clinical Gastroenterology and Hepatology.2025;[Epub]     CrossRef
  • From mechanisms to management: Early detection and improved treatment of MASLD and its related hepatocellular carcinoma
    Dingwu Li, Xiang Zhang
    Hepatology Communications.2025;[Epub]     CrossRef
  • 12,282 View
  • 347 Download
  • 20 Web of Science
  • Crossref

Editorial

Hepatic neoplasm

The latest global burden of liver cancer: A past and present threat
Joo Hyun Oh, Dae Won Jun
Clin Mol Hepatol 2023;29(2):355-357.
Published online March 9, 2023
DOI: https://doi.org/10.3350/cmh.2023.0070

Citations

Citations to this article as recorded by  Crossref logo
  • Molecular and cellular secrets revealed: How umbilical cord-derived mesenchymal stem cells can target hepatocellular carcinoma
    Mohammad Sadegh Izadi, Reza Arefnezhad, Amirmasoud Asadi, Aryan Rezaee, Leila Kalantari, Farzad Nasrpour Tahouneh, Mohammad Mehdi Shadravan, Seyyed Taher Seyyed Mahmoudi, Zahra GhaniBeygi, Fatemeh Rostamnezhad, Armin Razman, Fardad Ejtehadi, Fatemeh Rezae
    Tissue and Cell.2026; 98: 103200.     CrossRef
  • Data efficient deep learning for liver and liver tumor segmentation: A comprehensive survey
    Nisha, Pramod Kumar Mishra
    Neurocomputing.2026; 663: 131937.     CrossRef
  • Exploring the potential of nanotechnology for early detection of cancer disease by microfluidic paper based analytical devices
    Maryam Sharifi, Samaneh Ghafouri, Balal Khalilzadeh, Farhad Bani, Habib Tajalli, Ibrahim Isildak
    Biosensors and Bioelectronics.2026; 294: 118243.     CrossRef
  • Gut microbiota's role in NAFLD- and HBV/HCV-related hepatocellular carcinoma: Mechanisms and therapeutic implications
    Gursimran Singh, Shazia Ansari, Satyam Yadav, Khadga Raj Aran
    Microbial Pathogenesis.2026; 211: 108273.     CrossRef
  • Uncovering the antiproliferative effects of magnolol in liver cancer: a multi-omics study integrating computational chemistry, network pharmacology, bioinformatics and in vitro experimental validations
    Yu Cai, Yutong Liu, Chang Tian, Fende Liu, Xiaojun Wang
    Molecular Diversity.2026;[Epub]     CrossRef
  • The correlation between social support and hopelessness among cancer survivors: a meta-analysis
    Lu-Ting Shen, Jian-Zeng Lan, Attiq-Ur-Rehman, Wei Li, Meng-Wei Ge, Rui Feng, Kang Zhong, Si-qi Gao, Hong-Lin Chen
    Cancer Causes & Control.2026;[Epub]     CrossRef
  • CRISPR-Cas-enabled nanocarriers in hepatocellular carcinoma: Emerging gene-editing strategies for precision liver therapy
    Ramaiyan Velmurugan, Yokesh Shanmugam, Lokeshvar Ravikumar
    Gastroenterology & Endoscopy.2026; 4(2): 86.     CrossRef
  • In vitro and in silico antimicrobial, antioxidant, and cytotoxic potentials of endophytic Alternaria alternata MPL5 from Mentha piperita
    Nisha Yadav, Himanshu Jangid, Anuprita Ray, Arun Karnwal, Gaurav Kumar, Deepak Kumar
    Discover Applied Sciences.2026;[Epub]     CrossRef
  • Comparative cytotoxic and molecular effects of deltamethrin and acetamiprid in normal and cancerous human liver cell lines
    Cansu Aydın, Selin Özkan-Kotiloğlu, Serap Yalçın-Azarkan
    Cell Biochemistry and Biophysics.2026;[Epub]     CrossRef
  • Inter‐Reader Agreement for Contrast‐Enhanced Ultrasound Liver Imaging Reporting and Data System Major Features and Final Categorization
    Cristina M. Kuon Yeng Escalante, Tania Siu Xiao, Yuko Kono, Fabio Piscaglia, Stephanie R. Wilson, Alexandra Medellin, Shuchi K. Rodgers, Virginia Planz, Aya Kamaya, David T. Fetzer, Annalisa Berzigotti, Paul S. Sidhu, Corinne E. Wessner, Kristen Bradigan,
    Journal of Ultrasound in Medicine.2025; 44(2): 349.     CrossRef
  • Curcumin-encapsulated glucan nanoparticles as an oxidative stress modulator against human hepatic cancer cells
    Tiago Roquito, Mariana Colaço, João Panão Costa, Olga Borges
    Colloids and Surfaces B: Biointerfaces.2025; 245: 114326.     CrossRef
  • Role of Locoregional Therapy on Survival After Living Donor Liver Transplantation for Hepatocellular Carcinoma--Experience from a High-volume Center
    Vibha Varma, Phani K. Nekarakanti, Shaleen Agarwal, Rajesh Dey, Subash Gupta
    Journal of Clinical and Experimental Hepatology.2025; 15(3): 102490.     CrossRef
  • Synergistic hybrid nanostructures for Ultra-Sensitive photoelectrochemical detection of hepatocellular carcinoma ctDNA
    Meltem Okan, Zeynep Çağlayan Arslan, Firdevs Aydın, Demet Asil, Haluk Külah
    Microchemical Journal.2025; 208: 112547.     CrossRef
  • Therapeutic Efficacy Studies on the Monoterpenoid Hinokitiol in the Treatment of Different Types of Cancer
    Md. Shimul Bhuia, Raihan Chowdhury, Meher Afroz, Md. Showkot Akbor, Md. Sakib Al Hasan, Jannatul Ferdous, Rubel Hasan, Marcus Vinícius Oliveira Barros de Alencar, Mohammad S. Mubarak, Muhammad Torequl Islam
    Chemistry & Biodiversity.2025;[Epub]     CrossRef
  • Targeting glypican 3 by immunotoxins: the promise of immunotherapy in hepatocellular carcinoma
    Elham Rismani, Nikoo Hossein-Khannazer, Moustapha Hassan, Elahe Shams, Mustapha Najimi, Massoud Vosough
    Expert Opinion on Therapeutic Targets.2025; 29(1-2): 59.     CrossRef
  • A novel aminohydroxy sulfonamide formulated in PEGylated liposomes with potential antitumor activity
    Carla Caddeo, Ilaria Nigro, Lucia Chiummiento, Maria Funicello, Paolo Lupattelli, Alessandro Santarsiere, Xavier Fernàndez-Busquets, Donatella Valenti, Emanuele Rosa, Rocchina Miglionico, Maria Francesca Armentano, Antonio Vassallo
    Journal of Drug Delivery Science and Technology.2025; 106: 106739.     CrossRef
  • Pulsed field ablation in medicine: irreversible electroporation and electropermeabilization theory and applications
    Edward J Jacobs, Boris Rubinsky, Rafael V Davalos
    Radiology and Oncology.2025; 59(1): 1.     CrossRef
  • Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B
    Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto
    Clinical and Molecular Hepatology.2025; 31(Suppl): S182.     CrossRef
  • Study on the Mechanism of QRICH1 Mediating PRMT1 to Regulate the Arginine Methylation Modification of cGAS to Promote Arsenics-Induced Pyroptosis in Hepatocellular Carcinoma Cells
    Jiayuan Zhang, Tian Tian, Shanshan Tian, Jinhai Yao, Yingwan Zhang, Rujia Xie, Ting Yang, Bing Han
    Journal of Hepatocellular Carcinoma.2025; Volume 12: 597.     CrossRef
  • HTRecNet: a deep learning study for efficient and accurate diagnosis of hepatocellular carcinoma and cholangiocarcinoma
    Jingze Li, Yupeng Niu, Junwu Du, Jiani Wu, Weichen Guo, Yujie Wang, Jian Wang, Jiong Mu
    Frontiers in Cell and Developmental Biology.2025;[Epub]     CrossRef
  • Integrated Analysis of Bulk and Single-Cell RNA Sequencing Data Reveal a Novel Prognostic Signature of Combining Cuproptosis- and Ferroptosis-Related Genes in Hepatocellular Carcinoma
    Hua Wei, Jiaxin Peng
    International Journal of Molecular Sciences.2025; 26(6): 2779.     CrossRef
  • Comprehensive insights of etiological drivers of hepatocellular carcinoma: Fostering targeted nano delivery to anti-cancer regimes
    Dipanjan Ghosh, Aharna Guin, Aryan Kumar, Amlan Das, Santanu Paul
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2025; 1880(3): 189318.     CrossRef
  • Three new sesquiterpenes with cytotoxic activity from Croton tiglium
    Wen-Ying Zhou, Xiao-Xiao Zheng, Yang-Mei Ou, Yang-Lin Ou, Hong-Yu Jang, Yu-Xin Peng, Yi-Yi Wang, Bi-Qing Zhao, Li Li
    Phytochemistry Letters.2025; 67: 102957.     CrossRef
  • HCC in MASLD: radiological appearance, diagnosis and treatment
    Marco Dioguardi Burgio, Roberto Cannella, Federica Vernuccio, Maxime Ronot, Valérie Vilgrain
    Hepatoma Research.2025;[Epub]     CrossRef
  • Effectiveness of herbal medicine for liver cancer treatment as revealed by a bibliometric and visualization analysis
    Yusha Shi, Juwei Wang, Yahui Zhang, Kai Wu, Yibo Zhu, Kaiwen Yan, Qin Ouyang
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Caracterización de la enfermedad hepática crónica, cirrosis y progresión a carcinoma hepatocelular en una entidad promotora de salud en Colombia: estudio retrospectivo de diez años
    Joshua Kock-Sierra, Juan Felipe Betancur-Pulgarín, Jhon Edwar Bolaños-López, Luz Eugenia Pérez-Jaramillo, Carlos José Bello-Gándara, Farley Johanna González-Patiño, José David Sanabria-Vanegas, José David Manga-Peña, Carlos Andrés Badillo-Blanco
    Hepatología.2025; 6(2): 107.     CrossRef
  • Extracellular vesicles as a promising platform of precision medicine in liver cancer
    Keyang Xu, Qibiao Wu, Zhao Lingyun, Romario Nguyen, Fatema Safri, William Yang, Yikun Xu, Yun Ye, Hiu Yee Kwan, Qiang Wang, Xiuming Liang, Muhammad J.A. Shiddiky, Majid E. Warkiani, Jacob George, Liang Qiao, Jianfeng Bao
    Pharmacological Research.2025; 217: 107800.     CrossRef
  • Co-embedding of curcumin and gold nanoparticles with ZIF-8 nanoparticles for the treatment of liver cancer and its impact on metabolomics
    Xiaohui Wang, Lin Zhou, Yingying Shi, Wang Wang, Peng Li, Rui Cui, Yajuan Wu, Feng Wang, Qiuzheng Du
    European Journal of Pharmaceutics and Biopharmaceutics.2025; 214: 114773.     CrossRef
  • Imiquimod‐Loaded Phospholipid‐Free Small Unilamellar Vesicles Activate the Tumor Immune Microenvironment to Treat Liver Cancer and Liver Metastases
    Vanessa Chan, Hsin‐Mei Lee, Haruka Takata, Sheng‐Liang Cheng, Yu‐Ting Yen, Lisa Pfeifer, Luke Rushton, Po‐Han Chao, Feng Zhao, Chun Yat Ong, Nojoud Al‐Fayez, Tatsuhiro Ishida, Yunching Chen, Shyh‐Dar Li
    Advanced Healthcare Materials.2025;[Epub]     CrossRef
  • DynTransNet: Dynamic Transformer Network with multi-scale attention for liver cancer segmentation
    Siming Zheng, A. S. M. Sharifuzzaman Sagar, Yu Chen, Zehao Yu, Shi Ying, Yongyi Zeng
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Burden of liver cancer in the European region from 1990 to 2021: a sub-analysis of the global burden of disease study
    Onika Kazi, Shokoufeh Hamidzadeh, Babak Ehsani Zunuz, Abdolsabour Khordoo, Seyede Saba Mazloomi, Hossein Khademsedaghat, Mohammad Amin Khadembashiri
    Annals of Medicine & Surgery.2025; 87(7): 4053.     CrossRef
  • Role of Liquid Biopsy for Early Detection, Prognosis, and Therapeutic Monitoring of Hepatocellular Carcinoma
    Faris Alrumaihi
    Diagnostics.2025; 15(13): 1655.     CrossRef
  • Baicalin promotes anti-tumor immunity in hepatocellular carcinoma through HIF-1α/Lactate/CXCL9 axis
    Xuemei Yang, Weicong Chen, Haitao Sun, Chunyu He, Yang Liu, Mengchen Qin, Wentao Jiang, Yiqin Wang, Songqi He
    Biochemical Pharmacology.2025; 241: 117157.     CrossRef
  • Computational study of microwave-driven drug delivery with realistic tumor modeling and optimized heating protocols for hepatocellular carcinoma
    Gabriele Adabbo, Assunta Andreozzi, Marcello Iasiello, Paolo Antonio Netti
    International Journal of Thermal Sciences.2025; 218: 110140.     CrossRef
  • Rapid and Sensitive Detection of Liver Cancer Markers Based on a Microtapered Long-Period Grating Sensor Coated With Gold Nanorods
    Xiaoyu Li, Zhiruo Wang, Lei Hu, Jiangying Xia, Siqi Li, Yan Kuai, Weiwei Fu, Zhigang Cao, Min Wang, Benli Yu, Zhijia Hu
    IEEE Sensors Journal.2025; 25(14): 26608.     CrossRef
  • Novel Therapeutics for Hepatocellular Carcinoma
    Mohamed I. Elsaid, Ashish Manne
    Clinics in Liver Disease.2025; 29(4): 673.     CrossRef
  • Primary Hepatocellular Carcinoma Developing Within a B-cell Primary Hepatic Lymphoma in a Hepatitis C Positive Patient
    Tushar Kumar, Harmanjit Kaur, Surbhi Singh, Lakshmisree A Vemulakonda, Rajat Bhargava
    Cureus.2025;[Epub]     CrossRef
  • Advances in Liver Tumour Diagnosis and Treatment: Etiology, Classification, and the Emerging Role of Machine Learning
    Yana Gaur, Abhay Chaudhary, Ajith Abraham
    IEEE Access.2025; 13: 131549.     CrossRef
  • Primary liver cancer burden and its association with health development in the Western Pacific, 1990–2021
    Teng-Chao Zhou, Dan Qin, Peng Yan, Bin Lan, Qing Wang, Jie Tan
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Host Immune Response in Chronic Hepatitis Delta: Implications for Pathogenesis and Therapy
    Arshi Khanam, Abutaleb Ameer, Poonam Mathur, Cihan Yurdaydin, Shyam Kottilil
    Pathogens.2025; 14(8): 828.     CrossRef
  • ZEB1 stratifies the response to Sorafenib and Mdivi-1 combination therapy in hepatocellular carcinoma
    H. Freudenstein, M. Strecker, S. Gylstorff, W. Shi, M. Boettcher, S. Medunjanin, C. Catapano, C. Siba, C. Wex, T. Wartmann, A. Y. Sanin, M. Franz, J. Arend, D. Mougiakakos, M. Pech, R. S. Croner, U. D. Kahlert, F. Stelter
    Scientific Reports.2025;[Epub]     CrossRef
  • Mechanistic insights into aristolochic acid-induced hepatocellular carcinoma: a multi-dimensional analysis integrating network toxicology, machine learning, and molecular dynamics simulation
    Can Liu, Ru Qiao, Peng He, Wang Chen, Xiangting Gao, Fuyuan He
    Toxicon.2025; 267: 108576.     CrossRef
  • Surgery Without Scalpel: Histotripsy as a Non-Invasive and Non-Thermal Modality for Liver Tumor Ablation
    Daniel Paramythiotis, Dimitrios Tsavdaris, Georgios Tsavdaris, Adam Hatzidakis, Kyriakos Psarras, Alexandros Mekras, Christos Georgiades, Antonios Michalopoulos
    Journal of Clinical Medicine.2025; 14(18): 6391.     CrossRef
  • Medical travel patterns for hepatocellular carcinoma treatment in South Korea: National Health Insurance data from 2013 to 2021
    Sungmin Kim, Naeun Kim, Hyung-Sik Lee, Mina Kim, Hoseob Kim, Youngmin Choi
    World Journal of Gastrointestinal Oncology.2025;[Epub]     CrossRef
  • Asialoglycoprotein receptor-1 mediated targeted drug delivery to liver cancer cells using stimuli responsive galactosylated electrospun nanofibers
    Pramodh Rao N, Juby K. Ajish, K. S. Ajish Kumar
    International Journal of Biological Macromolecules.2025; 329: 147793.     CrossRef
  • Association between metabolites and hepatocellular carcinoma: findings from a two-sample Mendelian randomization study
    Tung Hoang, Van Mai Truong, Tho Thi Anh Tran, Bao Le Thai Tran, Ngoc Hong Cao
    Journal of Liver Cancer.2025; 25(2): 251.     CrossRef
  • Liver Augmentation: Rationale, Current Status, and Future Directions
    Jirapa Chansangrat, Sameer Gadani
    Techniques in Vascular and Interventional Radiology.2025; 28(4): 101086.     CrossRef
  • 3D-bioprinted liver cancer models derived from primary hepatocytes for simulating cancer initiation and drug screening
    Yuanyuan Zhao, Yuxin Li, Wenjie Zhang, Hongyan Jiang, Lina Mao, Runbang He, Yue Ma, Qiangsong Wang, Pengyu Huang
    Hepatology Communications.2025;[Epub]     CrossRef
  • Enzymatic Self-Immobilization Enhances Chemiluminescence for Selective Tumor Imaging and Image-Guided Surgery
    Ming Liu, Zhecheng Ma, Yu Wang, Li Wu, Zhiyuan Tian, Jian-Hong Tang
    Analytical Chemistry.2025; 97(45): 25129.     CrossRef
  • The Multifaceted Role of Osteopontin in Modulating the Tumor Microenvironment
    Yu Gu, William J. Muller
    Cancer Research.2025; 85(21): 4049.     CrossRef
  • Real-World Treatment Patterns and Clinical Outcomes in Patients with Unresectable Hepatocellular Carcinoma: Results from the OREIOS Study
    Stephen Lam Chan, Valeriy Breder, Yu-Yun Shao, David Tai, Imam Waked, Sandip Ganguly, Ashwaq Alolayan, Ahmed Aboutaleb, Heba Farag, Min-Hee Ryu
    Liver Cancer.2025; : 1.     CrossRef
  • Exploring the Therapeutic Potential of TROP2 Gene Silencing in Hepatocellular Carcinoma
    Fatma Yakoub, Hanem Hassan, Samah Mamdouh, Tarek Aboushousha, Fatma B. Rashidi, Mohamed A. El- Desouky
    Recent Patents on Biotechnology.2025; 20(1): 166.     CrossRef
  • TGF-β-driven NK Cells plasticity in hepatocellular carcinoma
    Valentina Reverberi, Anna Montali, Andrea Vecchi, Marzia Rossi, Alessio Pelagatti, Sara Doselli, Benedetta Farina, Andrea Olivani, Giorgio Economopoulos, Raffaele Dalla Valle, Diletta Laccabue, Francesca Ferraglia, Amalia Penna, Paola Fisicaro, Carolina B
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation
    Reza Elahi, Yassine Alami Idrissi, Anwaar Saeed
    Cancer Treatment Reviews.2025; 141: 103046.     CrossRef
  • Modulation of Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Gastrointestinal Cancers by Phytochemicals
    Pratibha Pandey, Meenakshi Verma, Samra Siddiqui, Ali G. Alkhathami, Mohd Saeed, Ajay Singh, Fahad Khan
    Pharmaceutical Research.2025;[Epub]     CrossRef
  • Recent Update on Nanoparticles Based Approaches for Management of Cancer: Wave from Traditional to Advanced Technology
    Abhishek Sharma, Mridul Modgil, Gaurav Joshi, Preeti Bisht
    Current Cancer Drug Targets.2025; 25(11): 1397.     CrossRef
  • A comparative analysis of machine learning classifiers for chronic liver disease prediction in rats
    Aqsa Nadeem, Sonia Bisht, Abhishek Kaushal, Sangeetha Gupta
    Journal of Pharmacy and Pharmacology.2025;[Epub]     CrossRef
  • Advancing Hepatocellular Carcinoma Therapy with Next-Generation Molecular and Immunotherapeutics
    Mudassir Hassan, Ijaz Hussain, Kafeel Ahmad, Saima Zafar, Adeel Khalid, Muhammad Haseeb, Nazim Hussain, Muhammad Adeel Ghafar
    Journal of Hepatocellular Carcinoma.2025; Volume 12: 2907.     CrossRef
  • Anticancer activity of polyphenolic Punica granatum peel extracts obtained by hybrid ultrasound‐microwave assisted extraction: Evaluation on HeLa and HepG2 cells
    Gerardo Manuel González‐González, Sandra Cecilia Esparza‐González, Sendar Daniel Nery‐Flores, Jesús Antonio Morlett‐Chávez, Juan Alberto Ascacio‐Valdés, Adriana Carolina Flores‐Gallegos, Aidé Saenz‐Galindo, Raúl Rodríguez‐Herrera
    Environmental Quality Management.2024; 33(4): 295.     CrossRef
  • Itraconazole halts hepatocellular carcinoma progression by modulating sonic hedgehog signaling in rats: A novel therapeutic approach
    Osama A. Mohammed, Ahmed S. Doghish, Lobna A. Saleh, Mushabab Alghamdi, Mohannad Mohammad S. Alamri, Jaber Alfaifi, Masoud I.E. Adam, Muffarah Hamid Alharthi, Abdullah M. Alshahrani, Abdullah Hassan Alhalafi, Waad Fuad BinAfif, Assad Ali Rezigalla, Mustaf
    Pathology - Research and Practice.2024; 253: 155086.     CrossRef
  • Subverting the Canon: Novel Cancer-Promoting Functions and Mechanisms for snoRNAs
    Matthew Huo, Sudhir Kumar Rai, Ken Nakatsu, Youping Deng, Mayumi Jijiwa
    International Journal of Molecular Sciences.2024; 25(5): 2923.     CrossRef
  • Poorly Differentiated Hepatocellular Carcinoma Cells Avoid Apoptosis by Interacting with T Cells via CD40–CD40 Ligand Linkage
    Ngo Vinh Hanh, Le Thi Thanh Thuy, Vu Ngoc Hieu, Hoang Hai, Hiroko Ikenaga, Misako Sato-Matsubara, Sawako Uchida-Kobayashi, Hayato Urushima, Nguyen Van Khanh, Nguyen Thi Ha, Hiroji Shinkawa, Shoji Kubo, Naoko Ohtani, Masaru Enomoto, Akihiro Tamori, Norifum
    The American Journal of Pathology.2024; 194(7): 1230.     CrossRef
  • Hijacking and rewiring of host CircRNA/miRNA/mRNA competitive endogenous RNA (ceRNA) regulatory networks by oncoviruses during development of viral cancers
    Mohammad Javad Kamali, Mohammad Salehi, Mehrnaz Mostafavi, Reza Morovatshoar, Mitra Akbari, Narges Latifi, Omid Barzegari, Fatemeh Ghadimi, Abdolreza Daraei
    Reviews in Medical Virology.2024;[Epub]     CrossRef
  • Genomic ancestry and cancer among Latin Americans
    Alejandro Ruíz-Patiño, Leonardo Rojas, Jairo Zuluaga, Oscar Arrieta, Luis Corrales, Claudio Martín, Sandra Franco, Luis Raez, Christian Rolfo, Natalia Sánchez, Andrés Felipe Cardona
    Clinical and Translational Oncology.2024; 26(8): 1856.     CrossRef
  • The Deterioration of Sarcopenia Post-Transarterial Radioembolization with Holmium-166 Serves as a Predictor for Disease Progression at 3 Months in Patients with Advanced Hepatocellular Carcinoma: A Pilot Study
    Claudio Trobiani, Nicolò Ubaldi, Leonardo Teodoli, Marcello Andrea Tipaldi, Federico Cappelli, Sara Ungania, Giulio Vallati
    Journal of Personalized Medicine.2024; 14(5): 511.     CrossRef
  • ULK1 Mediated Autophagy-Promoting Effects of Rutin-Loaded Chitosan Nanoparticles Contribute to the Activation of NF-κB Signaling Besides Inhibiting EMT in Hep3B Hepatoma Cells
    Peng Wu, Xiaoyong Wang, Min Yin, Wenjie Zhu, Zheng Chen, Yang Zhang, Ziyu Jiang, Longqing Shi, Qiang Zhu
    International Journal of Nanomedicine.2024; Volume 19: 4465.     CrossRef
  • Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma
    Xin Li, Yu-Fei Pan, Yi-Bin Chen, Qian-Qian Wan, Yun-Kai Lin, Tai-Yu Shang, Meng-You Xu, Tian-Yi Jiang, Meng-Miao Pei, Ye-Xiong Tan, Li-Wei Dong, Xu-Ying Wan
    Cell Death & Disease.2024;[Epub]     CrossRef
  • Artificial intelligence in liver cancer — new tools for research and patient management
    Julien Calderaro, Laura Žigutytė, Daniel Truhn, Ariel Jaffe, Jakob Nikolas Kather
    Nature Reviews Gastroenterology & Hepatology.2024; 21(8): 585.     CrossRef
  • Angiogenic protein profiling, phytochemical screening and in silico anti-cancer targets validation of stem, leaves, fruit, and seeds of Calotropis procera in human liver and breast cancer cell lines
    Muhammad Farooq Khan, Rawan Frhan Alanazi, Almohannad A. Baabbad, Nawaf D. Almoutiri, Mohammad Ahmad Wadaan
    Environmental Research.2024; 256: 119180.     CrossRef
  • Olsalazine pretreatment augments chemosensitivity of gemcitabine in hepatocellular carcinoma
    Ayush Sharma, Abu Sufiyan Chhipa, Srashti Verma, Palak Parikh, Snehal Patel
    Journal of Biochemical and Molecular Toxicology.2024;[Epub]     CrossRef
  • Burden of liver cancer attributable to high fasting plasma glucose: a global analysis based on the global burden of disease study 2019
    Minmin Wang, Jingyi Liu, Liang Yan, Jia Wang, Yinzi Jin, Zhi-Jie Zheng
    The Journal of nutrition, health and aging.2024; 28(6): 100261.     CrossRef
  • Risk of Bleeding in Hepatocellular Carcinoma Patients Treated with Atezolizumab/Bevacizumab: A Systematic Review and Meta-Analysis
    Young-Gi Song, Kyeong-Min Yeom, Eun Ae Jung, Sang Gyune Kim, Young Seok Kim, Jeong-Ju Yoo
    Liver Cancer.2024; : 1.     CrossRef
  • Tumor Growth in Overdrive: Detailing an Aggressive Course of Hepatocellular Carcinoma
    Simardeep Singh, Thilini Delungahawatta, Marcos Wolff, Christopher J. Haas, Ned Snyder
    Case Reports in Hepatology.2024;[Epub]     CrossRef
  • Injectable self-healing hydrogel as a rising therapeutic strategy for the loco-regional management of cancer
    Shruti Srivastav, Abhilasha Singh, Manjul Pratap Singh, Ranjit Singh, Parveen Kumar, Preeti Kush
    Journal of Drug Delivery Science and Technology.2024; 98: 105913.     CrossRef
  • Luteolin: A promising modulator of apoptosis and survival signaling in liver cancer
    Prangya Rath, Abhishek Chauhan, Anuj Ranjan, Diwakar Aggarwal, Isha Rani, Renuka Choudhary, Moyad Shahwan, Seema Ramniwas, Hemant Joshi, Shafiul Haque, Darin Mansor Mathkor, Hardeep Singh Tuli
    Pathology - Research and Practice.2024; 260: 155430.     CrossRef
  • Preclinical human and murine models of hepatocellular carcinoma (HCC)
    Pharidah Rajan Ibrahim Omar Sundi, Velaphi C. Thipe, Mohamed Abdullahi Omar, Temitope Isaac Adelusi, Jalene Gedefa, Olamide T. Olaoba
    Clinics and Research in Hepatology and Gastroenterology.2024; 48(7): 102418.     CrossRef
  • Role of Hepatocyte Nuclear Factor 4 Alpha in Liver Cancer
    Manasi Kotulkar, Diego Paine-Cabrera, Udayan Apte
    Seminars in Liver Disease.2024; 44(03): 383.     CrossRef
  • Editorial: Case reports in PET imaging 2023
    Carmelo Caldarella, Matteo Bauckneht, Ramin Sadeghi
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Porous Organic Polymer-Based Nanocomposites for Hypoxia Relieving and Enhanced Chemotherapy in Hepatocellular Carcinoma
    Poulami Mukherjee, Subhabrata Guha, Antara Ghosh, Korak Kar, Gaurav Das, Sumanta Kumar Sahu
    ACS Applied Bio Materials.2024; 7(9): 6138.     CrossRef
  • Nano-Formulations of Natural Antioxidants for the Treatment of Liver Cancer
    Mariateresa Cristani, Andrea Citarella, Federica Carnamucio, Nicola Micale
    Biomolecules.2024; 14(8): 1031.     CrossRef
  • Regulation of Tumor Microenvironment through YAP/TAZ under Tumor Hypoxia
    Sung Hoon Choi, Do Young Kim
    Cancers.2024; 16(17): 3030.     CrossRef
  • Inhibitory Activity of Compounds Isolated from Ligustrum robustum (Roxb.) Against HepG2 Liver Cancer Cells: Isocubein and 4‐(2‐Acetoxyethyl)phenol as Potential Candidates
    Thi Anh Thu Nong, Thi Thanh Huong Le, Van Tuan Vu, Mai Quynh Nguyen, Dinh Quang Hung Can, Thi Hoang Yen Dong, Thi Phuong Thao Nguyen, Van Hung Hoang, Phu Hung Nguyen
    Chemistry & Biodiversity.2024;[Epub]     CrossRef
  • MATR3 promotes liver cancer progression by suppressing DHX58–mediated type I interferon response
    Zhaofeng Xiao, Huan Chen, Nan Xu, Yiyuan Chen, Shuai Wang, Xiao Xu
    Cancer Letters.2024; 604: 217231.     CrossRef
  • Current Insights into Molecular Mechanisms and Potential Biomarkers for Treating Radiation-Induced Liver Damage
    Biki Saha, Sneha Pallatt, Antara Banerjee, Abhijit G. Banerjee, Rupak Pathak, Surajit Pathak
    Cells.2024; 13(18): 1560.     CrossRef
  • Anti-tumor efficacy of Calculus bovis: Suppressing liver cancer by targeting tumor-associated macrophages
    Ishita Kathuria, Bhupesh Singla
    World Journal of Gastroenterology.2024; 30(38): 4249.     CrossRef
  • PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma
    Khaled Mohamed Nassar, Xue Yang, Adriana Baker, Rahul Gopalam, William C. Arnold, Timilehin T. Adeniran, Marian H. Hernandez Fernandez, Megharani Mahajan, Zhao Lai, Yidong Chen, Gangadhara R. Sareddy, Suryavathi Viswanadhapalli, Lu-Zhe Sun, Ratna K. Vadla
    Cancer Research Communications.2024; 4(10): 2610.     CrossRef
  • Biomarker Discovery in Liver Disease Using Untargeted Metabolomics in Plasma and Saliva
    Noah J. Daniels, Courtney E. Hershberger, Matthew Kerosky, Chase J. Wehrle, Roma Raj, Nihal Aykun, Daniela S. Allende, Federico N. Aucejo, Daniel M. Rotroff
    International Journal of Molecular Sciences.2024; 25(18): 10144.     CrossRef
  • Role of Imaging in Screening for Hepatocellular Carcinoma
    Irfan A. Kazi, Vinay Jahagirdar, Bareen W. Kabir, Almaan K. Syed, Asad W. Kabir, Abhilash Perisetti
    Cancers.2024; 16(19): 3400.     CrossRef
  • Unveiling novel prognostic biomarkers and therapeutic targets for HBV-associated hepatocellular carcinoma through integrated bioinformatic analysis
    Xue Ren, Niaoniao Feng
    Medicine.2024; 103(43): e40134.     CrossRef
  • Plasmodium infection downregulates hypoxia‑inducible factor 1α expression to suppress the vascularization and tumorigenesis of liver cancer
    Runling Wu, Xiao Chen, Huan Chen, Mei Li, Yun Liang
    Oncology Letters.2024;[Epub]     CrossRef
  • The role of inflammation induced by necroptosis in the development of fibrosis and liver cancer in novel knockin mouse models fed a western diet
    Ramasamy Selvarani, HoangVan Michelle Nguyen, Natesan Pazhanivel, Muthusamy Raman, Sunho Lee, Roman F. Wolf, Sathyaseelan S. Deepa, Arlan Richardson
    GeroScience.2024; 47(3): 2973.     CrossRef
  • A new tumor-treating device OM-100 with low-frequency magnetic fields inhibits proliferation and metastasis in liver cancer
    Xin Zhang, Zhaoxian Yan, Lifa Huang, Xinyan Yu, Rui Huang
    BMC Cancer.2024;[Epub]     CrossRef
  • Unveiling the Tumor Microenvironment Through Fibroblast Activation Protein Targeting in Diagnostic Nuclear Medicine: A Didactic Review on Biological Rationales and Key Imaging Agents
    Juliette Fouillet, Jade Torchio, Léa Rubira, Cyril Fersing
    Biology.2024; 13(12): 967.     CrossRef
  • Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 4: Liver and locally recurrent rectal cancer
    Hwa Kyung Byun, Gyu Sang Yoo, Soo-Yoon Sung, Jin-Ho Song, Byoung Hyuck Kim, Yoo-Kang Kwak, Yeon Joo Kim, Yeon-Sil Kim, Kyung Su Kim
    Radiation Oncology Journal.2024; 42(4): 247.     CrossRef
  • Antimicrobial activity, induction of ROS generation in HepG2 liver cancer cells, and chemical composition of Pterospermum heterophyllum
    Quang Trung Tu, Thi Thanh Huong Le, Mai Quynh Nguyen, Phu Hiep Hoang, Van Hung Hoang, Van Khang Pham, Phu Hung Nguyen
    Open Chemistry.2024;[Epub]     CrossRef
  • Unveiling key drivers of hepatocellular carcinoma: a synergistic approach with network pharmacology, machine learning-driven ligand discovery and dynamic simulations
    D.K. Sabir, J.A. Bin Jumah, I. Ancy
    SAR and QSAR in Environmental Research.2024; 35(11): 1045.     CrossRef
  • A Study on Hepatoprotective Activities of Vitex negundo Linn and Hygrophila auriculata in D-Galactosamine-Induced Rat Models
    Anjali Khantal, Nidhi Bais
    International Journal of Newgen Research in Pharmacy & Healthcare.2024; : 220.     CrossRef
  • Hepatoprotective Activity of Vitex Negundo and Hygrophila auriculata Extracts in combination
    Anjali Khantal, Nidhi Bais
    International Journal of Newgen Research in Pharmacy & Healthcare.2024; : 73.     CrossRef
  • PLGA and cancer: a comprehensive patent-based review on the present state of art
    Venessa Nath, Mohini Singh, Bani Kumar Jana, Tumpa Sarkar, Niva Rani Gogoi, Bhaskar Mazumder
    Pharmaceutical Patent Analyst.2024; 13(4-6): 201.     CrossRef
  • Green synthesis and characterization of silicate nanostructures coated with Pluronic F127/gelatin for triggered drug delivery in tumor microenvironments
    Ndumiso Vukile Mdlovu, Ruey-Shin Juang, Meng-Tzu Weng, Kuen-Song Lin
    International Journal of Biological Macromolecules.2023; 251: 126337.     CrossRef
  • Serum resistin and the risk for hepatocellular carcinoma in diabetic patients
    Mona Mohamed Ibrahim Abdalla
    World Journal of Gastroenterology.2023; 29(27): 4271.     CrossRef
  • Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma
    Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee
    Clinical and Molecular Hepatology.2023; 29(3): 794.     CrossRef
  • Application of Clinical Decision Support Sys-tem Based on Artificial Intelligence in Hepatocellular Carcinoma
    笑楠 汪
    Advances in Clinical Medicine.2023; 13(07): 11368.     CrossRef
  • Risk factors and prevention of liver cancer: A bibliometric and visual analysis
    Min Yang, Huiqin Zhang, Jieqiu Zhang, Xiaopeng Yao
    Medicine.2023; 102(47): e35740.     CrossRef
  • 13,359 View
  • 184 Download
  • 98 Web of Science
  • Crossref

Review

Hepatic neoplasm

Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease
Karim Seif El Dahan, Darine Daher, Amit G. Singal
Clin Mol Hepatol 2023;29(Suppl):S207-S219.
Published online September 14, 2022
DOI: https://doi.org/10.3350/cmh.2022.0247
Non-alcoholic fatty liver disease (NAFLD) may progress to cirrhotic or non-cirrhotic hepatocellular carcinoma (HCC), and is currently recognized as the fastest growing cause of HCC worldwide. Accordingly, professional society guidelines recommend HCC surveillance in patients with cirrhosis from any etiology, and some may consider it beneficial in subgroups with non-cirrhotic NAFLD at higher risk for HCC. Notably, patients with NAFLD-related HCC are more likely to have HCC diagnosed at more advanced stages and have poorer outcomes when compared to other etiologies, and suboptimal effectiveness of HCC surveillance programs is a major culprit. In this review, we summarize the current guidelines for HCC surveillance and discuss its benefits versus potential harms for NAFLD patients. We also address the unique challenges of HCC surveillance in NAFLD, including higher proportion of NAFLD-related HCC without cirrhosis, poor recognition of at-risk patients, lack of consensus regarding the value of surveillance in non-cirrhotic NAFLD, subpar effectiveness of surveillance tools related to NAFLD phenotype, and preponderant surveillance underuse among NAFLD patients. Finally, we examine the effectiveness of currently used surveillance tools (i.e., ultrasound and alpha fetoprotein) and outline future perspectives including emerging risk stratification tools, imaging surveillance strategies (e.g., abbreviated magnetic resonance imaging protocols), blood-based biomarkers (e.g., GALAD and circulating tumor DNA panels), and interventions to improve surveillance adherence.

Citations

Citations to this article as recorded by  Crossref logo
  • Long-Term Survival and Recurrence in HCC vs. Non-HCC Liver Transplant Recipients: A Two-Decade Longitudinal Analysis
    Mahmoudreza Moein, Bridgette Nixon, Michael Leyderman, Ali Bassir, Brenden Maloney, Abolfazl Jamshidi, Matin Moallem Shahri, Amin Bahreini, Alireza Golkarieh, Reza Saidi
    Journal of Clinical and Experimental Hepatology.2025; 15(3): 102489.     CrossRef
  • Editorial: PIVKA‐II Facilitates Risk Stratification for HCC Following HCV Cure
    Tung‐Hung Su, Wei‐Chih Liao
    Alimentary Pharmacology & Therapeutics.2025; 61(3): 583.     CrossRef
  • NAFLD and NAFLD Related HCC: Emerging Treatments and Clinical Trials
    Tripti Khare, Karina Liu, Lindiwe Oslee Chilambe, Sharad Khare
    International Journal of Molecular Sciences.2025; 26(1): 306.     CrossRef
  • A Risk Prediction Model for Hepatocellular Carcinoma in the General Population Without Traditional Risk Factors for Liver Disease
    Byeong Geun Song, GoEun Park, Myung Ji Goh, Wonseok Kang, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn
    Journal of Gastroenterology and Hepatology.2025; 40(4): 979.     CrossRef
  • Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
    Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang
    Clinical and Molecular Hepatology.2025; 31(Suppl): S228.     CrossRef
  • Hepatocellular carcinoma risk in ICD-coded non-cirrhotic nonalcoholic fatty liver disease refined by fatty liver index: A nationwide South Korean cohort study
    Chang Hun Lee, Min Gu Kang, Shinyoung Oh, In Sun Goak, Chen Shen, Ha Ram Oh, Young Ran Park, Jong Seung Kim, Ji Hyun Park
    Clinics and Research in Hepatology and Gastroenterology.2025; 49(6): 102612.     CrossRef
  • High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease
    Tung-Hung Su, Sheng-Shun Yang, Mei-Hsuan Lee, Wei-Yu Kao, Shang-Chin Huang, Fen-Fang Chen, Francis SK Poon, Lung-Wen Tsai, Yi-Ting Chen, Che Lin, Weichung Wang, W Ray Kim, Jia-Horng Kao
    Clinical and Molecular Hepatology.2025; 31(3): 796.     CrossRef
  • Pathological Evolution and Internal Medicine Management of Nonalcoholic Fatty Liver Disease (NAFLD) in the Era of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Muhammad Moseeb Ali Hashim, Muhammad Aizaz Mohsin Khan, Muhammad Usama Ashraf, Saniya Mohsin, Kamran Zahoor, Javeria Niazi, Aiza Khan, Sania Muzaffar, Madiha Makhdumi, Omar Ahmed Ibad, Talha Kamran Khan, Sohaib Khalid
    Cureus.2025;[Epub]     CrossRef
  • Association Between Dietary Inflammatory Index and NAFLD: A Cross‐Sectional Study of the National Health and Nutrition Examination Survey
    Yuan He, Yuhang Yang, Pengfei Cheng, Wei Zhang, Jinghan Jia, Dawei Ye, Jinxi Wang, Jasbir Arora (RSS)
    Mediators of Inflammation.2025;[Epub]     CrossRef
  • Critical analysis of the liver cancer policies and programs in China: implications for international liver cancer control
    Xianwen Chen, Junnan Shi, Yan Xue, Yunfeng Lai, Menghuan Song, Carolina Oi Lam Ung, Hao Hu
    Global Health Research and Policy.2025;[Epub]     CrossRef
  • A CART-based prognostic model for risk stratification of postoperative early recurrence in hepatocellular carcinoma with microvascular invasion
    Jie Zeng, Ri-Jin Lu, Zheng Tao, Can Zeng, Kai-Xiang Mo, Weijie Cen, Yan Lin, Rong Liang, Le-Qun Li, Guo-Bin Wu, Jia-Zhou Ye, Rong-Yun Mai
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • A multicenter propensity score analysis of significance of hepatic resection type for early-stage hepatocellular carcinoma
    Shi-Chuan Tang, Kai-Ling Zhang, Kong-Ying Lin, Yi-Dan Tang, Jun Fu, Wei-Ping Zhou, Jian-Xi Zhang, Jie Kong, Xiao-Lu He, Zheng-Hong Sun, Cong Luo, Hong-Zhi Liu, Yong-Ping Lai, Yong-Yi Zeng
    Hepatology International.2024; 18(2): 623.     CrossRef
  • A risk prediction model for hepatocellular carcinoma in non‐alcoholic fatty liver disease without cirrhosis
    Gi‐Ae Kim, Yewan Park, Shin Ju Oh, Jooyi Jung, Seungbong Han, Hye‐Sook Chang, Sung Won Park, Tae Hyup Kim, Hye Won Park, Jaewon Choe, Jaeil Kim, Han Chu Lee
    Liver International.2024; 44(3): 738.     CrossRef
  • Diagnostic performance comparisons of two commonly used multi-biomarker-based scores for detection of hepatocellular carcinoma in non-alcoholic fatty liver disease
    Wei Ouyang, Ming-Da Wang, Ming-Cheng Guan, Yong-Kang Diao, Li-Yang Sun, Nan-Ya Wang, Feng Shen, Hong Zhu, Tian Yang
    iLIVER.2024; 3(2): 100098.     CrossRef
  • A review of MASLD-related hepatocellular carcinoma: progress in pathogenesis, early detection, and therapeutic interventions
    Yang Ma, Jinguo Wang, Wenping Xiao, Xiaoming Fan
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma
    Jiwon Hong, Jung Woo Eun, Geum Ok Baek, Jae Youn Cheong, Seryoung Park, Soon Sun Kim, Hyo Jung Cho, Su Bin Lim
    Clinical and Molecular Hepatology.2024; 30(3): 360.     CrossRef
  • Association of physical activity, including amount and maintenance, with the risk of HCC among patients with type 2 diabetes
    Wonkyung Han, Kyungdo Han, Seong Gyu Hwang, Sang Hoon Ahn, Mi Na Kim
    JHEP Reports.2024; 6(10): 101166.     CrossRef
  • MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options
    Yuming Shi, Erfan Taherifard, Ali Saeed, Anwaar Saeed
    Current Issues in Molecular Biology.2024; 46(6): 5965.     CrossRef
  • Mapping the Hidden Terrain of Hepatocellular Carcinoma: Exploring Regional Differences in Incidence and Mortality across Two Decades by Using the Largest US Datasets
    Yazan Abboud, Vraj P. Shah, Michael Bebawy, Ahmed Al-Khazraji, Kaveh Hajifathalian, Paul J. Gaglio
    Journal of Clinical Medicine.2024; 13(17): 5256.     CrossRef
  • Unveiling key drivers of hepatocellular carcinoma: a synergistic approach with network pharmacology, machine learning-driven ligand discovery and dynamic simulations
    D.K. Sabir, J.A. Bin Jumah, I. Ancy
    SAR and QSAR in Environmental Research.2024; 35(11): 1045.     CrossRef
  • Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non‐alcoholic fatty liver disease
    Ho Soo Chun, Minjong Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong‐Ho Lee, Ji‐Hye Kim, Seung Up Kim
    Liver International.2023; 43(3): 608.     CrossRef
  • Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?
    Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang
    Clinical and Molecular Hepatology.2023; 29(2): 404.     CrossRef
  • The latest global burden of liver cancer: A past and present threat
    Joo Hyun Oh, Dae Won Jun
    Clinical and Molecular Hepatology.2023; 29(2): 355.     CrossRef
  • Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: The Next Threat after Viral Hepatitis
    Mohamed Salaheldin, Heba Aly, Louis Lau, Shimaa Afify, Mohamed El-Kassas
    Diagnostics.2023; 13(16): 2631.     CrossRef
  • 14,361 View
  • 219 Download
  • 21 Web of Science
  • Crossref

Original Article

Hepatic neoplasm

Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area
Bo Hyun Kim, Dahhay Lee, Kyu-Won Jung, Young-Joo Won, Hyunsoon Cho
Clin Mol Hepatol 2022;28(2):242-253.
Published online February 7, 2022
DOI: https://doi.org/10.3350/cmh.2021.0355
Background/Aims
Primary liver cancer is one of the leading causes of cancer mortality worldwide. However, the causes of death have not been studied in detail in patients with liver cancer.
Methods
The causes of death and cause-specific mortality risks in patients with primary liver cancer, diagnosed during 2000–2016, were investigated using the nationwide population-based cancer registry data in South Korea (n=231,388). The cumulative incidence function and Fine-Gray models were used to estimate the cause-specific mortality under the competing risks. Risks of non-cancer deaths relative to the general population were compared by standardized mortality ratios (SMRs).
Result
s: Among 179,921 total deaths, 92.4%, 1.7%, and 6.0% of patients died of primary liver cancer, cancer from other sites, and non-cancer illnesses, respectively. Proportionate mortality from liver cancer remained high. The 5-year competing risks probability of death from liver cancer varied by tumor stage, from 42% to 94%, and it remained high 10 years after the diagnosis (61–95%). Competing mortality from other causes has continuously increased. The most common non-cancer causes of death were underlying liver diseases (SMR, 15.6; 95% confidence interval [CI], 15.1–16.1) and viral hepatitis (SMR, 46.5; 95% CI, 43.9–49.2), which demonstrated higher mortality risks compared to the Korean general population. Higher mortality risks of suicide (SMR, 2.6; 95% CI, 2.4–2.8) was also noted.
Conclusions
Patients with liver cancer are most likely to die from liver cancer and related liver disease, even 10 years after the diagnosis, highlighting a need for specialized long-term follow-up care.

Citations

Citations to this article as recorded by  Crossref logo
  • Tenofovir Is Associated With a Better Prognosis Than Entecavir for Hepatitis B Virus–Related Hepatocellular Carcinoma
    Sung Won Chung, Hyun Jun Um, Won-Mook Choi, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee
    Clinical Gastroenterology and Hepatology.2025; 23(2): 300.     CrossRef
  • Survival Benefits of Transarterial Chemoembolization Plus Ablation Therapy in Patients With Intermediate or Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study
    Jingyi Dai, Yadi Ding, Qiaomei Zheng, Guixin Zhao, Lingqing Zou, Jun Zhao, Yu Luo, Virasakdi Chongsuvivatwong
    Cancer Management and Research.2025; Volume 17: 483.     CrossRef
  • Bioactive Secondary Metabolites from Bauhinia variegata Linn. Roots: Isolation, Characterization, and Cytotoxic Evaluation
    Yousaf Kamal, Nighat Fatima, Amara Mumtaz, Irum Shahzadi, Abdul Mannan, Gerardo D. Anaya-Eugenio, Eric Daniel Salinas Arellano, Madiha Ahmed, Zahid Hussain, Esperanza J. Carcache de Blanco
    Current Pharmaceutical Design.2025; 31(15): 1239.     CrossRef
  • Pharmacological Evaluation of Angelica keiskei Extract: Molecular Interaction Analysis in Hepatocellular Carcinoma
    Alka Ashok Singh, Minseok Song, Gun-Do Kim
    Current Issues in Molecular Biology.2025; 47(6): 401.     CrossRef
  • Sex Disparity in Cancer and Non-cancer Mortality among Korean Cancer Survivors
    Ansun Jeong, Soyeoun Kim, Somin Jeon, Boyoung Park
    Journal of Cancer Prevention.2025; 30(4): 196.     CrossRef
  • Development and validation of a nomogram for predicting moderate-to-severe pain in hepatitis B virus-related liver cancer patients after CyberKnife treatment
    Yating Chi
    American Journal of Translational Research.2025; 17(9): 7058.     CrossRef
  • Association between Unplanned Conversion and Patient Survival after Laparoscopic Liver Resection for Hepatocellular Carcinoma: A Propensity Score Matched Analysis
    Boram Lee, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, MeeYoung Kang, Yeshong Park, Jinju Kim
    Journal of Clinical Medicine.2024; 13(4): 1116.     CrossRef
  • Achieving Textbook Outcomes after Laparoscopic Resection in Posterosuperior Segments of the Liver: The Impact of the Learning Curve
    Mizelle D’Silva, Jai-Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae-Won Lee, Bo-Ram Lee, Mee-Young Kang, Ye-Shong Park, Jin-Ju Kim
    Cancers.2024; 16(5): 930.     CrossRef
  • Organ‐specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicentre, retrospective study
    Jaekyung Cheon, Sanghoon Jung, Jung Sun Kim, Beodeul Kang, Hyeyoung Kim, Landon L. Chan, Lars Becker, Vincent E. Gaillard, Stephen L. Chan, Chan Kim, Hong Jae Chon
    Liver International.2024; 44(8): 1961.     CrossRef
  • Development and validation of a prognostic nomogram including inflammatory indicators for overall survival in hepatocellular carcinoma patients treated primarily with surgery or loco-regional therapy: A single-center retrospective study
    Xin Wang, Jing Xu, Zhenya Jia, Guoping Sun
    Medicine.2024; 103(50): e40889.     CrossRef
  • Development and validation of prognostic nomograms for large hepatocellular carcinoma after HAIC
    Wang Yao, Ran Wei, Jia Jia, Wang Li, Mengxuan Zuo, Shuqing Zhuo, Ge Shi, Peihong Wu, Chao An
    Therapeutic Advances in Medical Oncology.2023;[Epub]     CrossRef
  • Impact of sarcopenia on clinical outcomes for patients with resected hepatocellular carcinoma: a retrospective comparison of Eastern and Western cohorts
    Berend R. Beumer, Kosei Takagi, Stefan Buettner, Yuzo Umeda, Takahito Yagi, Toshiyoshi Fujiwara, Jeroen L.A. van Vugt, Jan N.M. IJzermans
    International Journal of Surgery.2023; 109(8): 2258.     CrossRef
  • Isolated Hepatitis B Core Antibody Positivity and Long-Term Liver-Related Mortality in Korea: A Cohort Study
    Won Sohn, Yoosoo Chang, Yong Kyun Cho, Yun Soo Hong, Seungho Ryu
    American Journal of Gastroenterology.2023; 118(1): 95.     CrossRef
  • Barriers to palliative care in hepatocellular carcinoma: A review of the literature
    Mostafa Abasseri, Shakira Hoque, BA Slavica Kochovska, Kim Caldwell, Linda Sheahan, Amany Zekry
    Journal of Gastroenterology and Hepatology.2023; 38(7): 1047.     CrossRef
  • Dihydrotanshinone I inhibits hepatocellular carcinoma cells proliferation through DNA damage and EGFR pathway
    Linjun Wang, Xiangwei Xu, Dexing Chen, Chenghang Li
    PeerJ.2023; 11: e15022.     CrossRef
  • Primary non-response to antiviral therapy affects the prognosis of hepatitis B virus-related hepatocellular carcinoma
    Peng Wang, Xinhui Wang, Xiaoli Liu, Fengna Yan, Huiwen Yan, Dongdong Zhou, Lihua Yu, Xianbo Wang, Zhiyun Yang
    BMC Cancer.2023;[Epub]     CrossRef
  • Identification of ELOVL3 as a novel prognostic marker for liver cancer
    Yiyang Chen, Wanbang Zhou, Yiju Gon, Xi Ou
    AFMN Biomedicine.2023; 40(3): 279.     CrossRef
  • Applications of molecular barcode sequencing for the detection of low‐frequency variants in circulating tumour DNA from hepatocellular carcinoma
    Hye Won Lee, Esl Kim, Kyung Joo Cho, Hye Jung Park, Jieun Seo, Hyeonah Lee, Eunha Baek, Jong Rak Choi, Kwang‐Hyub Han, Seung‐Tae Lee, Jun Yong Park
    Liver International.2022; 42(10): 2317.     CrossRef
  • Incidence, mortality, and survival of liver cancer using Korea central cancer registry database: 1999-2019
    Sung Yeon Hong, Mee Joo Kang, Taegyu Kim, Kyu-Won Jung, Bong-Wan Kim
    Annals of Hepato-Biliary-Pancreatic Surgery.2022; 26(3): 211.     CrossRef
  • 10,279 View
  • 148 Download
  • 21 Web of Science
  • Crossref

Review

Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance
Mina Komuta
Clin Mol Hepatol 2022;28(3):396-407.
Published online January 14, 2022
DOI: https://doi.org/10.3350/cmh.2021.0287
Treatment of intrahepatic cholangiocarcinoma (iCCA) is currently at a significant turning point due to the identification of isocitrate dehydrogenase (IDH) mutations and fibroblast growth factor receptor (FGFR) fusions that can be targeted with currently available therapies. Clinical trials of these targeted therapies have been promising, and the iCCA patients who may benefit from these targeted treatments can be identified by pathological examination prior to molecular investigations. This is because IDH mutations and FGFR fusions are mainly seen in the small duct type iCCA, a subtype of iCCA defined by the 5th World Health Organization classification, which can be recognized by the pathological diagnostic process. Therefore, pathology plays an important role in precision medicine for iCCA, not only in confirming the diagnosis, but also in identifying the iCCA patients who may benefit from targeted treatments. However, caution is advised with the pathological diagnosis, as iCCA shows tumour heterogeneity, making it difficult to distinguish small duct type iCCA from hepatocellular carcinoma (HCC), and combined HCC-CCA. This review focuses on the pathological/molecular features of both subtypes of iCCA (large and small duct types), as well as their diagnostic pitfalls, clinical relevance, and future perspectives.

Citations

Citations to this article as recorded by  Crossref logo
  • FXYD3 Promotes Tumor Progression by Binding With IRF7 to Regulate JAK2/STAT5 Signaling in Intrahepatic Cholangiocarcinoma
    Yan Zhou, Xiaofeng Shen, Shuo Zhang, XiaoHong Pu, Zipeng Xu, Xiang Zhao, Wei Feng, Yuan Liang, Xingtao He, Aihua Yang, Yudong Qiu, Yihang Yuan, Chaobo Chen, Jun Chen
    Advanced Science.2026;[Epub]     CrossRef
  • Lactate metabolism-driven tumor heterogeneity and molecular signatures in intrahepatic cholangiocarcinoma
    An-Ke Wu, Jun-Yi Li, Kai Zhang, Martin Meng, Xue Wang, Yue Liu, Peng Xie, Wei-Qi Rong, Fan Wu, Hong-Guang Wang, Xuan Meng, Jian-Xiong Wu
    World Journal of Gastroenterology.2026;[Epub]     CrossRef
  • Surgical interpretation of the WHO subclassification of intrahepatic cholangiocarcinoma: a narrative review
    Masayuki Akita, Hiroaki Yanagimoto, Daisuke Tsugawa, Yoh Zen, Takumi Fukumoto
    Surgery Today.2025; 55(1): 1.     CrossRef
  • Standardizing the reporting of cholangiocarcinoma: the society of abdominal radiology disease focused panel on cholangiocarinoma lexicon
    Robert M. Marks, Hina Arif, Maria Antonietta Bali, Ryan L. Brunsing, Guilherme M. Cunha, Hala Khasawneh, Maria El Homsi, Charanjeet Singh, Raj Paspulati, Andrea Kierans, Aliya Qayyum
    Abdominal Radiology.2025; 50(7): 2858.     CrossRef
  • SQSTM1/p62 confers resistance of intrahepatic cholangiocarcinoma cells to 5-Fluorouracil by promoting Nrf2 nuclear translocation
    Xuanming Luo, Qinwen Tai, Xuan Liu, Xingni Zhou, Wenxiang Li, Houbao Liu, Zhenbin Ding, Miyesaier Abudureyimu
    Molecular & Cellular Toxicology.2025; 21(4): 917.     CrossRef
  • Correspondence to editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma”
    Yu-Hang Ye, Shao-Lai Zhou
    Clinical and Molecular Hepatology.2025; 31(1): e90.     CrossRef
  • Conversion treatment for advanced intrahepatic cholangiocarcinoma: Opportunities and challenges
    Jun-Jie Liu, Mi Zhou, Tong Yuan, Zhi-Yong Huang, Zun-Yi Zhang
    World Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Contrast-enhanced ultrasound imaging characteristics of intrahepatic cholangiocarcinoma with actionable gene variants detected by comprehensive cancer gene panel testing
    Kazunori Nakaoka, Eizaburo Ohno, Seiji Yamada, Teiji Kuzuya, Tamotsu Sudo, Sayaka Ueno, Hiroyuki Tanaka, Yutaka Sasaki, Ryoji Miyahara, Senju Hashimoto, Yoshiki Hirooka
    International Journal of Clinical Oncology.2025; 30(7): 1398.     CrossRef
  • Diagnosis and Treatment of Intrahepatic Cholangiocarcinoma
    Takamichi Ishii, Etsuro Hatano
    Kanzo.2025; 66(6): 213.     CrossRef
  • Comparison of MRI and prognostic features of intrahepatic cholangiocarcinoma between patients with and without hepatitis B virus infection
    Se Jin Choi, Dong Hwan Kim, Sang Hyun Choi, So Yeon Kim, Seung Soo Lee, Jae Ho Byun, Hyung Jin Won, Yong Moon Shin
    Abdominal Radiology.2025; 50(12): 5820.     CrossRef
  • Association between ultrasound-based biliary and parenchymal intrahepatic mass-forming cholangiocarcinoma subtypes and clinicopathological features and survival
    Cong-Jian Wen, Hui Liu, Li-Ping Sun, Chong-Ke Zhao, Hao-Hao Yin, Li-Fan Wang, Ming-Rui Zhu, Yi-Kang Sun, Ya-Qin Zhang, Zi-Tong Chen, Xi Wang, Han-Sheng Xia, Hong Han, Hui-Xiong Xu, Bo-Yang Zhou
    Insights into Imaging.2025;[Epub]     CrossRef
  • Liver transplantation for intrahepatic cholangiocarcinoma: Insights from a National Registry Study in China
    Pengcheng Wei, Delin Ma, Chen Lo, Yongjing Luo, Jie Gao, Lei Huang, Jiye Zhu, Guangming Li, Shusen Zheng, Zhao Li
    Medicine.2025; 104(42): e44942.     CrossRef
  • Exploratory study on the role of Clonorchis sinensis infection in promoting cholangiocarcinoma progression
    Shitao Li, Yiqi Jiang, Jun Kawanokuchi, Xueling Deng, Yuhong Wu, Yu Chen, Lixia Zeng, Ganghuan Deng, Damian Li, Tingzheng Zhan, Dengyu Liu, Ning Ma, Zeli Tang
    Parasites & Vectors.2025;[Epub]     CrossRef
  • Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management
    Liangtao Ye, Julia S. Schneider, Najib Ben Khaled, Peter Schirmacher, Carolin Seifert, Lea Frey, Yulong He, Andreas Geier, Enrico N. De Toni, Changhua Zhang, Florian P. Reiter
    Liver Cancer.2024; 13(1): 6.     CrossRef
  • UBA3 promotes the occurrence and metastasis of intrahepatic cholangiocarcinoma through MAPK signaling pathway
    Huhu Zhang, Jiahua Yang, Qinghang Song, Xiaoyan Ding, Fulin Sun, Lina Yang
    Acta Biochimica et Biophysica Sinica.2024; 56(2): 199.     CrossRef
  • Intrahepatic cholangiocarcinoma: histological diversity and the role of the pathologist
    Mina Komuta
    Journal of Liver Cancer.2024; 24(1): 17.     CrossRef
  • Targeted therapies in advanced biliary malignancies: a clinical review
    Udhayvir S. Grewal, Shiva J. Gaddam, Muhammad S. Beg, Timothy J. Brown
    Expert Review of Anticancer Therapy.2024; 24(9): 869.     CrossRef
  • Identification of molecular subtypes based on bile acid metabolism in cholangiocarcinoma
    Mingxia Deng, Jing Liu, Li Zhang, Yan Lou, Yunqing Qiu
    BMC Cancer.2024;[Epub]     CrossRef
  • Integrative analysis of multiple genomic data from intrahepatic cholangiocarcinoma organoids enables tumor subtyping
    Hee Seung Lee, Dai Hoon Han, Kyungjoo Cho, Soo Been Park, Chanyang Kim, Galam Leem, Dawoon E. Jung, Soon Sung Kwon, Chul Hoon Kim, Jung Hyun Jo, Hye Won Lee, Si Young Song, Jun Yong Park
    Nature Communications.2023;[Epub]     CrossRef
  • Establishment and characterization of a new intrahepatic cholangiocarcinoma cell line, ICC-X3
    Hao Xu, Wei Luo, Zhenjie Zhao, Xin Miao, Changpeng Chai, Jinjing Hu, Huan Tang, Hui Zhang, Wence Zhou
    Human Cell.2023; 36(2): 854.     CrossRef
  • A Case of Prostatic Metastasis from Intrahepatic Cholangiocarcinoma: An Extremely Rare Event
    Sanathan Aiyadurai, Tulika Garg, Tass Sayeed, Zainab Shahbaz, Idowu O Adewole, Enoh Nguty Nkeng, Abia Joseph, Datiobong Udoeyop, Yusra Qamar, Aadil Khan
    Cureus.2023;[Epub]     CrossRef
  • Non-Inflamed Tumor Microenvironment and Methylation/Downregulation of Antigen-Presenting Machineries in Cholangiocarcinoma
    Naoshi Nishida, Tomoko Aoki, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Hiroshi Ida, Satoru Hagiwara, Yasunori Minami, Kazuomi Ueshima, Masatoshi Kudo
    Cancers.2023; 15(8): 2379.     CrossRef
  • Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies
    Xianzhe Yu, Lingling Zhu, Ting Wang, Jiang Chen
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Clinicopathological, etiological and molecular characteristics of intrahepatic cholangiocarcinoma subtypes classified by mucin production and immunohistochemical features
    Yi Chen, Xiaoling Liu, Liyun Huang, Lihong Chen, Bin Wang
    Expert Review of Molecular Diagnostics.2023; 23(5): 445.     CrossRef
  • MCM6 promotes intrahepatic cholangiocarcinoma progression by upregulating E2F1 and enhancing epithelial–mesenchymal transition
    Chongqing Gao, Jing Li, Fuling Zeng, Lijuan Wang, Kaiyun Chen, Dong Chen, Jian Hong, Chen Qu
    Carcinogenesis.2023; 44(4): 279.     CrossRef
  • Novel cell subtypes of SPP1 + S100P+, MS4A1-SPP1 + S100P+ were key subpopulations in intrahepatic cholangiocarcinoma
    Zixue Xuan, Linqing Liu, Guobing Zhang, Xiaowei Zheng, Jinying Jiang, Kai Wang, Ping Huang
    Biochimica et Biophysica Acta (BBA) - General Subjects.2023; 1867(9): 130420.     CrossRef
  • Liver Transplantation for Incidental Cholangiocarcinoma or Combined Hepatocellular Carcinoma/Cholangiocarcinoma—Own Experiences and Review of the Literature
    Laura Schwenk, Oliver Rohland, Aladdin Ali-Deeb, Felix Dondorf, Utz Settmacher, Falk Rauchfuß
    Cancers.2023; 15(14): 3609.     CrossRef
  • Beyond the Lab and Into the Hospital: An Outlook on the Clinical Utility of Spatial Omics Technologies
    Dean M. Pucciarelli, Benjamin Y. Lu, Inti Zlobec, Marcello DiStasio
    GEN Biotechnology.2023; 2(5): 360.     CrossRef
  • Targeted mutation-based therapy for intrahepatic cholangiocarcinoma
    Facai Yang, Yinghe Qiu, Bin Yi
    Hepatoma Research.2023;[Epub]     CrossRef
  • Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions
    Rocio I R Macias, Vincenzo Cardinale, Timothy J Kendall, Matias A Avila, Maria Guido, Cedric Coulouarn, Chiara Braconi, Adam E Frampton, John Bridgewater, Diletta Overi, Stephen P Pereira, Marco Rengo, Jakob N Kather, Angela Lamarca, Federica Pedica, Alej
    Gut.2022; 71(8): 1669.     CrossRef
  • 12,218 View
  • 408 Download
  • 30 Web of Science
  • Crossref

Editorial

Hepatic neoplasm

Biopsy or cytology for diagnosing hepatic focal lesions?
Haeryoung Kim
Clin Mol Hepatol 2021;27(2):278-280.
Published online March 4, 2021
DOI: https://doi.org/10.3350/cmh.2021.0031

Citations

Citations to this article as recorded by  Crossref logo
  • The utility of next‐generation sequencing in challenging liver FNA biopsies
    Dana J. Balitzer, Nancy Y. Greenland
    Cancer Cytopathology.2024; 132(11): 714.     CrossRef
  • Laser tweezer Raman spectroscopy combined with deep neural networks for identification of liver cancer cells
    Weng Shuyun, Fengjie Lin, Changbin Pan, Qiyi Zhang, Hong Tao, Min Fan, Luyun Xu, Kien Voon Kong, Yuanmei Chen, Duo Lin, Shangyuan Feng
    Talanta.2023; 264: 124753.     CrossRef
  • 6,701 View
  • 93 Download
  • 2 Web of Science
  • Crossref

Original Article

Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance
Jeong Won Jang, Jin Seoub Kim, Hye Seon Kim, Kwon Yong Tak, Heechul Nam, Pil Soo Sung, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Lewis R. Roberts
Clin Mol Hepatol 2021;27(1):207-218.
Published online December 3, 2020
DOI: https://doi.org/10.3350/cmh.2020.0115
Background/Aims
The role of hepatitis B virus (HBV) integration into the host genome in hepatocarcinogenesis following hepatitis B surface antigen (HBsAg) seroclearance remains unknown. Our study aimed to investigate and characterize HBV integration events in chronic hepatitis B (CHB) patients who developed hepatocellular carcinoma (HCC) after HBsAg seroclearance.

Methods
Using probe-based HBV capturing followed by next-generation sequencing technology, HBV integration was examined in 10 samples (seven tumors and three non-tumor tissues) from seven chronic carriers who developed HCC after HBsAg loss. Genomic locations and patterns of HBV integration were investigated.

Result
s: HBV integration was observed in six patients (85.7%) and eight (80.0%) of 10 tested samples. HBV integration breakpoints were detected in all of the non-tumor (3/3, 100%) and five of the seven (71.4%) tumor samples, with an average number of breakpoints of 4.00 and 2.43, respectively. Despite the lower total number of tumoral integration breakpoints, HBV integration sites in the tumors were more enriched within the genic area. In contrast, non-tumor tissues more often showed intergenic integration. Regarding functions of the affected genes, tumoral genes with HBV integration were mostly associated with carcinogenesis. At enrollment, patients who did not remain under regular HCC surveillance after HBsAg seroclearance had a large HCC, while those on regular surveillance had a small HCC.

Conclusions
The biological functions of HBV integration are almost comparable between HBsAg-positive and HBsAgserocleared HCCs, with continuing pro-oncogenic effects of HBV integration. Thus, ongoing HCC surveillance and clinical management should continue even after HBsAg seroclearance in patients with CHB.

Citations

Citations to this article as recorded by  Crossref logo
  • Landscape of Somatic and Age‐Related Pathogenic Structural Variations in Hepatocellular Carcinoma Revealed by Long‐Read Sequencing
    Zhewen Wei, Yinghao Cao, Hongchao Liu, Mei Liu, Bolun Zhang, Jianming Ying, Jianqiang Cai, Xinyu Bi, Jianjun Zhao, Jianguo Zhou, Zhiyu Li, Zhen Huang, Jianmei Liu, Xueyan Lv, Zhiwen Luo, Zhicheng Wei, Xiaoshi Zhang, Yi Yang, Yiqiao Deng, Yanjiang Yin, Jin
    MedComm.2026;[Epub]     CrossRef
  • Statistical Cure After Hepatectomy for Hepatitis B Virus-Associated Hepatocellular Carcinoma: A Risk-Stratification Model
    Yi-Fan Li, Lan-Qing Yao, Chao Li, Hong Ren, Jin-Bo Gong, Han Wu, Li-Hui Gu, Ying-Jian Liang, Yu-Ze Yang, Kong-Ying Lin, Zi-Qiang Li, Qi-Xuan Zheng, Ting-Hao Chen, Ya-Hao Zhou, Hong Wang, Hong-Wei Guo, Jia-Hao Xu, Zhong Chen, Feng Shen, Ming-Da Wang, Tian
    Annals of Surgical Oncology.2025; 32(6): 4396.     CrossRef
  • Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0
    Di Wu, Jia-Horng Kao, Teerha Piratvisuth, Xiaojing Wang, Patrick T.F. Kennedy, Motoyuki Otsuka, Sang Hoon Ahn, Yasuhito Tanaka, Guiqiang Wang, Zhenghong Yuan, Wenhui Li, Young-Suk Lim, Junqi Niu, Fengmin Lu, Wenhong Zhang, Zhiliang Gao, Apichat Kaewdech,
    Clinical and Molecular Hepatology.2025; 31(Suppl): S134.     CrossRef
  • Prediction of long-term HBsAg seroclearance in patients with HBeAg-negative chronic hepatitis B
    Hae Lim Lee, Soon Kyu Lee, Ji Won Han, Hyun Yang, Heechul Nam, Pil Soo Sung, Hee Yeon Kim, Sung Won Lee, Do Seon Song, Jung Hyun Kwon, Chang Wook Kim, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang
    JHEP Reports.2025; 7(7): 101391.     CrossRef
  • Male preference for TERT alterations and HBV integration in young-age HBV-related HCC: implications for sex disparity
    Jin Seoub Kim, Hye Seon Kim, Kwon Yong Tak, Ji Won Han, Heechul Nam, Pil Soo Sung, Sung Won Lee, Jung Hyun Kwon, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang
    Clinical and Molecular Hepatology.2025; 31(2): 509.     CrossRef
  • Risk of Hepatocellular Carcinoma Decreases After Antiviral Therapy–Induced HBsAg Seroclearance
    Han Ah. Lee, Hyun Woong Lee, Yeon Seok Seo, Dong Hyun Sinn, Sang Hoon Ahn, Beom Kyung Kim, Seung Up Kim
    Journal of Gastroenterology and Hepatology.2025; 40(7): 1675.     CrossRef
  • Distinguishing True Immune Tolerant Hepatitis B Patients: Insights From Long‐Term Clinical Outcomes
    Jung Hyun Kwon, Sung Won Lee, Hee‐Yeon Kim, Do Seon Song, Soon Kyu Lee, Heechul Nam, Soon Woo Nam, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang
    Journal of Viral Hepatitis.2025;[Epub]     CrossRef
  • Functional cure of chronic hepatitis B virus infection: current therapeutic regimens
    Yi-Wei Shi, Rui Pu, Yi-Bo Ding, Wen-Bin Liu, Zi-Shuai Li, Jia-Yi Zhao, Yi-Fan Chen, Guang-Wen Cao
    Hepatoma Research.2025;[Epub]     CrossRef
  • Detection of HBV DNA integration in plasma cell-free DNA of different HBV diseases utilizing DNA capture strategy
    Zerui Yang, Jingyan Zeng, Yueyue Chen, Mengchun Wang, Hongchun Luo, Ai-Long Huang, Haijun Deng, Yuan Hu
    Virologica Sinica.2024; 39(4): 655.     CrossRef
  • Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on “Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients”
    Hae Lim Lee, Jeong Won Jang
    Clinical and Molecular Hepatology.2024; 30(4): 692.     CrossRef
  • The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy
    Mingming Zhang, Han Chen, Huan Liu, Hong Tang
    Biomarker Research.2024;[Epub]     CrossRef
  • Hepatocellular carcinoma in HBsAg seroclearance: clinical features, recurrence, and prognosis following curative hepatectomy
    Wei Xu, Huai Gong, Bolun Li, Xinmin Yin
    Therapeutic Advances in Medical Oncology.2024;[Epub]     CrossRef
  • Surveillance Following Hepatitis B Surface Antigen Loss: An Issue Requiring Attention
    Shuai-Wen Huang, Hong Long, Jia-Quan Huang
    Pathogens.2024; 14(1): 8.     CrossRef
  • Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    European Journal of Internal Medicine.2023; 107: 66.     CrossRef
  • Comparable Mortality Between Asian Patients with Chronic Hepatitis B Under Long-Term Antiviral Therapy vs Matched Control: A Population-Based Study
    Byungyoon Yun, Juyeon Oh, Sang Hoon Ahn, Jin-Ha Yoon, Beom Kyung Kim
    American Journal of Gastroenterology.2023; 118(6): 1001.     CrossRef
  • Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim
    European Journal of Clinical Investigation.2023;[Epub]     CrossRef
  • A longitudinal study to detect hepatitis B surface and core-related antigens in chronic hepatitis B patients with hepatitis B surface antigen seroclearance using highly sensitive assays
    Danny Ka-Ho Wong, Takako Inoue, Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Ka-Shing Cheung, Wai-Kay Seto, Yasuhito Tanaka, Man-Fung Yuen
    Journal of Clinical Virology.2023; 160: 105375.     CrossRef
  • Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis
    Han Ah Lee, Seung Up Kim, Yeon Seok Seo, Sang Hoon Ahn, Chai Hong Rim
    Hepatology Communications.2023; 7(2): e0011.     CrossRef
  • Effects of hepatitis B virus infection and strategies for preventing mother-to-child transmission on maternal and fetal T-cell immunity
    Huihui Lu, Weihua Cao, Luxue Zhang, Liu Yang, Xiaoyue Bi, Yanjie Lin, Wen Deng, Tingting Jiang, Fangfang Sun, Zhan Zeng, Yao Lu, Lu Zhang, Ruyu Liu, Yuanjiao Gao, Shuling Wu, Hongxiao Hao, Xiaoxue Chen, Leiping Hu, Mengjiao Xu, Qiqiu Xiong, Jianping Dong,
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • The role of different viral biomarkers on the management of chronic hepatitis B
    Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai Kay Seto, Man-Fung Yuen
    Clinical and Molecular Hepatology.2023; 29(2): 263.     CrossRef
  • Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis
    Daniel Q. Huang, Nobuharu Tamaki, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Hye Won Lee, Seng Gee Lim, Tae Seop Lim, Masayuki Kurosaki, Hiroyuki Marusawa, Toshie Mashiba, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Namiki Izumi,
    Hepatology.2023; 77(5): 1746.     CrossRef
  • Efficacy of Antiviral Prophylaxis up to 6 or 12 Months From Completion of Rituximab in Resolved Hepatitis B Patients: A Multicenter, Randomized Study
    Heejoon Jang, Su Jong Yu, Hong Ghi Lee, Tae Min Kim, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Jung-Hwan Yoon, Yoon Jun Kim
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy
    Beom Kyung Kim, Sang Hoon Ahn
    Journal of the Formosan Medical Association.2023; 122(12): 1238.     CrossRef
  • Reply to: ‘A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Has the correct patient cohort been targeted?’
    Hyun Yang, Ji Hoon Kim, Ji Won Han, Soon Kyu Lee, Jeong Won Jang
    Journal of Hepatology.2023; 79(4): e155.     CrossRef
  • A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance
    Hyun Yang, Si Hyun Bae, Heechul Nam, Hae Lim Lee, Sung Won Lee, Sun Hong Yoo, Myeong Jun Song, Jung Hyun Kwon, Soon Woo Nam, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang
    Journal of Hepatology.2022; 77(3): 632.     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B

    Clinical and Molecular Hepatology.2022; 28(2): 276.     CrossRef
  • The Investigation of Hepatitis B Vaccine Immune Responses in Occult Hepatitis B Virus-Infected Patients
    Jing Peng, Xueying Yao, Chunyan Yuan, Xiaoli Liu, Renxiang Xia, Jian He, Rui Li, Yunqing Yao
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    Cancers.2022; 14(20): 5002.     CrossRef
  • Hepatitis B virus DNA integration as a novel biomarker of hepatitis B virus-mediated pathogenetic properties and a barrier to the current strategies for hepatitis B virus cure
    Romina Salpini, Stefano D’Anna, Livia Benedetti, Lorenzo Piermatteo, Upkar Gill, Valentina Svicher, Patrick T. F. Kennedy
    Frontiers in Microbiology.2022;[Epub]     CrossRef
  • Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis
    Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim
    Diagnostics.2022; 13(1): 3.     CrossRef
  • Comprehensive investigation of HBV-related hepatocellular carcinoma and choice of anti-HBV therapy
    Huihui Lu, Wei Yi, Fangfang Sun, Zhan Zeng, Lu Zhang, Minghui Li, Yao Xie
    Biosafety and Health.2021; 3(4): 190.     CrossRef
  • Viral Biomarkers for Hepatitis B Virus-Related Hepatocellular Carcinoma Occurrence and Recurrence
    Yuanyuan Liu, Vaishnavi Veeraraghavan, Monica Pinkerton, Jianjun Fu, Mark W. Douglas, Jacob George, Thomas Tu
    Frontiers in Microbiology.2021;[Epub]     CrossRef
  • Association between HBs Ag quantification and the risk of hepatocellular carcinoma in patients treated with tenofovir disoproxil fumarate or entecavir
    Jung Hyun Lim, Jung Hwan Yu, Young Ju Suh, Jin-Woo Lee, Young-Joo Jin
    Medicine.2021; 100(39): e27417.     CrossRef
  • Distinct Patterns of HBV Integration and TERT Alterations between in Tumor and Non-Tumor Tissue in Patients with Hepatocellular Carcinoma
    Jeong-Won Jang, Hye-Seon Kim, Jin-Seoub Kim, Soon-Kyu Lee, Ji-Won Han, Pil-Soo Sung, Si-Hyun Bae, Jong-Young Choi, Seung-Kew Yoon, Dong-Jin Han, Tae-Min Kim, Lewis R. Roberts
    International Journal of Molecular Sciences.2021; 22(13): 7056.     CrossRef
  • 10,892 View
  • 275 Download
  • 37 Web of Science
  • Crossref

Special topic: Alcoholic liver diseases
The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Hepatic neoplasm

Alcohol and hepatocarcinogenesis
Makiko Taniai
Clin Mol Hepatol 2020;26(4):736-741.
Published online October 1, 2020
DOI: https://doi.org/10.3350/cmh.2020.0203
An excessive alcohol intake may result in fatty liver, acute/chronic hepatitis, cirrhosis, and lead to hepatocellular carcinoma (HCC). The aim of this review is to clarify the present condition and the mechanisms of alcohol-related hepatocarcinogenesis and clinical risk factors for alcohol-related HCC. There are several possible mechanisms through which alcohol may induce hepatocarcinogenesis, including the mutagenic effects of acetaldehyde toxicity through the formation of protein and DNA adducts and the production of reactive oxygen species due to the excessive hepatic deposition of iron, changes to lipid peroxidation and metabolism, inflammation and an impaired immune response and modifications to DNA methylation. Furthermore, it has been reported that alcohol accelerates liver carcinogenesis through several signaling pathways including gut-liver axis. From a clinical perspective, it is well known that alcohol interacts with other factors, such as age, gender, viral hepatitis, obesity, and diabetes leading to an increased risk of HCC.

Citations

Citations to this article as recorded by  Crossref logo
  • Leveraging cancer metabolism to translate into effective therapeutics
    Jie Xu, Linlin Guo, Yi Wang, Xiaoping Li, Ping Yi, Chunming Cheng
    Seminars in Cancer Biology.2026; 118: 44.     CrossRef
  • Liver cancer risk stratification using deep learning on nationwide longitudinal health screening data: a retrospective cohort study
    Yewon Choi, Sungmin Cho, Changdai Gu, Chungho Kim, Bomi Park, Hwiyoung Kim
    BMC Medical Informatics and Decision Making.2026;[Epub]     CrossRef
  • A Multi-Stimuli-Responsive Steroid-Based Nanosystem for Apigenin Delivery and Time-Dependent Anti-HCC Activity In Vitro
    Luwen Luo, Yaoxiao Liang, Luchang Chen, Weipeng Yang, Shenglin You, Chunying Luo, Cheng Lin
    Journal of Inorganic and Organometallic Polymers and Materials.2026;[Epub]     CrossRef
  • NADH-Activated Near-Infrared Fluorescent Probe for Efficient Screening of ADH/ALDH2 Dual Agonists for Alcohol Detoxification
    Jiwei Li, Xunfang Ding, Qilin Zhou, Lei Sun, Jin Yan, Qian Li, Hao Liu, Renshi Li, Fanchao Feng, Bo Chen, Jiangwei Tian
    Analytical Chemistry.2026;[Epub]     CrossRef
  • Global, regional, and national burden of liver cancer due to alcohol use, 1990–2021: results from the Global Burden of Disease study 2021
    Qihong Wang, Wen Jia, Jiao Liu, Qian Zhao, Zhuo Yang
    European Journal of Gastroenterology & Hepatology.2025; 37(4): 466.     CrossRef
  • Construction and validation of a diagnostic model for cholangiocarcinoma based on tumor-educated platelet RNA expression profiles
    Haiyang Hu, Jiefeng He, Haoliang Zhao
    Oncologie.2025; 27(2): 277.     CrossRef
  • Role of hepatotropic viruses in promoting hepatocellular carcinoma—current knowledge and recent advances
    Piotr Starnawski, Klaudia Nowak, Zuzanna Augustyn, Dominik Malicki, Aleksandra Piąta, Dominika Lorek, Jakub Janczura
    Medical Oncology.2025;[Epub]     CrossRef
  • Current status and perspectives of molecular mechanisms of gender difference in hepatocellular carcinoma: The tip of the iceberg?
    Zhi-Quan Xu, Shi-Qiao Luo, Zhong-Jun Wu, Rui Liao
    BioScience Trends.2025; 19(3): 266.     CrossRef
  • The epidemiology, etiology, and future prophylactic options for cancers in Mainland China
    Hongsen Chen, Jie Xu, Wenbin Liu, Xi Chen, Ping Li, Guangwen Cao
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Reactive Oxygen Species as Key Molecules in the Pathogenesis of Alcoholic Fatty Liver Disease and Nonalcoholic Fatty Liver Disease: Future Perspectives
    Zhiqing Zhang, Hong Yang, Fei Han, Peng Guo
    Current Issues in Molecular Biology.2025; 47(6): 464.     CrossRef
  • Hepatocellular carcinoma in patients without cirrhosis
    Karina Sato-Espinoza, Mayra Valdivia-Herrera, Perapa Chotiprasidhi, Javier Diaz-Ferrer
    World Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Gut bacteria and the host synergies promote resveratrol metabolism and induce tolerance in ALD mice
    Song-xia Zhang, Fang-fang Hu, Huan Chen, Jing Guo, Zhong-wen Xiang, Xin Ding, Meng-ling Ye, Wen-li Ye, Jun-hong Chen, Xin Wang, Wen-jing Han, Hong-hao Zhou, Wei Zhang, Yun Huang, Lie-lin Wu, Guang-hui Lian, Yao Chen
    npj Biofilms and Microbiomes.2025;[Epub]     CrossRef
  • Cis-Regulatory Alterations in FOXP4 Modulate Esophageal Cancer Susceptibility Induced by Chronic Alcohol Exposure
    Siyuan Niu, Jialing Ma, Shasha Liu, Yueping Li, Xinying Yue, Miaoxin Pan, Lina Song, Yutong Wu, Zifei Yang, Yuqian Tan, Linglong Gu, Chaolong Wang, Jiang Chang
    Cancer Research.2025; 85(14): 2591.     CrossRef
  • Identification of a novel ferroptosis-related gene signature in hepatocellular carcinoma: clinical significance, tumor microenvironment, drug sensitivity, and gene landscape analysis
    Yunzhao Hu, Chenchen Hao, Chengyuan Dong, Ping Tao, Jia Wang, Qun Lu
    Discover Oncology.2025;[Epub]     CrossRef
  • Precision Strategy for Hepatocellular Carcinoma Surveillance after Hepatitis C Cure: Debates across Guidelines
    Masaaki Mino, Eiji Kakazu, Tatsuya Kanto
    Gut and Liver.2025; 19(5): 651.     CrossRef
  • Construction of a hepatocellular carcinoma high-risk population rating scale and independent predictors' assessment
    Manyu Li, Jing Sun, Yan Wang, Jun Ma, Xiaotian Hao, Yan Liu, Cheng Zhou, Haiwei Zhou
    The American Journal of the Medical Sciences.2024; 367(3): 181.     CrossRef
  • Contributing roles of mitochondrial dysfunction and hepatocyte apoptosis in liver diseases through oxidative stress, post-translational modifications, inflammation, and intestinal barrier dysfunction
    Karli R. LeFort, Wiramon Rungratanawanich, Byoung-Joon Song
    Cellular and Molecular Life Sciences.2024;[Epub]     CrossRef
  • Inequities in primary liver cancer in Europe: The state of play
    Loreta A. Kondili, Jeffrey V. Lazarus, Peter Jepsen, Frank Murray, Jörn M. Schattenberg, Marko Korenjak, Lucia Craxì, Maria Buti
    Journal of Hepatology.2024; 80(4): 645.     CrossRef
  • Components from Curcuma longa (Turmeric) Against Hepatobiliary Diseases Based on Gut–Liver Axis: Pharmacotherapeutic Properties and Potential Clinical Applications
    Tianhui Gao, Shuyi Wang, Zongping Zhu, Liting Lin, Yirong Luo, Meigui Lu, Wan Liao
    The American Journal of Chinese Medicine.2024; 52(02): 387.     CrossRef
  • Impact of MAFLD criteria on postoperative recurrence of non-B, non-C HCC
    Yusuke Johira, Takashi Nakahara, Kenji Yamaoka, Yasutoshi Fujii, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Shiro Oka
    European Journal of Gastroenterology & Hepatology.2024; 36(4): 430.     CrossRef
  • A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
    Yu-Jie Jiang, Ye-Ming Cao, Yong-Bing Cao, Tian-Hua Yan, Cheng-Lin Jia, Ping He
    Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 1511.     CrossRef
  • A polygenetic risk score combined with environmental factors better predict susceptibility to hepatocellular carcinoma in Chinese population
    Yuanlin Zou, Jicun Zhu, Caijuan Song, Tiandong Li, Keyan Wang, Jianxiang Shi, Hua Ye, Peng Wang
    Cancer Medicine.2024;[Epub]     CrossRef
  • CRISPR/Cas9 screen reveals that targeting TRIM34 enhances ferroptosis sensitivity and augments immunotherapy efficacy in hepatocellular carcinoma
    Feifan Yao, Suiqing Zhou, Ruizhi Zhang, Yining Chen, Wei Huang, Kai Yu, Nanmu Yang, Xiangjun Qian, Xiaofeng Tie, Jiali Xu, Yu Zhang, Tasiken Baheti, Jing Xu, Xinzheng Dai, Xiaopei Hao, Liren Zhang, Xuehao Wang, Qing Li
    Cancer Letters.2024; 593: 216935.     CrossRef
  • Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
    Byeong Geun Song, Aryoung Kim, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn
    Liver Cancer.2024; 13(5): 561.     CrossRef
  • Causal associations between platelet count, alcohol consumption, and the risk of liver hepatocellular carcinoma based on a Mendelian randomization study
    Lihua Yu, Leisheng Wang, Yuzheng Xue, Yilin Ren, Tianhao Liu, Hao Hu
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Hepatocellular Carcinoma: Prevention, Diagnosis, and Treatment
    Fei Feng, Yue Zhao
    Medical Principles and Practice.2024; 33(5): 414.     CrossRef
  • Inflammatory Response in the Pathogenesis and Treatment of Hepatocellular Carcinoma: A Double-Edged Weapon
    Linda Galasso, Lucia Cerrito, Valeria Maccauro, Fabrizio Termite, Irene Mignini, Giorgio Esposto, Raffaele Borriello, Maria Elena Ainora, Antonio Gasbarrini, Maria Assunta Zocco
    International Journal of Molecular Sciences.2024; 25(13): 7191.     CrossRef
  • Meaningful nomograms based on systemic immune inflammation index predicted survival in metastatic pancreatic cancer patients receiving chemotherapy
    Yanan Sun, Jiahe Hu, Rongfang Wang, Xinlian Du, Xiaoling Zhang, Jiaoting E, Shaoyue Zheng, Yuxin Zhou, Ruishu Mou, Xuedong Li, Hanbo Zhang, Ying Xu, Yuan Liao, Wenjie Jiang, Lijia Liu, Ruitao Wang, Jiuxin Zhu, Rui Xie
    Cancer Medicine.2024;[Epub]     CrossRef
  • Alcohol does not impact chronic hepatitis C treatment outcomes but increases risk for progressive liver disease: Findings from a prospective multicentre Australian study (OPERA‐C)
    Paul J. Clark, Patricia C. Valery, Simone I. Strasser, Martin Weltman, Alex Thompson, Miriam T. Levy, Barbara Leggett, Amany Zekry, Julian Rong, Marie Sinclair, Jacob George, William Sievert, Gerry MacQuillan, Edmund Tse, Amanda Nicoll, Amanda Wade, Wendy
    Drug and Alcohol Review.2024; 43(6): 1559.     CrossRef
  • Role of Epigenetic Factors in Determining the Biological Behavior and Prognosis of Hepatocellular Carcinoma
    Sami Akbulut, Zeynep Kucukakcali, Tevfik Tolga Sahin, Cemil Colak, Sezai Yilmaz
    Diagnostics.2024; 14(17): 1925.     CrossRef
  • Significance of Immune and Non-Immune Cell Stroma as a Microenvironment of Hepatocellular Carcinoma—From Inflammation to Hepatocellular Carcinoma Progression
    Jacek Baj, Magdalena Kołodziej, Joanna Kobak, Jacek Januszewski, Kinga Syty, Piero Portincasa, Alicja Forma
    International Journal of Molecular Sciences.2024; 25(19): 10233.     CrossRef
  • Epigenetic tuning of tumour-associated macrophages (TAMs): a potential approach in hepatocellular carcinoma (HCC) immunotherapy
    Israa M. Helal, Monica A. Kamal, Mostafa K. Abd El-Aziz, Hend M. El Tayebi
    Expert Reviews in Molecular Medicine.2024;[Epub]     CrossRef
  • Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
    Seren M. Gedallovich, Paul Y. Kwo
    Clinical and Molecular Hepatology.2024; 30(4): 1050.     CrossRef
  • Comprehensive review and updated analysis of DNA methylation in hepatocellular carcinoma: From basic research to clinical application
    Lin Su, Jiawen Bu, Jiahui Yu, Mila Jin, Guanliang Meng, Xudong Zhu
    Clinical and Translational Medicine.2024;[Epub]     CrossRef
  • Application of nanotechnology in the treatment of hepatocellular carcinoma
    Liu Cai, Yanyuan Du, Hongtai Xiong, Honggang Zheng
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • ADRB2 serves as a novel biomarker and attenuates alcoholic hepatitis via the SIRT1/PGC-1α/PPARα pathway: integration of WGCNA, machine learning and experimental validation
    Li Song, Shuo Huang, Honghao Yan, Qing Ma, Qihan Luo, Jiang Qiu, Minxia Chen, Zongyuan Li, He Jiang, Yufan Chen, Fangming Chen, Yu Du, Haozhe Fu, Lisha Zhao, Kanglu Zhao, Ping Qiu
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • A nonlinear relationship between alcohol consumption and cognitive function in elderly people: a population-based study from NHANES 2011–2014
    Kaiqi Chen, Yunhua Li, Rui Yue, Zhao Jin, Shikui Cui, Xijian Zhang, Danping Zhu, Qihui Li
    Frontiers in Aging Neuroscience.2024;[Epub]     CrossRef
  • Identification and validation of functional roles for three MYC-associated genes in hepatocellular carcinoma
    Sha Li, Pei Xue, Xun Diao, Qi-Yu Fan, Kun Ye, Xiao-Mei Tang, Jia Liu, Zhong-Yan Huang, Qing-Hai Tang, Cheng-You Jia, Rui Xin, Zhong-Wei Lv, Ji-Bin Liu, Yu-Shui Ma, Da Fu
    Journal of Advanced Research.2023; 54: 133.     CrossRef
  • The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma
    Kyoko Oura, Asahiro Morishita, Sae Hamaya, Koji Fujita, Tsutomu Masaki
    International Journal of Molecular Sciences.2023; 24(3): 2805.     CrossRef
  • Discontinuing Hepatitis Activity Reduced Hepatocellular Carcinoma Recurrence after Primary Curative Therapy
    Chern-Horng Lee, Chien-Heng Shen, Cho-Li Yen, Tzung-Hai Yen, Sen-Yung Hsieh
    Journal of Personalized Medicine.2023; 13(3): 397.     CrossRef
  • The effects of moderate alcohol consumption on non-alcoholic fatty liver disease
    Hyunwoo Oh, Won Sohn, Yong Kyun Cho
    Clinical and Molecular Hepatology.2023; 29(Suppl): S261.     CrossRef
  • Ring finger protein 12 activates AKT signalling to promote the progression of liver cancer by interacting with EGFR
    Chengpeng Yu, Dean Rao, Tiantian Wang, Jiaqi Sheng, Enjun Lv, Long Zhang, Xun Lu, Jingjing Yu, Huifang Liang, Jia Song, Wenjie Huang
    Journal of Cellular and Molecular Medicine.2023; 27(11): 1523.     CrossRef
  • The association between alcohol consumption and the risk of hepatocellular carcinoma according to glycemic status in Korea: A nationwide population-based study
    Eun Ju Cho, Goh Eun Chung, Jeong-Ju Yoo, Yuri Cho, Dong Wook Shin, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Su Jong Yu
    PLOS Medicine.2023; 20(6): e1004244.     CrossRef
  • Increased age, bilirubin, international normalized ratio, and creatinine score to triglyceride ratio are associated with alcohol-associated primary liver carcinoma: a single-centered retrospective study
    Xiaoqing Jia, Rong Li, Xiaoting Zhang, Tao Zhou, Dalong Sun, Na Yang, Zheng Luo
    Lipids in Health and Disease.2023;[Epub]     CrossRef
  • Association between pro-inflammatory diet and liver cancer risk: a systematic review and meta-analysis
    Kaixia Chen, Fen Yang, Xinhong Zhu, Guiyuan Qiao, Chunmei Zhang, Junxiu Tao, Xiaolian Gao, Mingzhong Xiao
    Public Health Nutrition.2023; 26(12): 2780.     CrossRef
  • Alcohol: Immunomodulatory Effects and Cancer
    Juan C. Molina, Jesús D. Guerrero-Morán, Claudia González-Espinosa
    Revista de Investigación Clínica.2023; 75(3): 129.     CrossRef
  • Epigenetics in hepatocellular carcinoma
    Ganji Purnachandra Nagaraju, Begum Dariya, Prameswari Kasa, Sujatha Peela, Bassel F. El-Rayes
    Seminars in Cancer Biology.2022; 86: 622.     CrossRef
  • Alcohol triggered bile acid disequilibrium by suppressing BSEP to sustain hepatocellular carcinoma progression
    Wenbo Chen, Qisong Zhang, Ming Ding, Jingjing Yao, Yajuan Guo, Wenxin Yan, Shaofang Yu, Qinghong Shen, Min Huang, Yaqiu Zheng, Yuefang Lin, Ying Wang, Zhongqiu Liu, Linlin Lu
    Chemico-Biological Interactions.2022; 356: 109847.     CrossRef
  • GARS is implicated in poor survival and immune infiltration of hepatocellular carcinoma
    Jinghui Wang, Bing Yang, Dingxue Wang, Rui Han, Zhanyang Bi, Lizhu Lin
    Cellular Signalling.2022; 94: 110302.     CrossRef
  • The pathogenesis of liver cancer and the therapeutic potential of bioactive substances
    Song Gao, Xingyue Jiang, Liang Wang, Shanshan Jiang, Hanyuan Luo, Yan Chen, Cheng Peng
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • The Effect of Alcohol Consumption in Unresectable Hepatocellular Carcinoma with Transarterial Chemoembolization
    Bo Sun, Lijie Zhang, Dongqiao Xiang, Qing Li, Yanqiao Ren, Yanyan Cao, Tao Sun, Weihua Zhang, Linxia Wu, Licheng Zhu, Lei Chen, Huangxuan Zhao, Chuansheng Zheng, Alessandro Granito
    Journal of Oncology.2022; 2022: 1.     CrossRef
  • Association of Diabetes Mellitus and Alcohol Abuse with Cancer: Molecular Mechanisms and Clinical Significance
    Bao Q. Lam, Rashmi Srivastava, Jason Morvant, Sharmila Shankar, Rakesh K. Srivastava
    Cells.2021; 10(11): 3077.     CrossRef
  • The Emerging Influences of Alpha-Fetoprotein in the Tumorigenesis and Progression of Hepatocellular Carcinoma
    Ye Xu, Qinglong Guo, Libin Wei
    Cancers.2021; 13(20): 5096.     CrossRef
  • 11,893 View
  • 230 Download
  • 55 Web of Science
  • Crossref

Original Article

Hepatic neoplasm

Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial
Sang Min Yoon, So Yeon Kim, Young-Suk Lim, Kang Mo Kim, Ju Hyun Shim, Danbi Lee, Jihyun An, Jinhong Jung, Jong Hoon Kim, Han Chu Lee
Clin Mol Hepatol 2020;26(4):506-515.
Published online July 10, 2020
DOI: https://doi.org/10.3350/cmh.2020.0038
Background/Aims
Stereotactic body radiation therapy (SBRT) is used as an alternative ablative treatment in patients with hepatocellular carcinoma (HCC) not suitable for curative treatments. The purpose of this prospective study was to evaluate the long-term efficacy of SBRT for small (≤5 cm) HCCs.
Methods
A phase II, single-arm clinical trial on SBRT for small HCCs was conducted at an academic tertiary care center. The planned SBRT dose was 45 Gy with a fraction size of 15-Gy over 3 consecutive days. The primary endpoint was 2-year local control rate. Radiologic responses were assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) and the modified RECIST criteria.
Result
s: Between 2013 and 2016, 50 patients (53 lesions) were enrolled, with a median follow-up period of 47.8 months (range, 2.9–70.6). Patients’ age ranged from 41 to 74 years, and 80% were male. Median tumor size was 1.3 cm (range, 0.7–3.1). The 2- and 5-year local control rates were 100% and 97.1%, respectively. The 5-year overall survival rate was 77.6%. Six months after SBRT, radiologic responses were evident in 44 lesions (83%) according to the RECIST criteria and 49 (92.4%) according to the modified RECIST criteria. None of the patients showed grade ≥3 adverse events.
Conclusions
SBRT showed excellent results as an ablative treatment for patients with small HCCs while showing minimal toxicities. SBRT can be a good alternative for both curative and salvage intents in patients with HCCs that are unsuitable for curative treatments.

Citations

Citations to this article as recorded by  Crossref logo
  • α/β for Hepatocellular Carcinoma Tumors Treated with Radiation Therapy
    Lise Wei, Yaxuan Huang, Randall K. Ten Haken, Teodor Stanescu, Laura A. Dawson, Theodore S. Lawrence, Jeremy M.G. Taylor
    International Journal of Radiation Oncology*Biology*Physics.2026;[Epub]     CrossRef
  • Exploring the Evolving Landscape of Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma
    Deepti Sharma, Divya Khosla, Babu L. Meena, Hanuman P. Yadav, Rakesh Kapoor
    Journal of Clinical and Experimental Hepatology.2025; 15(1): 102386.     CrossRef
  • Stereotactic body radiotherapy alone versus stereotactic body radiotherapy after incomplete transarterial therapy for hepatocellular carcinoma
    Youngju Song, Jinhong Jung, Jin‐hong Park, So Yeon Kim, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Sang Min Yoon
    Journal of Medical Imaging and Radiation Oncology.2025; 69(1): 144.     CrossRef
  • Comparison of stereotactic body radiotherapy and transcatheter arterial chemoembolization for hepatocellular carcinoma: Systematic review and meta‐analysis
    Satoshi Komiyama, Atsuya Takeda, Yudai Tateishi, Yuichiro Tsurugai, Takahisa Eriguchi, Nobuyuki Horita
    Radiotherapy and Oncology.2025; 202: 110614.     CrossRef
  • Development and Validation of a Prediction Model for Cardiac Events in Patients With Hepatocellular Carcinoma Undergoing Stereotactic Body Radiation Therapy
    Hye In Lee, Jaeman Son, Byungchul Cho, Youngmoon Goh, Jinhong Jung, Jin-hong Park, Eui Kyu Chie, Kyung Su Kim, Young-Hak Kim, Hyun-Cheol Kang, Sang Min Yoon
    International Journal of Radiation Oncology*Biology*Physics.2025; 122(5): 1272.     CrossRef
  • Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
    Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang
    Clinical and Molecular Hepatology.2025; 31(Suppl): S228.     CrossRef
  • Proton beam therapy in the management of hepatocellular carcinoma
    Kenneth S. H. Chok, Tiffany Y. T. Joeng, Darren M. C. Poon
    Expert Review of Gastroenterology & Hepatology.2025; 19(5): 495.     CrossRef
  • Modern approach to hepatocellular carcinoma treatment
    Francesco Cortese, Fotis Anagnostopoulos, Maria Vittoria Bazzocchi, Silvio Caringi, Antonio Rosario Pisani, Matteo Renzulli, Ioannis Paraskevopoulos, Letizia Laera, Alessia Surgo, Stavros Spiliopoulos, Riccardo Memeo, Riccardo Inchingolo
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Dynamic Tumor Tracking (DTT) for Hepatocellular Carcinoma Using the Vero4DRT Gimbaled Linac Stereotactic Body Radiation Therapy (SBRT) System
    Ronan L. McDermott, Emma M. Dunne, Lok In Josephine Ma, Alanah M Bergman, Marie-Laure A. Camborde, Tania Karan, Ante Mestrovic, Emilie E. Carpentier, Mitchell C. C. Liu, Devin Schellenberg, Roy M. K. Ma
    Cancers.2025; 17(17): 2926.     CrossRef
  • Stereotactic hepatic radiation therapy and immunotherapy in hepatocellular carcinoma
    Carmen Cañadillas Navero, Íñigo San Miguel Arregui, Luis Alberto Pérez Romasanta
    Revisiones en Cáncer.2025;[Epub]     CrossRef
  • China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition)
    Jian Zhou, Huichuan Sun, Zheng Wang, Wenming Cong, Mengsu Zeng, Weiping Zhou, Lianxin Liu, Tianfu Wen, Ming Kuang, Bixiang Zhang, Kaishan Tao, Guohong Han, Zhiping Yan, Maoqiang Wang, Ruibao Liu, Jinhe Guo, Zhaochong Zeng, Ping Liang, Zhenggang Ren, Jinli
    Liver Cancer.2025; : 1.     CrossRef
  • The #HOPE4LIVER Single-arm Pivotal Trial for Histotripsy of Primary and Metastatic Liver Tumors
    Timothy J. Ziemlewicz, Jeffrey J. Critchfield, Mishal Mendiratta-Lala, Philipp Wiggermann, Maciej Pech, Xavier Serres-Créixams, Meghan Lubner, Tze Min Wah, Peter Littler, Clifford R. Davis, Govindarajan Narayanan, Sarah B. White, Osman Ahmed, Zach S. Coll
    Annals of Surgery.2025; 282(6): 908.     CrossRef
  • Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Meta-Analysis and International Stereotactic Radiosurgery Society Practice Guidelines
    Sun Hyun Bae, Seok-Joo Chun, Joo-Hyun Chung, Eunji Kim, Jin-Kyu Kang, Won Il Jang, Ji Eun Moon, Isaure Roquette, Xavier Mirabel, Tomoki Kimura, Masayuki Ueno, Ting-Shi Su, Alison C. Tree, Matthias Guckenberger, Simon S. Lo, Marta Scorsetti, Ben J. Slotman
    International Journal of Radiation Oncology*Biology*Physics.2024; 118(2): 337.     CrossRef
  • Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study
    Bo Hyun Kim, Hee Chul Park, Tae Hyun Kim, Young-Hwan Koh, Jung Yong Hong, Yuri Cho, Dong Hyun Sinn, Boram Park, Joong-Won Park
    JHEP Reports.2024; 6(4): 100991.     CrossRef
  • Chemoembolization versus Radiotherapy for Single Hepatocellular Carcinomas of ≤3 cm Unsuitable for Image-Guided Tumor Ablation
    Jihye Lim, Euichang Kim, Sehee Kim, So Yeon Kim, Jin Hyoung Kim, Sang Min Yoon, Ju Hyun Shim
    Gut and Liver.2024; 18(1): 125.     CrossRef
  • Canine primary liver tumors treated with stereotactic body radiation therapy: A case series
    Qiao Ying Pauline Chan, Deanna Morrow, David Lurie
    Veterinary Radiology & Ultrasound.2024; 65(2): 121.     CrossRef
  • Optimal hypofractionated radiation therapy schemes for early-stage hepatocellular carcinoma
    Feng Liu, Doris R. Brown, Michael T. Munley
    Radiotherapy and Oncology.2024; 194: 110223.     CrossRef
  • Stereotactic body radiation therapy in patients with centrally located hepatocellular carcinoma: A retrospective, single-arm, multi-center study
    Dan-Xue Zheng, Yi-Xing Chen, Jing Sun, Yong Hu, Ping Yang, Yang Zhang, Xue-Zhang Duan, Zhao-Chong Zeng
    Clinical and Translational Radiation Oncology.2024; 46: 100767.     CrossRef
  • Dynamic liver volume change in predicting hepatic decompensation and long‐term effects of stereotactic body radiation therapy
    Sumin Lee, Jonggi Choi, Jin‐hong Park, Chae Yeon Lim, Eunyeong Yang, Sang Min Yoon, Jinhong Jung
    Journal of Gastroenterology and Hepatology.2024; 39(8): 1648.     CrossRef
  • Stereotactic body radiotherapy is an alternative to radiofrequency ablation for single HCC ≤5.0 cm
    Zhoutian Yang, Shiliang Liu, Li Hu, Jinbin Chen, Juncheng Wang, Yangxun Pan, Li Xu, Mengzhong Liu, Minshan Chen, Mian Xi, Yaojun Zhang
    JHEP Reports.2024; 6(10): 101151.     CrossRef
  • Clinical outcomes and safety of external beam radiotherapy with extensive intrahepatic targets for advanced hepatocellular carcinoma: A single institutional clinical experience
    Sunmin Park, Chai Hong Rim, Won Sup Yoon
    Saudi Journal of Gastroenterology.2024; 30(6): 399.     CrossRef
  • Long-term outcomes of more than a decade treating patients with stereotactic body radiation therapy for hepatocellular carcinoma
    Wilhelm den Toom, Eva M. Negenman, Francois E.J.A. Willemssen, Erik van Werkhoven, Robert J. Porte, Roeland F. de Wilde, Dave Sprengers, Imogeen E. Antonisse, Ben J.M. Heijmen, Alejandra Méndez Romero
    Clinical and Translational Radiation Oncology.2024; 49: 100878.     CrossRef
  • Long-Term Outcome of a Multicenter Prospective Study on Efficacy and Safety of High-Dose Stereotactic Body Radiation Therapy ≥48-h Interfraction Interval for ≤5 cm Hepatocellular Carcinoma
    Jin-Kyu Kang, Mi-Sook Kim, Won Il Jang, Chul Ju Han, Jin Kim, Su Cheol Park, Young-Joo Shin, Chul Won Choi, Wan Jeon, Tosol Yu, Ah Ram Chang, Hae Jin Park, Younghee Park, Eun Seog Kim, Sunmi Jo, Woo Chul Kim, Hun Jung Kim, Sun Hyun Bae, Eunji Kim
    Liver Cancer.2024; 14(3): 248.     CrossRef
  • Advances in external beam radiation for hepatocellular carcinoma, stereotactic body radiation therapy (SBRT) and particle therapy
    Lokesh Seth, Kevin L. Stephans
    Hepatoma Research.2024;[Epub]     CrossRef
  • Therapeutic Outcome of Stereotactic Body Radiotherapy for Small Hepatocellular Carcinoma Lesions – A Systematic Review and Network Meta-analysis
    L.-Q. Li, T.-S. Su, Q.-Y. Wu, Z.-T. Lin, S.-X. Liang
    Clinical Oncology.2023; 35(10): 652.     CrossRef
  • Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    European Journal of Internal Medicine.2023; 107: 66.     CrossRef
  • Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview
    Yukinori Matsuo
    Current Oncology.2023; 30(2): 2493.     CrossRef
  • Advances in Radiation Therapy for Primary Liver Cancer
    Kyle C. Cuneo, Daniel J. Herr
    Surgical Oncology Clinics of North America.2023; 32(3): 415.     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Journal of Liver Cancer.2023; 23(1): 1.     CrossRef
  • Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis
    Daniel Q. Huang, Nobuharu Tamaki, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Hye Won Lee, Seng Gee Lim, Tae Seop Lim, Masayuki Kurosaki, Hiroyuki Marusawa, Toshie Mashiba, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Namiki Izumi,
    Hepatology.2023; 77(5): 1746.     CrossRef
  • Stereotactic Body Radiation Therapy versus Surgical Resection for Stage I/II Hepatocellular Carcinoma
    Emrullah Birgin, Svetlana Hetjens, Moses Tam, Camilo Correa-Gallego, Nuh N. Rahbari
    Cancers.2023; 15(8): 2330.     CrossRef
  • Clinical impact of carbon‐ion radiotherapy on hepatocellular carcinoma with Child‐Pugh B cirrhosis
    Yuichi Hiroshima, Masaru Wakatsuki, Takashi Kaneko, Hirokazu Makishima, Naomi Nagatake Okada, Shigeo Yasuda, Hitoshi Ishikawa, Hiroshi Tsuji
    Cancer Medicine.2023; 12(13): 14004.     CrossRef
  • Local Therapies for Hepatocellular Carcinoma and Role of MRI-Guided Adaptive Radiation Therapy
    Yirong Liu, Brian Chou, Amulya Yalamanchili, Sara N. Lim, Laura A. Dawson, Tarita O. Thomas
    Journal of Clinical Medicine.2023; 12(10): 3517.     CrossRef
  • Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity
    Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2023; 29(3): 593.     CrossRef
  • Impact of radiation therapy and alpha-fetoprotein level on survival outcomes for patients with hepatocellular carcinoma: A population-based study
    Yahong Chen, Xueqing Yang, Xiawei Li
    Clinics and Research in Hepatology and Gastroenterology.2023; 47(8): 102196.     CrossRef
  • Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis
    Ha Il Kim, Jihyun An, Seungbong Han, Ju Hyun Shim
    Clinical and Molecular Hepatology.2023; 29(4): 1013.     CrossRef
  • Large hepatocellular carcinoma treated with sequential SBRT and immunotherapy with anti-VEGF (Vascular Endothelial Growth Factor) therapy
    Bardia Bidarmaghz, Marwan Idrees, Yoo Young Lee, Peter Hodgkinson
    BMJ Case Reports.2023; 16(12): e256931.     CrossRef
  • Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL
    Hye Won Lee, Soo Young Park, Yu Rim Lee, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    American Journal of Gastroenterology.2022; 117(2): 288.     CrossRef
  • Stereotactic body radiation therapy for primary liver tumors: An effective liver‐directed therapy in the toolbox
    Hannah J. Roberts, Jennifer Y. Wo
    Cancer.2022; 128(5): 956.     CrossRef
  • External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, In Kyung Min, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2022; 14(3): 711.     CrossRef
  • Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients
    Sumin Lee, Jinhong Jung, Jin-hong Park, So Yeon Kim, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Hee Hyun Park, Jong Hoon Kim, Sang Min Yoon
    BMC Cancer.2022;[Epub]     CrossRef
  • Hypofractionation in Hepatocellular Carcinoma – The Effect of Fractionation Size
    S. Lewis, A. Barry, M.A. Hawkins
    Clinical Oncology.2022; 34(5): e195.     CrossRef
  • Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity
    Shirley Lewis, Laura Dawson, Aisling Barry, Teodor Stanescu, Issa Mohamad, Ali Hosni
    JHEP Reports.2022; 4(8): 100498.     CrossRef
  • The role of stereotactic body radiotherapy in hepatocellular carcinoma: guidelines and evidences
    Yulin Hu, Caining Zhao, Ren Ji, Wenqi Chen, Qi Shen, CL Chiang, Jeff Chan, Lingyu Ma, Hongwei Yang, Tiffany Wong, Susannah Ellsworth, Chung-Mau Lo, Laura A. Dawson, Feng-Ming (Spring) Kong
    Journal of the National Cancer Center.2022; 2(3): 171.     CrossRef
  • Prognosis and Risk Factors of Recurrence in HBV-Related Small Hepatocellular Carcinoma After Stereotactic Body Radiation Therapy
    Yifan Han, Jianxiang Liu, Jiali Pan, Hongyu Chen, Ning Tan, Qian Kang, Yuqing Yang, Xiaoyuan Xu, Wengang Li
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • High rates of treatment stage migration for early hepatocellular carcinoma and association with adverse outcomes: An Australian multicenter study
    Kee Fong Loo, Richard J Woodman, Damjana Bogatic, Vidyaleha Chandran, Kate Muller, Mohamed Asif Chinnaratha, John Bate, Kirsty Campbell, Matthew Maddison, Sumudu Narayana, Hien Le, David Pryor, Alan Wigg
    JGH Open.2022; 6(9): 599.     CrossRef
  • Stereotactic body radiotherapy versus radiofrequency ablation as initial treatment of small hepatocellular carcinoma
    Hwang Sik Shin, Sae Hwan Lee, Baek Gyu Jun, Hong Soo Kim, Seong Hee Kang, Ji Young Park, Soo In Choi, Gab Jin Cheon, Young Don Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Ki Tae Suk, Dong Joon Kim, In Young Jo, Yong
    European Journal of Gastroenterology & Hepatology.2022; 34(11): 1187.     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Clinical and Molecular Hepatology.2022; 28(4): 583.     CrossRef
  • Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    Cancers.2022; 14(20): 5002.     CrossRef
  • Stereotactic body radiation therapy for elderly patients with small hepatocellular carcinoma: a retrospective observational study
    Jeong Yun Jang, Jinhong Jung, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jin-hong Park, Sang Min Yoon
    Journal of Liver Cancer.2022; 22(2): 136.     CrossRef
  • 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

    Korean Journal of Radiology.2022; 23(12): 1126.     CrossRef
  • Image-Guided Proton Therapy for Elderly Patients with Hepatocellular Carcinoma: High Local Control and Quality of Life Preservation
    Hiromitsu Iwata, Hiroyuki Ogino, Yukiko Hattori, Koichiro Nakajima, Kento Nomura, Kensuke Hayashi, Toshiyuki Toshito, Shigeru Sasaki, Shingo Hashimoto, Jun-etsu Mizoe, Yuta Shibamoto
    Cancers.2021; 13(2): 219.     CrossRef
  • A New Prognostic Model for Radiation-Based Hepatocellular Carcinoma Treatment
    Ting-Shi Su, Shi-Xiong Liang, Li-Qing Li, Qiu-Hua Liu, Xue-Zhang Duan, Jing Sun, Hai Zeng, Jian-Xu Li, Xiao-Fei Zhu, Hong-Qing Zhuang, Ping Liang
    SSRN Electronic Journal .2021;[Epub]     CrossRef
  • Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1
    Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho
    International Journal of Molecular Sciences.2021; 22(18): 10027.     CrossRef
  • External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals
    Jung Hyun Ji, Soo Young Park, Won Jeong Son, Hye Jung Shin, Hyein Lee, Hye Won Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Viral Hepatitis.2021; 28(6): 951.     CrossRef
  • Radiofrequency ablation versus stereotactic body radiation therapy for small (≤ 3 cm) hepatocellular carcinoma: A retrospective comparison analysis
    Yuri Jeong, Kyung Jin Lee, So Jung Lee, Yong Moon Shin, Min‐Ju Kim, Young‐Suk Lim, Han Chu Lee, Jinhong Jung, Jin‐hong Park, Jong Hoon Kim, So Yeon Kim, Sang Min Yoon
    Journal of Gastroenterology and Hepatology.2021; 36(7): 1962.     CrossRef
  • Updates on the Diagnosis and Management of Hepatocellular Carcinoma
    Muhammad Kamran, Aimun Raees, Wasim Jafri
    Euroasian Journal of Hepato-Gastroenterology.2021; 11(1): 32.     CrossRef
  • Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study
    Ting-Shi Su, Qiu-Hua Liu, Xiao-Fei Zhu, Ping Liang, Shi-Xiong Liang, Lin Lai, Ying Zhou, Yong Huang, Tao Cheng, Le-Qun Li
    Radiation Oncology.2021;[Epub]     CrossRef
  • Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Journal of Viral Hepatitis.2021; 28(11): 1570.     CrossRef
  • Multi-Institutional Retrospective Study of Radiotherapy for Hepatocellular Carcinoma in the Caudate Lobe
    Sung Uk Lee, Sang Min Yoon, Jason Chia-Hsien Cheng, Tae Hyun Kim, Bo Hyun Kim, Jin-hong Park, Jinhong Jung, Chiao-Ling Tsai, Yun Chiang, Joong-Won Park
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
    Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
    Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123.     CrossRef
  • The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
    Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Hepatocellular Carcinoma.2021; Volume 8: 467.     CrossRef
  • Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Hepatology International.2021; 15(5): 1083.     CrossRef
  • Stereotactic body radiotherapy vs radiofrequency ablation for the treatment of hepatocellular carcinoma: a meta-analysis
    Antonio Facciorusso, Andrea Chierici, Ivan Cincione, Rodolfo Sacco, Daryl Ramai, Babu P Mohan, Saurabh Chandan, Andrew Ofosu, Christian Cotsoglou
    Expert Review of Anticancer Therapy.2021; 21(6): 681.     CrossRef
  • Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, Hye Jung Shin, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2021; 13(23): 5892.     CrossRef
  • In reply to Huo et al.: Treating small hepatocellular carcinoma: Stereotactic body radiation therapy versus radiofrequency ablation
    S Park, J Jung, B Cho, SY Kim, S‐C Yun, Y‐S Lim, HC Lee, J Park, J‐h Park, JH Kim, SM Yoon
    Journal of Gastroenterology and Hepatology.2020; 35(12): 2293.     CrossRef
  • 11,845 View
  • 228 Download
  • 62 Web of Science
  • Crossref

Review

Hepatic neoplasm

Switching to systemic therapy after locoregional treatment failure: Definition and best timing
Sadahisa Ogasawara, Yoshihiko Ooka, Keisuke Koroki, Susumu Maruta, Hiroaki Kanzaki, Kengo Kanayama, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Eiichiro Suzuki, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Jun Kato, Naoya Kato
Clin Mol Hepatol 2020;26(2):155-162.
Published online January 15, 2020
DOI: https://doi.org/10.3350/cmh.2019.0021n
In patients with unresectable hepatocellular carcinoma (HCC) without both macrovascular invasion and extrahepatic metastasis, the initial treatment choice recommended is transarterial chemoembolization (TACE). Before sorafenib came into wide use, TACE had been pointlessly carried out repeatedly. It was in the early 2010s that the concept of TACE refractory was advocated. Two retrospective studies from Japan indicated that conversion from TACE to sorafenib the day after patients were deemed as TACE refractory improved overall survival compared with continued TACE, according to the definition by the Japan Society of Hepatology. Nowadays, phase 3 trials have shown clinical benefits of several novel molecular target agents. Compared with the era of sorafenib, sequential treatments with these molecular target agents have gradually prolonged patients’ survival and have become major strategies in patients with HCC. Taking these together, conversion from TACE to systemic therapies at the time of TACE refractory, compared with before, may have a greater impact on survival and may be considered deeper in the decisions-making process in patients with unresectable HCC who are candidate for TACE. Up-to-date information on the concept of TACE refractory is summarized in this review. We believe that the survival of patients with unresectable HCC without both macrovascular invasion and extrahepatic metastasis may be dramatically improved by optimal timing of TACE refractory and switching to systemic therapies.

Citations

Citations to this article as recorded by  Crossref logo
  • Macrophage hitchhiking for systematic suppression in postablative multifocal HCC
    Xuehan Li, Yan Zhang, Shun Li, Jiaqi Shi, Caiqi Liu, Xianjun Li, Yingjing Li, Shengnan Luo, Yuan Wang, Shihui Lai, Mingwei Li, Meng Zhang, Linlin Sun, Xiaoxue Du, Meng Zhou, Fan Xing, Qian Zhang, Zhiguang Wu, Tongsen Zheng
    Hepatology.2025; 81(1): 44.     CrossRef
  • Optimal sequencing of locoregional and systemic therapies for intermediate and advanced hepatocellular carcinoma: a network meta-analysis
    Wei Lu, Zhiyuan Li, Chen Pan, Bingliang Chen, Gang Zhang, Zhiming Yang, Jingcheng Hao
    Journal of Cancer Research and Clinical Oncology.2025;[Epub]     CrossRef
  • Transarterial chemoembolization combined with apatinib in the treatment of advanced hepatocellular carcinoma: a prospective, multi-center, real-world study (Ahend-HAP02)
    Hang Yuan, Zhen Li, Guang-Shao Cao, Fei Xu, Gang Wu, Peng-Xu Ding, Qiu-Liang Wei, Zu-Kuan Chang, Cheng Xing, Huan-Zhang Niu, Jun Yin, Quan-Jun Yao, Lin Zheng, Jin-Cheng Xiao, Cheng-Shi Chen, Hong-Tao Cheng, Deng-Wei Zong, Wei-Li Xia, Xiang Geng, Xiao-Hui
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Landscape and prognostic values of lymphocytes in patients with hepatocellular carcinoma undergoing transarterial embolization
    Rui-dong Zhao, Ding-jie Liu, Jia-wei Li, Yong Wang, Jun-hao Lin, Yi-tian Zhang, Yong Li, Mei-xiao Zhan, Zhi-nan Yin, Li-gong Lu, Bing Liu
    Journal of Leukocyte Biology.2024; 116(1): 186.     CrossRef
  • Efficacy and safety of TACE combined with tyrosine kinase inhibitors and camrelizumab for unresectable hepatocellular carcinoma: A systematic review and meta‑analysis
    Jiahui Yu, Duan Yan, Song Wei, Linfeng Yang, Pengsheng Yi
    Oncology Letters.2024;[Epub]     CrossRef
  • Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma
    Yuna Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Myung Ji Goh, Wonseok Kang, Seung Up Kim
    European Journal of Gastroenterology & Hepatology.2023; 35(2): 191.     CrossRef
  • Modified quantitative and volumetric response evaluation criteria for patients with hepatocellular carcinoma after transarterial chemoembolization
    Jiachen Xu, Yu Yin, Jun Yang, Li Chen, Zhi Li, Jian Shen, Wansheng Wang, Caifang Ni
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada
    Jason K. Wong, Howard J. Lim, Vincent C. Tam, Kelly W. Burak, Laura A. Dawson, Prosanto Chaudhury, Robert J. Abraham, Brandon M. Meyers, Gonzalo Sapisochin, David Valenti, Setareh Samimi, Ravi Ramjeesingh, Amol Mujoomdar, Ilidio Martins, Elijah Dixon, Maj
    Cancer Treatment Reviews.2023; 115: 102526.     CrossRef
  • Transarterial chemoembolization as an alternative to radioembolization is associated with earlier tumor recurrence than in radioembolization-eligible patients
    Sung Won Chung, Heejin Cho, Hyunjae Shin, Jeayeon Park, Ju Yeon Kim, Ji Hoon Hong, Moon Haeng Hur, Min Kyung Park, Yun Bin Lee, Su Jong Yu, Myungsu Lee, Yoon Jun Kim, Jin Chul Paeng, Jung-Hwan Yoon, Jin Wook Chung, Jeong-Hoon Lee, Hyo-Cheol Kim
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma – A systematic review
    Brandon M. Meyers, Jennifer J. Knox, David M. Liu, Deanna McLeod, Ravi Ramjeesingh, Vincent C. Tam, Howard J. Lim
    Cancer Treatment Reviews.2023; 118: 102584.     CrossRef
  • Transarterial chemoembolization for advanced hepatocellular carcinoma without macrovascular invasion or extrahepatic metastasis: analysis of factors prognostic of clinical outcomes
    Ji Hoon Kim, Jin Hyoung Kim, Hyun-Ki Yoon, Gi-Young Ko, Ji Hoon Shin, Dong Il Gwon, Heung-Kyu Ko, Hee Ho Chu, Seong Ho Kim, Gun Ha Kim, Yonghun Kim, Shakir Aljerdah
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity
    Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2023; 29(3): 593.     CrossRef
  • Double closed loop small bowel obstruction due to right diaphragmatic hernia after transcatheter arterial chemoembolization and microwave ablation for hepatocellular carcinoma
    Noppachai Siranart, Manichaya Sukonpatip, Walit Sowalertrat
    Clinical Journal of Gastroenterology.2023; 16(5): 673.     CrossRef
  • Predictive Role of Pretreatment Circulating miR-221 in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
    Nutcha Pinjaroen, Piyawan Chailapakul, Supachaya Sriphoosanaphan, Natthaya Chuaypen, Pisit Tangkijvanich
    Diagnostics.2023; 13(17): 2794.     CrossRef
  • A radiomics signature associated with underlying gene expression pattern for the prediction of prognosis and treatment response in hepatocellular carcinoma
    Dandan Wang, Linhan Zhang, Zhongqi Sun, Huijie Jiang, Jinfeng Zhang
    European Journal of Radiology.2023; 167: 111086.     CrossRef
  • Role of Immunological Cells in Hepatocellular Carcinoma Disease and Associated Pathways
    Ram Aasarey, Kajal Yadav, Brijendra Kumar Kashyap, Sarit Prabha, Pramod Kumar, Anil Kumar, Janne Ruokolainen, Kavindra Kumar Kesari
    ACS Pharmacology & Translational Science.2023; 6(12): 1801.     CrossRef
  • Efficacy and safety of tyrosine kinase inhibitors plus PD-1 inhibitor in patients with transarterial chemoembolization- refractory hepatocellular carcinoma: a two-center retrospective study
    Ya Gao, Haohao Lu, Zhifan Xiong
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Diaphragmatic perforation after transcatheter arterial chemoembolization of hepatocellular carcinoma via inferior phrenic artery: a case report
    Ji Soo Kim, Hyoung Nam Lee, Woong Hee Lee, Suk Hyun Bae
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Successful Combined S Systemic-Regional Chemotherapy for Advanced Intrahepatic Cholangiocarcinoma: Report of Two Cases
    P. G. Tarazov, T. I. Kagacheva, A. A. Polikarpov, A. V. Moiseenko
    Journal of oncology: diagnostic radiology and radiotherapy.2022; 5(1): 83.     CrossRef
  • Nationwide database analysis of insomnia, depression, and sleeping pill prescriptions in hepatocellular carcinoma patients
    Keishi Akada, Noriyuki Koyama, Yuji Miura, Ken Aoshima
    Current Medical Research and Opinion.2022; 38(8): 1333.     CrossRef
  • Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma
    Pil Soo Sung
    Clinical and Molecular Hepatology.2022; 28(3): 333.     CrossRef
  • Analysis of Lenvatinib’s Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma
    Kei Amioka, Tomokazu Kawaoka, Takahiro Kinami, Shintaro Yamasaki, Masanari Kosaka, Yusuke Johira, Shigeki Yano, Kensuke Naruto, Yuwa Ando, Yasutoshi Fujii, Shinsuke Uchikawa, Atsushi Ono, Masami Yamauchi, Michio Imamura, Yumi Kosaka, Kazuki Ohya, Nami Mor
    Cancers.2022; 14(20): 5066.     CrossRef
  • Sequential treatment after transcatheter arterial chemoembolization for patients with single large hepatocellular carcinoma
    Po‐Heng Chuang, Sheng‐Nan Lu
    Advances in Digestive Medicine.2022; 9(3): 141.     CrossRef
  • Plasma arginase-1 as a predictive marker for early transarterial chemoembolization refractoriness in unresectable hepatocellular carcinoma
    Wei-Li Xia, Shi-Jun Xu, Yuan Guo, Xiao-Hui Zhao, Hong-Tao Hu, Yan Zhao, Quan-Jun Yao, Lin Zheng, Dong-Yang Zhang, Chen-Yang Guo, Wei-Jun Fan, Hai-Liang Li
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Blood-based biomarkers for immune-based therapy in advanced HCC: Promising but a long way to go
    Pil Soo Sung, Isaac Kise Lee, Pu Reun Roh, Min Woo Kang, Jaegyoon Ahn, Seung Kew Yoon
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Surgery versus external beam radiotherapy for hepatocellular carcinoma involving the inferior vena cava or right atrium: A systematic review and meta‐analysis
    Han Ah Lee, Sunmin Park, Yeon Seok Seo, Won Sup Yoon, In‐Soo Shin, Chai Hong Rim
    Journal of Hepato-Biliary-Pancreatic Sciences.2021; 28(12): 1031.     CrossRef
  • Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities
    Cyrill Wehling, Michael T. Dill, Alexander Olkus, Christoph Springfeld, De-Hua Chang, Patrick Naumann, Thomas Longerich, Clemens Kratochwil, Arianeb Mehrabi, Uta Merle, Jan Pfeiffenberger, Christian Rupp, Karl Heinz Weiss, Markus Mieth
    Journal of Cancer Research and Clinical Oncology.2021; 147(8): 2471.     CrossRef
  • Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma
    Shigeo Shimose, Shunji Koya, Takumi Kawaguchi, Keisuke Hirota, Sachiyo Yoshio, Takashi Niizeki, Hiroo Matsuse, Takuji Torimura
    Clinical and Molecular Hepatology.2021; 27(4): 616.     CrossRef
  • Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1
    Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho
    International Journal of Molecular Sciences.2021; 22(18): 10027.     CrossRef
  • Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis
    Yanmei Dai, Huijie Jiang, Hao Jiang, Sheng Zhao, Xu Zeng, Ran Sun, Ruoshui Zheng
    Translational Oncology.2021; 14(12): 101238.     CrossRef
  • Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
    David Sooik Kim, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Cancers.2021; 14(1): 67.     CrossRef
  • Liver Injury and Use of Contrast-Enhanced Ultrasound for Evaluating Intrahepatic Recurrence in a Case of TACE-Refractory Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab Combination Therapy: A Case Report
    Satoshi Komiyama, Kazushi Numata, Katsuaki Ogushi, Makoto Chuma, Reiko Tanaka, Sawako Chiba, Masako Otani, Yoshiaki Inayama, Masayuki Nakano, Shin Maeda
    Diagnostics.2021; 11(8): 1394.     CrossRef
  • Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival
    Shigeo Shimose, Hideki Iwamoto, Masatoshi Tanaka, Takashi Niizeki, Tomotake Shirono, Akira Kajiwara, Yu Noda, Naoki Kamachi, Shusuke Okamura, Masahito Nakano, Ryoko Kuromatsu, Takumi Kawaguchi, Hironori Koga, Takuji Torimura
    Oncology.2021; 99(12): 756.     CrossRef
  • A case of sorafenib-induced severe thrombocytopenia during treatment of unresectable hepatocellular carcinoma
    Xiaoying Quan, Xiaoyan Chen, Lei Lei, Chunzhi Wu, Xiaoli Jia, Bin Ye
    Oncology and Translational Medicine.2021; 7(5): 235.     CrossRef
  • Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection
    Pil Soo Sung, Jeong Won Jang, Jaejun Lee, Soon Kyu Lee, Hae Lim Lee, Hyun Yang, Hee Chul Nam, Sung Won Lee, Si Hyun Bae, Jong Young Choi, Nam Ik Han, Seung Kew Yoon
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Value of miR-1271 and glypican-3 in evaluating the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization
    Zheng Guo, Jing Wang, Li Li, Rong Liu, Jin Fang, Bin Tie
    World Journal of Clinical Cases.2020; 8(16): 3493.     CrossRef
  • Initial treatment response to transarterial chemoembolization as a predictive factor for Child–Pugh class deterioration prior to refractoriness in hepatocellular carcinoma
    Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Yuki Tahata, Yasuharu Imai, Masahide Oshita, Kazuyoshi Ohkawa, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara
    Hepatology Research.2020; 50(11): 1275.     CrossRef
  • Effect of urea cream on sorafenib-associated hand–foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study
    Young-Sun Lee, Young K. Jung, Ji H. Kim, Sung B. Cho, Do Y. Kim, Moon Y. Kim, Hyung J. Kim, Yeon S. Seo, Ki T. Yoon, Young M. Hong, Jeong-Hoon Lee, Hyun W. Lee, Hyung J. Yim, Byoung K. Jang, Eun S. Jang, Jae Y. Jang, Sang Y. Hwang
    European Journal of Cancer.2020; 140: 19.     CrossRef
  • Research Progress of TACE Combined with Sorafenib in the Treatment of HCC
    欣 姚
    Asian Case Reports in Oncology.2020; 09(04): 17.     CrossRef
  • Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma
    Young Chang, Soung Won Jeong, Jae Young Jang, Yong Jae Kim
    International Journal of Molecular Sciences.2020; 21(21): 8165.     CrossRef
  • Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy
    Pil Soo Sung, Moon Hyung Choi, Hyun Yang, Soon Kyu Lee, Ho Jong Chun, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Joon-Il Choi, Young Joon Lee, Si Hyun Bae
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC
    Jaejun Lee, Pil Soo Sung, Hyun Yang, Soon Kyu Lee, Hee Chul Nam, Sun Hong Yoo, Hae Lim Lee, Hee Yeon Kim, Sung Won Lee, Jung Hyun Kwon, Jeong Won Jang, Chang Wook Kim, Soon Woo Nam, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
    Journal of Clinical Medicine.2020; 9(12): 4121.     CrossRef
  • Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials
    Keisuke Koroki, Sadahisa Ogasawara, Yoshihiko Ooka, Hiroaki Kanzaki, Kengo Kanayama, Susumu Maruta, Takahiro Maeda, Masayuki Yokoyama, Toru Wakamatsu, Masanori Inoue, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Taka
    Liver Cancer.2020; 9(5): 596.     CrossRef
  • 14,319 View
  • 434 Download
  • 49 Web of Science
  • Crossref

Original Articles

Hepatic neoplasm

Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard
Jamak Modaresi Esfeh, Kaveh Hajifathalian, Kianoush Ansari-Gilani
Clin Mol Hepatol 2020;26(1):54-59.
Published online November 15, 2019
DOI: https://doi.org/10.3350/cmh.2019.0039
Background/Aims
The American Association for the Study of Liver Diseases recommends ultrasound (US) screening for hepatocellular carcinoma (HCC) among cirrhotic patients, regardless of body mass index (BMI), every 6 months. We examined US sensitivity for diagnosis of HCC in obese patients.
Methods
Liver transplant patients data with HCC in explant was used (January 2012-December 2017). All patients underwent liver US within 3 months of diagnosis of HCC. Number/size of HCC lesions were extracted from radiologic and pathologic reports. Obesity was defined as BMI ≥30 kg/m2.
Result
s: One hundred sixteen patients were included. 80% were male, with mean BMI of 31 kg/m2. The most common underlying liver disease was hepatitis C virus (62%). At the time of diagnosis, median number of HCC lesions was 2 (interquartile range [IQR], 1–3), and median size of the largest lesion was 2.5 cm (IQR, 1.75–3.9). Overall sensitivity of US study for detection of HCC was 33% (95% confidence interval [CI], 29–48%). Sensitivity was 77% (95% CI, 62–93%) in patients with BMI<30 and 21% (95% CI, 11–30%) in patients with BMI≥30 (P<0.001). Size of the largest HCC lesion (P=0.290) and number of lesions (P=0.505) were not different between groups. Computed tomography (CT) scan detected HCC in 98% of the obese patients with negative US.
Conclusions
Sensitivity of US for detection of HCC is significantly lower among obese patients compared to overweight and normal weight patients. These patients may benefit from alternating between US and a different imaging modality.

Citations

Citations to this article as recorded by  Crossref logo
  • Advances in the Therapeutic Landscape of Hepatocellular Carcinoma: Current Strategies and Future Perspectives
    Asahiro Morishita, Kyoko Oura, Hiroki Tai, Rie Yano, Mai Nakahara, Tomoko Tadokoro, Koji Fujita, Shima Mimura, Joji Tani, Miwa Tatsuta, Takashi Himoto, Hideki Kobara
    Cancers.2026; 18(4): 609.     CrossRef
  • High-throughput proteomics-guided biomarker discovery of hepatocellular carcinoma
    Dongyoon Shin, Yeongshin Kim, Junho Park, Youngsoo Kim
    Biomedical Journal.2025; 48(1): 100752.     CrossRef
  • New insights into biomarkers and risk stratification to predict hepatocellular cancer
    Katrina Li, Brandon Mathew, Ethan Saldanha, Puja Ghosh, Adrian R. Krainer, Srinivasan Dasarathy, Hai Huang, Xiyan Xiang, Lopa Mishra
    Molecular Medicine.2025;[Epub]     CrossRef
  • Discovery and validation of a novel dual-target blood test for the detection of hepatocellular carcinoma across stages from cirrhosis
    Wenhao Teng, Hui Li, Hao Yang, Yu Chen, Liying Xi, Fuli Xin, Aiyuan Zhang, Lihui Yu, Lu Zheng, Ming Wang, Jian Bai, Fayong Ke, Yin Wang, Fuming Sun, Hui Zhang, Lin Wu, Jingfeng Liu
    BMC Medicine.2025;[Epub]     CrossRef
  • Abbreviated MRI-Based Surveillance Strategies for Early Hepatocellular Carcinoma Detection
    Hyo Jung Park, Dong Wook Kim, Won-Mook Choi, So Yeon Kim
    Journal of the Korean Society of Radiology.2025; 86(3): 335.     CrossRef
  • Serum Proteomic Profile Based on the TGF‐β Pathway Stratifies Risk of Hepatocellular Carcinoma
    Xiyan Xiang, Kirti Shetty, Herbert Yu, Bibhuti Mishra, Linda L. Wong, Xianghong Jasmine Zhou, Sanjaya K. Satapathy, James M. Crawford, Patricia S. Latham, Steven‐Huy Han, Brandon Mathew, Nabil N. Dagher, Lawrence Lau, Fellanza Cacaj, Anil K. Vegesna, Srin
    Liver International.2025;[Epub]     CrossRef
  • Performance of the multi-target hepatocellular carcinoma blood test: Design and rationale of the ALTUS study
    Binu V. John, Mark Camardo, Kyle Porter, Paul Z. Elias, Elle Kielar-Grevstad, Seema P. Rego, Neehar D. Parikh, Lewis R. Roberts, Alvin C. Silva, Amit G. Singal, Ju Dong Yang, Paul J. Limburg
    Hepatology Communications.2025;[Epub]     CrossRef
  • Current Surveillance Strategy Is Less Effective for Detecting Early-Stage Hepatocellular Carcinoma in Patients with Non-Viral and Non-Cirrhotic Liver Disease
    Jessica Spiers, Wenhao Li, Aloysious D. Aravinthan, Ayman Bannaga, Katharine Caddick, Emma L. Culver, Rosemary E. Faulkes, Victoria Gordon, Yaqza Hussain, Hamish Miller, Jenny Merry, Muhammad Saad, Abhishek Sheth, Tahir Shah, Shishir Shetty, Ankur Srivast
    Liver Cancer.2025; 14(5): 587.     CrossRef
  • Practical Considerations in Abdominal MRI: Sequences, Patient Preparation, and Clinical Applications
    Nicoleta Cazacu, Claudia G. Chilom, Cosmin Adrian, Costin A. Minoiu
    Methods and Protocols.2025; 8(6): 129.     CrossRef
  • Undiagnosed Liver Disease in Patients with Late-Stage Hepatocellular Carcinoma
    Benjamin Ngoi, Hardeep Kaur, Annabel Lane, Darshan Nitchingham, Amirhossein Norozi, Olga Sukocheva, Kathy Pietris, Joanne Morgan, Joan Ericka Flores, Edmund Tse
    Livers.2025; 5(4): 57.     CrossRef
  • Novel Blood-Based Biomarkers for HCC
    Suraj Pai, Neehar D. Parikh
    Current Hepatology Reports.2024; 23(1): 174.     CrossRef
  • The Impact of Metabolic Health and Obesity on Liver Transplant Candidates and Recipients
    Alexander S. Vogel, Rebecca Roediger, Dagny von Ahrens, Brett E. Fortune, Jonathan M. Schwartz, Shalom Frager, Kristina R. Chacko, Clara Y. Tow
    Life.2024; 14(6): 685.     CrossRef
  • Diagnostic performance comparisons of two commonly used multi-biomarker-based scores for detection of hepatocellular carcinoma in non-alcoholic fatty liver disease
    Wei Ouyang, Ming-Da Wang, Ming-Cheng Guan, Yong-Kang Diao, Li-Yang Sun, Nan-Ya Wang, Feng Shen, Hong Zhu, Tian Yang
    iLIVER.2024; 3(2): 100098.     CrossRef
  • Efficacy of blood plasma spectroscopy for early liver cancer diagnostics in obese patients
    Petr Hříbek, Ondřej Vrtělka, Kateřina Králová, Johana Klasová, Markéta Fousková, Lucie Habartová, Kristýna Kubíčková, Tomáš Kupsa, Tomáš Tůma, Vladimír Setnička, Petr Urbánek
    Annals of Hepatology.2024; 29(5): 101519.     CrossRef
  • in vivo and in situ robust quantitative optical biopsy of hepatocellular carcinoma and metastasis based on two-photon autofluorescence imaging
    Naikun Song, Bobo Gu
    Optics Letters.2024; 49(14): 4054.     CrossRef
  • Prospective Study of Non-Contrast, Abbreviated MRI for Hepatocellular Carcinoma Surveillance in Patients with Suboptimal Hepatic Visualisation on Ultrasound
    Mathew Vithayathil, Maria Qurashi, Pedro Rente Vicente, Ali Alsafi, Mitesh Naik, Alison Graham, Shahid Khan, Heather Lewis, Ameet Dhar, Belinda Smith, Nowlan Selvapatt, Pinelopi Manousou, Lucia Possamai, Hooshang Izadi, Adrian Lim, Paul Tait, Rohini Sharm
    Cancers.2024; 16(15): 2709.     CrossRef
  • Risk-stratified hepatocellular carcinoma screening according to the degree of obesity and progression to cirrhosis for diabetic patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in Japan: a cost-effectiveness study
    Akiko Kowada
    BMJ Open.2024; 14(11): e080549.     CrossRef
  • Performing liver imaging at a high level: quality and adequacy in LI-RADS
    Cheng William Hong, Guilherme M. Cunha, Takeshi Yokoo, Alexandra Roudenko, Zachary S. Kelm, Alice Fung, Mustafa R. Bashir, Sara Lewis, Cynthia Santillan, Robert Marks, Claude B. Sirlin, Kathryn J. Fowler, Victoria Chernyak
    Abdominal Radiology.2024; 50(6): 2502.     CrossRef
  • Correspondence on Editorial regarding “Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease”
    Won Sohn, Yong-Han Paik
    Clinical and Molecular Hepatology.2023; 29(1): 182.     CrossRef
  • Comparable Overall Survival in Patients with Hepatocellular Carcinoma Diagnosed within and outside a Surveillance Programme: The Potential Impact of Liver Cirrhosis
    Rosemary E. Faulkes, Zaira Rehman, Swetha Palanichamy, Nekisa Zakeri, Chris Coldham, Bobby V. M. Dasari, M. Thamara P. R. Perera, Neil Rajoriya, Shishir Shetty, Tahir Shah
    Cancers.2023; 15(3): 978.     CrossRef
  • Diagnostic accuracy of ultrasound and alpha-fetoprotein measurement for hepatocellular carcinoma surveillance: a retrospective comparative study
    Ahmed Haitham Abduljabbar
    Egyptian Journal of Radiology and Nuclear Medicine.2023;[Epub]     CrossRef
  • Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease
    Karim Seif El Dahan, Darine Daher, Amit G. Singal
    Clinical and Molecular Hepatology.2023; 29(Suppl): S207.     CrossRef
  • The high burden of comorbidities in Aboriginal and Torres Strait Islander Australians living with chronic hepatitis B in Far North Queensland, Australia, and the implications for patient management
    Jordan Riddell, Allison Hempenstall, Yoko Nakata, Sandra Gregson, Richard Hayes, Simon Smith, Marlow Coates, Lizzie Charlie, Christine Perrett, Victoria Newie, Tomi Newie, Sharna Radlof, Josh Hanson, Mohamed El-Kassas
    PLOS ONE.2023; 18(4): e0284151.     CrossRef
  • Current status of ultrasonography in national cancer surveillance program for hepatocellular carcinoma in South Korea: a large-scale multicenter study
    Sun Hong Yoo, Soon Sun Kim, Sang Gyune Kim, Jung Hyun Kwon, Han-Ah Lee, Yeon Seok Seo, Young Kul Jung, Hyung Joon Yim, Do Seon Song, Seong Hee Kang, Moon Young Kim, Young-Hwan Ahn, Jieun Han, Young Seok Kim, Young Chang, Soung Won Jeong, Jae Young Jang, J
    Journal of Liver Cancer.2023; 23(1): 189.     CrossRef
  • Hepatocellular carcinoma surveillance based on the Australian Consensus Guidelines: a health economic modelling study
    Anh Le Tuan Nguyen, Lei Si, John S Lubel, Nicholas Shackel, Kwang Chien Yee, Mark Wilson, Jane Bradshaw, Kerry Hardy, Andrew John Palmer, Christopher Leigh Blizzard, Barbara de Graaff
    BMC Health Services Research.2023;[Epub]     CrossRef
  • Vibrational and chiroptical analysis of blood plasma for hepatocellular carcinoma diagnostics
    Ondřej Vrtělka, Kateřina Králová, Markéta Fousková, Lucie Habartová, Petr Hříbek, Petr Urbánek, Vladimír Setnička
    The Analyst.2023; 148(12): 2793.     CrossRef
  • Screening for Hepatocellular Carcinoma:Image Quality Is Everything!
    Richard G. Barr, Leslie M. Scoutt
    Radiology.2023;[Epub]     CrossRef
  • Magnetic Resonance Imaging-Based Surveillance of Hepatocellular Carcinoma: Current Status and Future Perspectives
    Hyo Jung Park, So Yeon Kim, Young-Suk Lim
    Current Hepatology Reports.2023; 22(3): 83.     CrossRef
  • Diagnostic performance of US LI-RADS in hepatocellular carcinoma surveillance
    Ahmed Haitham Abduljabbar, Mohammad A. Wazzan
    Egyptian Journal of Radiology and Nuclear Medicine.2023;[Epub]     CrossRef
  • Hepatocellular Carcinoma Genetic Classification
    Zurabi Lominadze, Mohammed Rifat Shaik, Dabin Choi, Duha Zaffar, Lopa Mishra, Kirti Shetty
    The Cancer Journal.2023; 29(5): 249.     CrossRef
  • Occult Regions of Suppressed Coherence in Liver B-Mode Images
    Katelyn Offerdahl, Matthew Huber, Will Long, Nick Bottenus, Rendon Nelson, Gregg Trahey
    Ultrasound in Medicine & Biology.2022; 48(1): 47.     CrossRef
  • Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma
    Naga P. Chalasani, Kyle Porter, Abhik Bhattacharya, Adam J. Book, Brenda M. Neis, Kong M. Xiong, Tiruvidaimarudur S. Ramasubramanian, David K. Edwards, Irene Chen, Scott Johnson, Lewis R. Roberts, John B. Kisiel, K. Rajender Reddy, Amit G. Singal, Marilyn
    Clinical Gastroenterology and Hepatology.2022; 20(1): 173.     CrossRef
  • Fatty Liver Disease: Diagnosis and Stratification
    Yedidya Saiman, Andres Duarte-Rojo, Mary E. Rinella
    Annual Review of Medicine.2022; 73(1): 529.     CrossRef
  • External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, In Kyung Min, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2022; 14(3): 711.     CrossRef
  • Long‐term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study
    Young Eun Chon, Soo Young Park, Seung Up Kim, Han Pyo Hong, Jae Seung Lee, Hye Won Lee, Mi Na Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Viral Hepatitis.2022; 29(4): 289.     CrossRef
  • Current Landscape and Future Perspectives of Abbreviated MRI for Hepatocellular Carcinoma Surveillance
    Hyo Jung Park, Nieun Seo, So Yeon Kim
    Korean Journal of Radiology.2022; 23(6): 598.     CrossRef
  • Using quantitative immunohistochemistry in patients at high risk for hepatocellular cancer
    Sobia Zaidi, Richard Amdur, Xiyan Xiang, Herbert Yu, Linda L. Wong, Shuyun Rao, Aiwu R. He, Karan Amin, Daewa Zaheer, Raj K. Narayan, Sanjaya K. Satapathy, Patricia S. Latham, Kirti Shetty, Chandan Guha, Nancy R. Gough, Lopa Mishra
    Genes & Cancer.2022; 13: 9.     CrossRef
  • Highly Integrated Multiplexing and Buffering Electronics for Large Aperture Ultrasonic Arrays
    Robert Wodnicki, Haochen Kang, Di Li, Douglas N. Stephens, Hayong Jung, Yizhe Sun, Ruimin Chen, Lai-Ming Jiang, Nestor E. Cabrera-Munoz, Josquin Foiret, Qifa Zhou, Katherine W. Ferrara
    BME Frontiers.2022;[Epub]     CrossRef
  • Surveillance for hepatocellular carcinoma: It is time to move forward
    Bo Hyun Kim, Yuri Cho, Joong-Won Park
    Clinical and Molecular Hepatology.2022; 28(4): 810.     CrossRef
  • Potential of a Non-Contrast-Enhanced Abbreviated MRI Screening Protocol (NC-AMRI) in High-Risk Patients under Surveillance for HCC
    François Willemssen, Quido de Lussanet de la Sablonière, Daniel Bos, Jan IJzermans, Robert De Man, Roy Dwarkasing
    Cancers.2022; 14(16): 3961.     CrossRef
  • Spiking Neural Network Based on Multi-Scale Saliency Fusion for Breast Cancer Detection
    Qiang Fu, Hongbin Dong
    Entropy.2022; 24(11): 1543.     CrossRef
  • Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease
    Mirella Fraquelli, Tin Nadarevic, Agostino Colli, Cristina Manzotti, Vanja Giljaca, Damir Miletic, Davor Štimac, Giovanni Casazza
    Cochrane Database of Systematic Reviews.2022;[Epub]     CrossRef
  • Diagnostic Accuracy of Ultrasound in Predicting Extrathyroidal Extension and Its Relation to Body Mass Index in a North American Population
    Mahmoud Omar, Abdallah S. Attia, Peter P. Issa, Bryce R. Christensen, Kavin Sugumar, Ahmed Alnahla, Deena Hadedeya, Hosam Shalaby, Neel Gupta, Mohamed Shama, Eman Toraih, Emad Kandil
    Biomedicines.2022; 10(10): 2408.     CrossRef
  • Adipositas aus viszeralonkologischer Perspektive
    Till Hasenberg, Barbara König
    Zentralblatt für Chirurgie - Zeitschrift für Allgemeine, Viszeral-, Thorax- und Gefäßchirurgie.2022; 147(06): 574.     CrossRef
  • HRD1 attenuates the high uptake of [18F]FDG in hepatocellular carcinoma PET imaging
    Ai-Mei Li, Xia-Wen Lin, Jing-Tao Shen, Min Li, Qi-Huang Zheng, Zheng-Yang Zhou, Ming Shi
    Nuclear Medicine and Biology.2021; 96-97: 27.     CrossRef
  • External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals
    Jung Hyun Ji, Soo Young Park, Won Jeong Son, Hye Jung Shin, Hyein Lee, Hye Won Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Viral Hepatitis.2021; 28(6): 951.     CrossRef
  • Fat and Hidden Liver Cancer
    Sailish Honap, Jude A. Oben
    Clinical Liver Disease.2021; 17(2): 49.     CrossRef
  • Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease
    Agostino Colli, Tin Nadarevic, Damir Miletic, Vanja Giljaca, Mirella Fraquelli, Davor Štimac, Giovanni Casazza
    Cochrane Database of Systematic Reviews.2021;[Epub]     CrossRef
  • Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
    Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
    Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123.     CrossRef
  • The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
    Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Hepatocellular Carcinoma.2021; Volume 8: 467.     CrossRef
  • Individualized surveillance of chronic hepatitis B patients according to hepatocellular carcinoma risk based on PAGE-B scores
    Ji Hyun Kim, Seong Hee Kang, Minjong Lee, Hoon Sung Choi, Baek Gyu Jun, Tae Suk Kim, Dae Hee Choi, Ki Tae Suk, Moon Young Kim, Young Don Kim, Gab Jin Cheon, Soon Koo Baik, Dong Joon Kim
    European Journal of Gastroenterology & Hepatology.2021; 33(12): 1564.     CrossRef
  • AFP-L3 for the diagnosis of early hepatocellular carcinoma
    Jian-Ming Zhou, Ting Wang, Kun-He Zhang
    Medicine.2021; 100(43): e27673.     CrossRef
  • Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1
    Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho
    International Journal of Molecular Sciences.2021; 22(18): 10027.     CrossRef
  • Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, Hye Jung Shin, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2021; 13(23): 5892.     CrossRef
  • Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Hepatology International.2021; 15(5): 1083.     CrossRef
  • Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Journal of Viral Hepatitis.2021; 28(11): 1570.     CrossRef
  • Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements
    Abhilash Perisetti, Hemant Goyal, Rachana Yendala, Ragesh B Thandassery, Emmanouil Giorgakis
    World Journal of Gastroenterology.2021; 27(24): 3466.     CrossRef
  • Diagnosis efficacy of CEUS for hepatic inflammatory lesions
    Yuanyuan Guo, Xiachuan Qin, Shaoxian Chen, Xuebin Liu, Peng Gu
    Journal of Clinical Laboratory Analysis.2020;[Epub]     CrossRef
  • Improved detection of hepatocellular carcinoma by dynamic computed tomography in cirrhotic patients with chronic hepatitis B: A multicenter study
    Ji Hyun Kim, Seong Hee Kang, Minjong Lee, Hoon Sung Choi, Baek Gyu Jun, Tae Suk Kim, Dae Hee Choi, Ki Tae Suk, Moon Young Kim, Young Don Kim, Gab Jin Cheon, Soon Koo Baik, Dong Joon Kim
    Journal of Gastroenterology and Hepatology.2020; 35(10): 1795.     CrossRef
  • Evaluation of diagnostic accuracy of serum calcium channel α2δ1 subunit in hepatocellular carcinoma-related cirrhosis
    Ahmed Elmetwally Ahmed, Essam Bayoumi, Ahmed E Khayyal, Al Saied Al Refaey, Hagar Elessawy
    Egyptian Liver Journal.2020;[Epub]     CrossRef
  • Imaging Modalities for Hepatocellular Carcinoma Surveillance: Expanding Horizons beyond Ultrasound
    Hyo Jung Park, So Yeon Kim
    Journal of Liver Cancer.2020; 20(2): 99.     CrossRef
  • 12,438 View
  • 224 Download
  • 61 Web of Science
  • Crossref

Hepatic neoplasm

Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B
Haneulsaem Shin, Yeon Woo Jung, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Yeun-Yoon Kim, Jin-Young Choi, Seung Up Kim
Clin Mol Hepatol 2019;25(4):390-399.
Published online May 31, 2019
DOI: https://doi.org/10.3350/cmh.2018.0103
Background/Aims
A risk prediction model for the development of hepatocellular carcinoma (HCC) from indeterminate nodules detected on computed tomography (CT) (RadCT score) in patients with chronic hepatitis B (CHB)-related cirrhosis was proposed. We validated this model for indeterminate nodules on magnetic resonance imaging (MRI).
Methods
Between 2013 and 2016, Liver Imaging Reporting and Data System (LI-RADS) 2/3 nodules on MRI were detected in 99 patients with CHB. The RadCT score was calculated.
Result
s: The median age of the 72 male and 27 female subjects was 58 years. HCC history and liver cirrhosis were found in 47 (47.5%) and 44 (44.4%) patients, respectively. The median RadCT score was 112. The patients with HCC (n=41, 41.4%) showed significantly higher RadCT scores than those without (median, 119 vs. 107; P=0.013); the Chinese university-HCC and risk estimation for HCC in CHB (REACH-B) scores were similar (both P>0.05). Arterial enhancement, T2 hyperintensity, and diffusion restriction on MRI were not significantly different in the univariate analysis (all P>0.05); only the RadCT score significantly predicted HCC (hazard ratio [HR]=1.018; P=0.007). Multivariate analysis showed HCC history was the only independent HCC predictor (HR=2.374; P=0.012). When the subjects were stratified into three risk groups based on the RadCT score (<60, 60–105, and >105), the cumulative HCC incidence was not significantly different among them (all P>0.05, log-rank test).
Conclusions
HCC history, but not RadCT score, predicted CHB-related HCC development from LI-RADS 2/3 nodules. New risk models optimized for MRI-defined indeterminate nodules are required.

Citations

Citations to this article as recorded by  Crossref logo
  • Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma
    Hong Jun Lee, Jae Seung Lee, Hyesung So, Ja Kyung Yoon, Jin-Young Choi, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim
    Yonsei Medical Journal.2024; 65(7): 371.     CrossRef
  • Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    European Journal of Internal Medicine.2023; 107: 66.     CrossRef
  • Early Detection of Hepatocarcinogenicity in Rats Using MRI with Ferric–Tannic Nanoparticles
    Jannarong Intakhad, Arpamas Vachiraarunwong, Jantira Sanit, Aiyarin Kittilukkana, Sarawut Kongkarnka, Rawiwan Wongpoomchai, Chalermchai Pilapong
    Analytical Chemistry.2023; 95(27): 10241.     CrossRef
  • Cysteine‐rich intestinal protein 1 enhances the progression of hepatocellular carcinoma via Ras signaling
    Hong‐Yu He, Li Hu
    The Kaohsiung Journal of Medical Sciences.2022; 38(1): 49.     CrossRef
  • Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL
    Hye Won Lee, Soo Young Park, Yu Rim Lee, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    American Journal of Gastroenterology.2022; 117(2): 288.     CrossRef
  • Long‐term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study
    Young Eun Chon, Soo Young Park, Seung Up Kim, Han Pyo Hong, Jae Seung Lee, Hye Won Lee, Mi Na Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Viral Hepatitis.2022; 29(4): 289.     CrossRef
  • Expression Profiles and Prognostic Value of Multiple Inhibitory Checkpoints in Head and Neck Lymphoepithelioma-Like Carcinoma
    Wen-Qing Zou, Wei-Jie Luo, Yan-Fen Feng, Fang Liu, Shao-Bo Liang, Xue-Liang Fang, Ye-Lin Liang, Na Liu, Ya-Qin Wang, Yan-Ping Mao
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, In Kyung Min, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2022; 14(3): 711.     CrossRef
  • Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir
    Jin Won Chang, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yeon Seok Seo, Han Ah Lee, Mi Na Kim, Yu Rim Lee, Seong Gyu Hwang, Kyu Sung Rim, Soon Ho Um, Won Young Tak, Young Oh Kweon, Soo Young Park, Seung Up Kim
    Journal of Viral Hepatitis.2021; 28(1): 95.     CrossRef
  • Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma
    Soojin Kim, Kyung Hyun Kim, Beom Kyung Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim, Seung Up Kim
    Journal of Gastroenterology and Hepatology.2021; 36(5): 1317.     CrossRef
  • Validation of the HCC‐RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy
    Fatih Güzelbulut, Pınar Gökçen, Güray Can, Gupse Adalı, Ayça Gökçen Değirmenci Saltürk, Özgür Bahadır, Kamil Özdil, Hamdi Levent Doğanay
    Journal of Viral Hepatitis.2021; 28(5): 826.     CrossRef
  • Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization
    Yuna Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Current Oncology.2021; 28(1): 965.     CrossRef
  • External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals
    Jung Hyun Ji, Soo Young Park, Won Jeong Son, Hye Jung Shin, Hyein Lee, Hye Won Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Viral Hepatitis.2021; 28(6): 951.     CrossRef
  • Effect of antiviral therapy in patients with low HBV DNA level on transarterial chemoembolization for hepatocellular carcinoma
    Myung Pyo Kim, Jae Kook Yang, Baek Gyu Jun, Young Don Kim, Gab Jin Cheon, Hee Jae Jung, Jeong‐Ju Yoo, Sang Gyune Kim, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Hong Soo Kim, Sae Hwan Lee
    Journal of Viral Hepatitis.2021; 28(7): 1011.     CrossRef
  • Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
    Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
    Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123.     CrossRef
  • Individualized surveillance of chronic hepatitis B patients according to hepatocellular carcinoma risk based on PAGE-B scores
    Ji Hyun Kim, Seong Hee Kang, Minjong Lee, Hoon Sung Choi, Baek Gyu Jun, Tae Suk Kim, Dae Hee Choi, Ki Tae Suk, Moon Young Kim, Young Don Kim, Gab Jin Cheon, Soon Koo Baik, Dong Joon Kim
    European Journal of Gastroenterology & Hepatology.2021; 33(12): 1564.     CrossRef
  • Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Journal of Viral Hepatitis.2021; 28(11): 1570.     CrossRef
  • Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1
    Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho
    International Journal of Molecular Sciences.2021; 22(18): 10027.     CrossRef
  • Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, Hye Jung Shin, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2021; 13(23): 5892.     CrossRef
  • Improved detection of hepatocellular carcinoma by dynamic computed tomography in cirrhotic patients with chronic hepatitis B: A multicenter study
    Ji Hyun Kim, Seong Hee Kang, Minjong Lee, Hoon Sung Choi, Baek Gyu Jun, Tae Suk Kim, Dae Hee Choi, Ki Tae Suk, Moon Young Kim, Young Don Kim, Gab Jin Cheon, Soon Koo Baik, Dong Joon Kim
    Journal of Gastroenterology and Hepatology.2020; 35(10): 1795.     CrossRef
  • 9,992 View
  • 152 Download
  • 20 Web of Science
  • Crossref

Hepatic neoplasm

A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea
Jae Seung Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Jin Sil Seong, Kwang-Hyub Han, Do Young Kim
Clin Mol Hepatol 2020;26(1):24-32.
Published online May 20, 2019
DOI: https://doi.org/10.3350/cmh.2018.0065
Background/Aims
Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC), but there is much controversy about TACE refractoriness. The aim of this study was to identify trends in the actual clinical application of TACE and recognition of TACE refractoriness by Korean experts.
Methods
In total, 17 questionnaires on TACE refractoriness were administered to 161 clinicians via an online survey. Multiple answers were allowed for some questions.
Result
s: Most clinicians agreed that there is a need for standardization of TACE application through specific scoring systems (n=124, 77.0%). TACE refractoriness was predominantly expected by participants when recurrences were detected within 1 month (n=70, 43.5%), there were 4 to 6 tumors (n=77, 47.8%), the maximal tumor size was 3–5 cm (n=49, 30.4%), and when there was insufficient tumor necrosis despite TACE being repeated more than three times (n=78, 48.4%). Overall, sorafenib therapy (n=137) and radiotherapy (n=114) were preferred when repeated TACE was considered ineffective.
Conclusions
Treatment of HCC is often based on the clinical judgment of clinicians because of the heterogeneity among individuals. Experts need to continue discussions on the standardization and sub-classification of HCC treatment guidelines in Korea.

Citations

Citations to this article as recorded by  Crossref logo
  • The Value of Hepatic Artery Infusion Chemotherapy (HAIC) in the Treatment of Patients with Hepatocellular Carcinoma (HCC) Resistant to Transcatheter Arterial Chemoembolization (TACE)
    鹏 蒋
    Advances in Clinical Medicine.2025; 15(03): 324.     CrossRef
  • Personalized peripheral vascular interventional embolization for tumor: tailoring treatment to improve outcomes
    Xinyue Qi, Jintai Liu, Tianlong Liu, Huaxin Hao
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Research Progress of lncRNA-ATB/miR-141-3p/GP73 Ax-is-Mediated EMT Promoting TACE Refractoriness
    棋 耿
    Advances in Clinical Medicine.2024; 14(01): 903.     CrossRef
  • High-Risk Hepatocellular Carcinoma: Hepatic Arterial Infusion Chemotherapy versus Transarterial Chemoembolization
    Baogen Zhang, Biqing Huang, Fan Yang, Jiandong Yang, Man Kong, Jing Wang, Yaoxian Xiang, Kangjie Wang, Ruchen Peng, Kun Yang, Chao An, Dong Yan
    Journal of Hepatocellular Carcinoma.2024; Volume 11: 651.     CrossRef
  • Recent Hepatocellular Carcinoma Managements in Korea: Focus on the Updated Guidelines in 2022
    Yuri Cho, Bo Hyun Kim, Young-Suk Lim
    Digestive Disease Interventions.2024; 08(03): 169.     CrossRef
  • Modified quantitative and volumetric response evaluation criteria for patients with hepatocellular carcinoma after transarterial chemoembolization
    Jiachen Xu, Yu Yin, Jun Yang, Li Chen, Zhi Li, Jian Shen, Wansheng Wang, Caifang Ni
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective
    Myung Ji Goh, Dong Hyun Sinn, Jong Man Kim, Min Woo Lee, Dong Ho Hyun, Jeong Il Yu, Jung Yong Hong, Moon Seok Choi
    Clinical and Molecular Hepatology.2023; 29(2): 197.     CrossRef
  • Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity
    Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2023; 29(3): 593.     CrossRef
  • Impact of Low Skeletal Muscle Mass on Long-Term Outcomes in Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization: A Retrospective Multi-Center Study
    Heechul Nam, Hyun Yang, Ho Soo Chun, Han Ah Lee, Joon Yeul Nam, Jeong Won Jang, Yeon Seok Seo, Do Young Kim, Yoon Jun Kim, Si Hyun Bae
    Cancers.2023; 15(21): 5195.     CrossRef
  • A retrospective study of transarterial chemoembolization (TACE) combined with lenvatinib compared with TACE monotherapy for BCLC B2 stage hepatocellular carcinoma
    Junning Liu, Shu Yan, Guangnian Zhang, Linfeng Yang, Song Wei, Pengsheng Yi
    Oncology Letters.2023;[Epub]     CrossRef
  • Efficacy of Transarterial Chemoembolization (TACE) for Early-Stage Hepatocellular Carcinoma
    Moonhyung Lee, Hyun Phil Shin
    Medicina.2023; 59(12): 2174.     CrossRef
  • Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients
    Sumin Lee, Jinhong Jung, Jin-hong Park, So Yeon Kim, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Hee Hyun Park, Jong Hoon Kim, Sang Min Yoon
    BMC Cancer.2022;[Epub]     CrossRef
  • Transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition
    Shen Zhang, Bin-Yan Zhong, Lei Zhang, Wan-Sheng Wang, Cai-Fang Ni
    World Journal of Gastrointestinal Surgery.2022; 14(6): 528.     CrossRef
  • A Nomogram Based on Preoperative Lipiodol Deposition after Sequential Retreatment with Transarterial Chemoembolization to Predict Prognoses for Intermediate-Stage Hepatocellular Carcinoma
    Xiang-Ke Niu, Xiao-Feng He
    Journal of Personalized Medicine.2022; 12(9): 1375.     CrossRef
  • New Evidence of Oral Branched-Chain Amino Acid Supplementation on the Prognosis of Patients With Advanced Liver Disease
    Hankil Lee, Jeong-Ju Yoo, Sang Hoon Ahn, Beom Kyung Kim
    Clinical and Translational Gastroenterology.2022; 13(12): e00542.     CrossRef
  • Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study
    Hye Kyung Hyun, Eun Ju Cho, Soo Young Park, Young Mi Hong, Soon Sun Kim, Hwi Young Kim, Nae-Yun Heo, Jung Gil Park, Dong Hyun Sinn, Wonseok Kang, Song Won Jeong, Myeong Jun Song, Hana Park, Danbi Lee, Yong Sun Lee, Sung Bum Cho, Chan Sik An, Hyung Jin Rhe
    Digestive Diseases and Sciences.2021; 66(7): 2427.     CrossRef
  • Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma
    Jae Seung Lee, Young Eun Chon, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Wonseok Kang, Moon Seok Choi, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Hwi Young Kim, Tae Hun Kim, Kwon Yoo,
    Yonsei Medical Journal.2021; 62(1): 12.     CrossRef
  • Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
    Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
    Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123.     CrossRef
  • Benefits of Local Treatment Including External Radiotherapy for Hepatocellular Carcinoma with Portal Invasion
    Han Lee, Sunmin Park, Yeon Seo, Won Yoon, Chai Rim
    Biology.2021; 10(4): 326.     CrossRef
  • Knockdown of Atg7 suppresses Tumorigenesis in a murine model of liver cancer
    Kyung Joo Cho, Sun Yeong Shin, Hyuk Moon, Beom Kyung Kim, Simon Weonsang Ro
    Translational Oncology.2021; 14(9): 101158.     CrossRef
  • Stepwise-Hierarchical Pooled Analysis for Synergistic Interpretation of Meta-analyses Involving Randomized and Observational Studies: Methodology Development
    In-Soo Shin, Chai Hong Rim
    Journal of Medical Internet Research.2021; 23(9): e29642.     CrossRef
  • Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma – The Changing Tides
    Abdul Rehman Khan, Xuyong Wei, Xiao Xu
    Journal of Hepatocellular Carcinoma.2021; Volume 8: 1089.     CrossRef
  • Salvage External Beam Radiotherapy after Incomplete Transarterial Chemoembolization for Hepatocellular Carcinoma: A Meta-Analysis and Systematic Review
    Dae Yang, Sunmin Park, Chai Rim, Won Yoon, In-Soo Shin, Han Lee
    Medicina.2021; 57(10): 1000.     CrossRef
  • Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1
    Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho
    International Journal of Molecular Sciences.2021; 22(18): 10027.     CrossRef
  • Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study
    Jaejun Lee, Ji-Won Han, Pil-Soo Sung, Soon-Kyu Lee, Hyun Yang, Hee-Chul Nam, Sun-Hong Yoo, Hae-Lim Lee, Hee-Yeon Kim, Sung-Won Lee, Jung-Hyun Kwon, Jeong-Won Jang, Chang-Wook Kim, Soon-Woo Nam, Jung-Suk Oh, Ho-Jong Chun, Si-Hyun Bae, Jong-Young Choi, Seun
    Journal of Clinical Medicine.2021; 10(18): 4045.     CrossRef
  • Differences in radiotherapy application according to regional disease characteristics of hepatocellular carcinoma
    Chai Hong Rim
    Journal of Liver Cancer.2021; 21(2): 113.     CrossRef
  • Current role of systemic therapy in transarterial chemotherapy refractory hepatocellular carcinoma patients
    Hansung Kang, Hye Won Lee
    International Journal of Gastrointestinal Intervention.2021; 10(4): 183.     CrossRef
  • Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
    David Sooik Kim, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Cancers.2021; 14(1): 67.     CrossRef
  • Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial
    Beom Kyung Kim, Do Young Kim, Hwa Kyung Byun, Hye Jin Choi, Seung-Hoon Beom, Hye Won Lee, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Jinsil Seong, Kwang-Hyub Han
    International Journal of Radiation Oncology*Biology*Physics.2020; 107(1): 106.     CrossRef
  • Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
    Cheol-Hyung Lee, Yun Bin Lee, Minseok Albert Kim, Heejoon Jang, Hyunwoo Oh, Sun Woong Kim, Eun Ju Cho, Kyung-Hun Lee, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Tae-You Kim, Yoon Jun Kim
    Clinical and Molecular Hepatology.2020; 26(3): 328.     CrossRef
  • Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma
    Young Chang, Soung Won Jeong, Jae Young Jang, Yong Jae Kim
    International Journal of Molecular Sciences.2020; 21(21): 8165.     CrossRef
  • A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC
    Jaejun Lee, Pil Soo Sung, Hyun Yang, Soon Kyu Lee, Hee Chul Nam, Sun Hong Yoo, Hae Lim Lee, Hee Yeon Kim, Sung Won Lee, Jung Hyun Kwon, Jeong Won Jang, Chang Wook Kim, Soon Woo Nam, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
    Journal of Clinical Medicine.2020; 9(12): 4121.     CrossRef
  • 13,725 View
  • 317 Download
  • 31 Web of Science
  • Crossref

Hepatic neoplasm

Safety margin of embolized area can reduce local recurrence of hepatocellular carcinoma after superselective transarterial chemoembolization
Kittipitch Bannangkoon, Keerati Hongsakul, Teeravut Tubtawee, Teerha Piratvisuth
Clin Mol Hepatol 2019;25(1):74-85.
Published online February 28, 2019
DOI: https://doi.org/10.3350/cmh.2018.0072
Background/Aims
We aimed to determine the relationship between the safety margin of an embolized area and local tumor recurrence (LTR) of patients with hepatocellular carcinoma (HCC) who underwent superselective transarterial chemoembolization (TACE).
Methods
The medical records of 77 HCC patients with 109 HCC nodules who underwent superselective TACE were retrospectively analyzed for LTR. Univariate and multivariate analyses were performed for 16 potential factors using Cox proportional hazard regression. Iodized oil deposition on cone-beam computed tomography (CBCT) imaging was divided into three grades: A=complete tumor staining and complete circumferential safety margin, B=complete tumor staining but incomplete safety margin, C=incomplete tumor staining. The effect of a safety margin on LTR was evaluated by comparison between grade A and B group.
Result
s: Univariate and multivariate analyses revealed that grade A iodized oil deposition and portal vein visualization were the only two independent significant factors of LTR (P<0.001 and P=0.029, respectively). The 12- and 24-month LTR rates of tumors for grade A (n=62), grade B (n=30), and grade C (n=17) were 16% vs. 41% vs. 100% and 16% vs. 61% vs. 100%, respectively (P<0.001). The tumors in the grade A group had a 75% risk reduction in LTR (odds ratio, 0.25; 95% confidence interval, 0.10 to 0.64; P=0.004) compared to the grade B group.
Conclusions
LTR was significantly lower when a greater degree of iodized oil deposition occurred with a complete circumferential safety margin. In superselective TACE, the safety margin of the embolized areas using intraprocedural CBCT affected LTR in HCC patients.

Citations

Citations to this article as recorded by  Crossref logo
  • Aplicaciones de la tomografía computarizada de haz cónico en procedimientos mínimamente invasivos guiados por imagen
    E. Serrano, J. Valcárcel José, A. Páez-Carpio, M. Matute-González, M.F. Werner, A. López-Rueda
    Radiología.2025; 67(1): 38.     CrossRef
  • Cone Beam computed tomography (CBCT) applications in image-guided minimally invasive procedures
    E. Serrano, J. Valcárcel José, A. Páez-Carpio, M. Matute-González, M.F. Werner, A. López-Rueda
    Radiología (English Edition).2025; 67(1): 38.     CrossRef
  • Efficacy of cone-beam computed tomography and guidance software in transarterial chemoembolization for hepatocellular carcinoma
    Shiro Miyayama
    EngMedicine.2025; 2(2): 100075.     CrossRef
  • Simplified Chronic Hepatitis B Antiviral Initiation Criteria in Thailand: An Economic Evaluation
    Piyameth Dilokthornsakul, Ratree Sawangjit, Pisit Tangkijvanich, Maneerat Chayanupatkul, Unchalee Permsuwan
    Value in Health Regional Issues.2024; 43: 101011.     CrossRef
  • Preliminary Study of the Treatment Strategy for Retaining Traumatic Foreign Bodies Involving the Carotid Artery
    Chuxi Zhang, Jinyang Wu, Wenbin Zhang, Hao Yuan, Chengshuai Yang, Yong Zhang, Shilei Zhang
    Journal of Craniofacial Surgery.2023; 34(2): 475.     CrossRef
  • Validation of the ALBI-TAE model and comparison of seven scoring systems for predicting survival outcome in patients with intermediate‐stage hepatocellular carcinoma undergoing chemoembolization
    Kittipitch Bannangkoon, Keerati Hongsakul, Teeravut Tubtawee
    Cancer Imaging.2023;[Epub]     CrossRef
  • Effect of COVID-19 Pandemic-Related Delays in Chemoembolization on the Survival of Patients with Hepatocellular Carcinoma
    Kittipitch Bannangkoon, Keerati Hongsakul, Teeravut Tubtawee, Phurich Janjindamai, Quirino Lai
    Canadian Journal of Gastroenterology and Hepatology.2023; 2023: 1.     CrossRef
  • Local Recurrence following Radiological Complete Response in Patients Treated with Subsegmental Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma
    Dong Il Gwon, Gun Ha Kim, Hee Ho Chu, Jin Hyoung Kim, Gi-Young Ko, Hyun-Ki Yoon
    Cancers.2023; 15(20): 4991.     CrossRef
  • Peritumoral portal enhancement during transarterial chemoembolization: a potential prognostic factor for patients with hepatocellular carcinoma
    Sofi Sennefelt Nyman, Angeliki Dimopoulou Creusen, Ulf Johnsson, Fredrik Rorsman, Johan Vessby, Charlotte Ebeling Barbier
    Acta Radiologica.2022; 63(10): 1323.     CrossRef
  • Emerging curative-intent minimally-invasive therapies for hepatocellular carcinoma
    Kylie E Zane, Paul B Nagib, Sajid Jalil, Khalid Mumtaz, Mina S Makary
    World Journal of Hepatology.2022; 14(5): 885.     CrossRef
  • Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE)
    Thierry de Baere, Maxime Ronot, Jin Wook Chung, Rita Golfieri, Roman Kloeckner, Joong-Won Park, Bernhard Gebauer, Nabil Kibriya, Ganapathy Ananthakrishnan, Shiro Miyayama
    CardioVascular and Interventional Radiology.2022; 45(10): 1430.     CrossRef
  • The Role of Immediate Post-Procedural Cone-Beam Computed Tomography (CBCT) in Predicting the Early Radiologic Response of Hepatocellular Carcinoma (HCC) Nodules to Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE)
    Marco Fronda, Francesco Mistretta, Marco Calandri, Fernanda Ciferri, Floriana Nardelli, Laura Bergamasco, Paolo Fonio, Andrea Doriguzzi Breatta
    Journal of Clinical Medicine.2022; 11(23): 7089.     CrossRef
  • Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma
    Jae Seung Lee, Young Eun Chon, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Wonseok Kang, Moon Seok Choi, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Hwi Young Kim, Tae Hun Kim, Kwon Yoo,
    Yonsei Medical Journal.2021; 62(1): 12.     CrossRef
  • Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
    Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
    Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123.     CrossRef
  • Usefulness of virtual parenchymal perfusion software visualizing embolized areas to determine optimal catheter position in superselective conventional transarterial chemoembolization for hepatocellular carcinoma
    Shiro Miyayama, Masashi Yamashiro, Rie Ikeda, Junichi Matsumoto, Nobuhiko Ogawa, Naoko Sakuragawa
    Hepatology Research.2021; 51(3): 313.     CrossRef
  • Percutaneous Irreversible Electroporation for Treatment of Small Hepatocellular Carcinoma Invisible on Unenhanced CT: A Novel Combined Strategy with Prior Transarterial Tumor Marking
    Feng Pan, Thuy D. Do, Dominik F. Vollherbst, Philippe L. Pereira, Götz M. Richter, Michael Faerber, Karl H. Weiss, Arianeb Mehrabi, Hans U. Kauczor, Christof M. Sommer
    Cancers.2021; 13(9): 2021.     CrossRef
  • Solid-in-Oil-in-Water Emulsion: An Innovative Paradigm to Improve Drug Stability and Biological Activity
    Anali Sawant, Seema Kamath, Hemanth KG, Girish Pai Kulyadi
    AAPS PharmSciTech.2021;[Epub]     CrossRef
  • Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1
    Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho
    International Journal of Molecular Sciences.2021; 22(18): 10027.     CrossRef
  • Comparison of local recurrence in transcatheter arterial chemoembolization of hepatocellular carcinoma with or without accumulation of iodized oil beyond corona enhancement area: Short-term results
    Yukinobu Watanabe, Masahiro Ogawa, Masahiro Kaneko, Mariko Kumagawa, Midori Hirayama, Naoki Matsumoto, Hiroshi Nakagawara, Toshiki Yamamoto, Mitsuhiko Moriyama
    Radiology and Oncology.2021; 56(1): 69.     CrossRef
  • Impact of cone-beam computed tomography with automated feeder detection software on the survival outcome of patients with hepatocellular carcinoma during treatment with conventional transarterial chemoembolization
    Kittipitch Bannangkoon, Keerati Hongsakul, Teeravut Tubtawee
    BMC Gastroenterology.2021;[Epub]     CrossRef
  • Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma
    Charlotte Ebeling Barbier, Femke Heindryckx, Hans Lennernäs
    International Journal of Molecular Sciences.2021; 22(23): 13051.     CrossRef
  • Feasibility and Techniques of Securing 3D-Safety Margin in Superselective Transarterial Chemoembolization to Improve Local Tumor Control for Small Hepatocellular Carcinoma: An Intend-to-Treat Analysis
    Ching Charoenvisal, Toshihiro Tanaka, Hideyuki Nishiofuku, Hiroshi Anai, Takeshi Sato, Takeshi Matsumoto, Nagaaki Marugami, Kimihiko Kichikawa
    Liver Cancer.2021; 10(1): 63.     CrossRef
  • In vivo evaluation of a monodisperse solid-in-oil-in-water miriplatin/ lipiodol emulsion in transcatheter arterial chemoembolization using a rabbit VX2 tumor model
    Daisuke Yasui, Aya Yamane, Hiroshi Itoh, Masayuki Kobayashi, Shin-ichiro Kumita, Gayle E. Woloschak
    PLOS ONE.2020; 15(8): e0222553.     CrossRef
  • Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation
    Byung-Yoon Yun, Hye Won Lee, In Kyung Min, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2020; 12(9): 2527.     CrossRef
  • Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion


    Sojung Han, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Dai Hoon Han, Beom Kyung Kim
    Journal of Hepatocellular Carcinoma.2020; Volume 7: 403.     CrossRef
  • 10,949 View
  • 220 Download
  • 23 Web of Science
  • Crossref

Reviews

Hepatic neoplasm

Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers
Yeun-Yoon Kim, Mi-Suk Park, Khalid Suliman Aljoqiman, Jin-Young Choi, Myeong-Jin Kim
Clin Mol Hepatol 2019;25(3):223-233.
Published online January 21, 2019
DOI: https://doi.org/10.3350/cmh.2018.0107
Gadoxetic acid, a hepatocyte-specific magnetic resonance imaging (MRI) contrast agent, has emerged as an important tool for hepatocellular carcinoma (HCC) diagnosis. Gadoxetic acid-enhanced MRI is useful for the evaluation of earlystage HCC, diagnosis of HCC precursor lesions, and highly sensitive diagnosis of HCC. Furthermore, functional information provided by gadoxetic acid-enhanced MRI can aid in the characterization of focal liver lesions. For example, whereas lesions lack functioning hepatocytes appear hypointense in the hepatobiliary phase, preserved or enhanced expression of organic anion transporting polypeptides in some HCCs as well as focal nodular hyperplasia lead to hyperintensity in the hepatobiliary phase; and a targetoid appearance on transitional phase or hepatobiliary phase imaging can be helpful for identifying the histopathological composition of tumors. While gadoxetic acid-enhanced MRI may improve the sensitivity of HCC diagnosis and provide new insights into the characterization of focal liver lesions, there are many challenges associated with its use. This article reviews the pros and cons of HCC diagnosis with gadoxetic acid-enhanced MRI and discuss some clues in the radiological differentiation of HCC from HCC mimickers.

Citations

Citations to this article as recorded by  Crossref logo
  • To Biopsy or Not to Biopsy? Re-examining the Role of Tissue Diagnosis in Hepatocellular Carcinoma
    Kaushal Madan, Ashish Kumar
    Journal of Clinical and Experimental Hepatology.2026; 16(1): 103209.     CrossRef
  • Shrinking hemangiomas amid advancing cirrhosis: A report of 2 cases
    Hari Movva, Christo Mathew, Shiv Patel, Jimmy George, Vikas Burugu, Peeyush Bhargava
    Radiology Case Reports.2026; 21(4): 1429.     CrossRef
  • MMP-9-responsive probe for fluorescence-magnetic resonance dual-mode imaging of hepatocellular carcinoma models with different metastatic capacities
    Qiuye Wang, Yabing Sun, Liangxue Lai, Haijing Cui, Yonglong Ye, Ming Yang, Weihao Zhu, Bo Yuan, Quanliang Mao, Wenzhi Ren, Aiguo Wu
    Chinese Chemical Letters.2025; 36(4): 110212.     CrossRef
  • Multiphase Computed Tomography Scan Findings for Artificial Intelligence Training in the Differentiation of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Based on Interobserver Agreement of Expert Abdominal Radiologists
    Nakarin Inmutto, Suwalee Pojchamarnwiputh, Wittanee Na Chiangmai
    Diagnostics.2025; 15(7): 821.     CrossRef
  • Diagnostic performances of adding transition and hepatobiliary phase to washout in gadoxetic acid-enhanced MRI for subcentimeter hepatocellular carcinoma
    Li Yang, Shengxiang Rao, Kaipu Jin, Lifang Wu, Mengsu Zeng, Ying Ding
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Recent Advances in Magnetic Resonance Imaging for the Diagnosis of Liver Cancer: A Comprehensive Review
    Faisal Alshomrani
    Diagnostics.2025; 15(16): 2016.     CrossRef
  • Predicting hepatic perfusion and clearance in hepatocellular carcinoma patients using Gd-EOB-DTPA-enhanced MRI
    Jinghui Feng, Xukun Zhang, Jinpeng Tan, Minghao Han, Dongxue Qi, Xiaoying Wang, Lihua Zhang
    Asian Journal of Surgery.2025;[Epub]     CrossRef
  • Intra-patient and inter-observer image quality analysis in liver MRI study with gadoxetic acid using two different multi-arterial phase techniques
    Francesca Castagnoli, Riccardo Faletti, Riccardo Inchingolo, Alberta Villanacci, Valeria Ruggeri, Domenico Zacà, Dow-Mu Koh, Luigi Grazioli
    British Journal of Radiology.2024; 97(1156): 868.     CrossRef
  • Prognostic significance of MRI features in patients with solitary large hepatocellular carcinoma following surgical resection
    Kyowon Gu, Ji Hye Min, Jeong Hyun Lee, Jaeseung Shin, Woo Kyoung Jeong, Young Kon Kim, Honsoul Kim, Sun-Young Baek, Jong Man Kim, Gyu Seong Choi, Jinsoo Rhu, Sang Yun Ha
    European Radiology.2024; 34(11): 7002.     CrossRef
  • Review of imaging findings in hepatic veno-occlusive disease
    Samuel Simpson, Elliot Breshears, Deepashri Basavalingu, Garvit Khatri, Sherwin Chan, John Fite, Paul Swanson, Manjiri Dighe
    European Journal of Radiology.2024; 177: 111526.     CrossRef
  • Clinical applications, safety profiles, and future developments of contrast agents in modern radiology: A comprehensive review
    Reabal Najjar
    iRADIOLOGY.2024; 2(5): 430.     CrossRef
  • Suspected focal nodular hyperplasia in male adults: 10-year experience from a large liver centre
    Carmelo Corallo, Joshua Bell, Adam Laverty, Maryam Mohsin, Raj Prasad, Raneem Albazaz
    Abdominal Radiology.2023; 48(7): 2292.     CrossRef
  • Gadoxetic acid in hepatocellular carcinoma and liver metastases: pearls and pitfalls
    H.M. Kwok, C.M. Chau, H.C.H. Lee, T. Wong, H.F. Chan, W.H. Luk, W.T.A. Yung, L.F. Cheng, K.F.J. Ma
    Clinical Radiology.2023; 78(10): 715.     CrossRef
  • Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC management
    Bachir Taouli, Ahmed Ba-Ssalamah, Julius Chapiro, Jagpreet Chhatwal, Kathryn Fowler, Tae Wook Kang, Gesine Knobloch, Dow-Mu Koh, Masatoshi Kudo, Jeong Min Lee, Takamichi Murakami, David J. Pinato, Kristina I. Ringe, Bin Song, Parissa Tabrizian, Jin Wang,
    European Radiology.2023; 33(12): 9152.     CrossRef
  • External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, In Kyung Min, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2022; 14(3): 711.     CrossRef
  • Dual-domain unsupervised network for removing motion artifact related to Gadoxetic acid-enhanced MRI
    Chongxin Bai, Kewen Liu, Shi Chen, Zhao Li, Weida Xie, Qingjia Bao, Chaoyang Liu
    Journal of Physics: Conference Series.2022; 2258(1): 012037.     CrossRef
  • Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting
    Cher Heng Tan, Shu-cheng Chou, Nakarin Inmutto, Ke Ma, RuoFan Sheng, YingHong Shi, Zhongguo Zhou, Akira Yamada, Ryosuke Tateishi
    Korean Journal of Radiology.2022; 23(7): 697.     CrossRef
  • Hepatocellular carcinoma pathologic grade prediction using radiomics and machine learning models of gadoxetic acid-enhanced MRI: a two-center study
    Yeo Eun Han, Yongwon Cho, Min Ju Kim, Beom Jin Park, Deuk Jae Sung, Na Yeon Han, Ki Choon Sim, Yang Shin Park, Bit Na Park
    Abdominal Radiology.2022; 48(1): 244.     CrossRef
  • Hepatobiliary phase of gadoxetic acid–enhanced MRI in patients with HCC: prognostic features before resection, ablation, or TACE
    Jae Seok Bae, Jung Hoon Kim, Dong Ho Lee, Jae Hyun Kim, Joon Koo Han
    European Radiology.2021; 31(6): 3627.     CrossRef
  • A Case of Metastatic Melanoma in the Liver Mimicking Hepatocellular Carcinoma
    Jae-Kyoung So, Ji-Yun Hong, Min-Woo Chung, Sung-Bum Cho
    Journal of Liver Cancer.2021; 21(1): 92.     CrossRef
  • Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
    Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
    Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123.     CrossRef
  • Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Journal of Viral Hepatitis.2021; 28(11): 1570.     CrossRef
  • The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
    Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Hepatocellular Carcinoma.2021; Volume 8: 467.     CrossRef
  • Malignant Tumors Misdiagnosed as Liver Hemangiomas
    Murat Baki Yıldırım, İbrahim Tayfun Şahiner, Arzu Poyanlı, Bülent Acunaş, Mine Güllüoǧlu, Cem İbiş, Yaman Tekant, İlgin Özden
    Frontiers in Surgery.2021;[Epub]     CrossRef
  • Diagnosis of focal liver lesions with deep learning-based multi-channel analysis of hepatocyte-specific contrast-enhanced magnetic resonance imaging
    Róbert Stollmayer, Bettina K Budai, Ambrus Tóth, Ildikó Kalina, Erika Hartmann, Péter Szoldán, Viktor Bérczi, Pál Maurovich-Horvat, Pál N Kaposi
    World Journal of Gastroenterology.2021; 27(35): 5978.     CrossRef
  • Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Hepatology International.2021; 15(5): 1083.     CrossRef
  • Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, Hye Jung Shin, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2021; 13(23): 5892.     CrossRef
  • External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals
    Jung Hyun Ji, Soo Young Park, Won Jeong Son, Hye Jung Shin, Hyein Lee, Hye Won Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Viral Hepatitis.2021; 28(6): 951.     CrossRef
  • Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma
    Han Ah Lee, Hyun Gil Goh, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Hyung Joon Yim, Min-Goo Lee, Hyunggin An, Yoon Tae Jeen, Jong Eun Yeon, Kwan Soo Byun, Yeon Seok Seo
    BMC Gastroenterology.2021;[Epub]     CrossRef
  • Realization of improved outcomes following liver resection in hepatocellular carcinoma patients aged 75 years and older
    Jong Man Kim, Jinsoo Rhu, Sang Yun Ha, Gyu-Seong Choi, Choon Hyuck David Kwon, Gaabsoo Kim, Jae-Won Joh
    Annals of Surgical Treatment and Research.2021; 101(5): 257.     CrossRef
  • Imaging After Locoregional Therapy for Hepatocellular Carcinoma With Emphasis on LIRADS Treatment Response Assessment Criteria
    Gitanjali Bajaj, Karthik Sundaram, Kedar Jambhekar, Roopa Ram
    Seminars in Ultrasound, CT and MRI.2021; 42(4): 390.     CrossRef
  • Management of indeterminate hepatic nodules and evaluation of factors predicting their malignant potential in patients with colorectal cancer
    Mizelle D’Silva, Jai Young Cho, Ho-Seong Han, Taupyk Yerlan, Yoo-Seok Yoon, Hae Won Lee, Jun Suh Lee, Boram Lee, Moonhwan Kim
    Scientific Reports.2021;[Epub]     CrossRef
  • Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein improves diagnostic accuracy for hepatocellular carcinoma
    Han Ah Lee, Yoo Ra Lee, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Yoon Tae Jeen, Jong Eun Yeon, Kwan Soo Byun, Yeon Seok Seo
    World Journal of Gastroenterology.2021; 27(28): 4687.     CrossRef
  • Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents
    Anum Aslam, Amita Kamath, Bradley Spieler, Mark Maschiocchi, Carl F. Sabottke, Victoria Chernyak, Sara C. Lewis
    Abdominal Radiology.2021; 46(8): 3565.     CrossRef
  • Hepatobiliary phase signal intensity: A potential method of diagnosing HCC with atypical imaging features among LR-M observations
    Jae Hyon Park, Yong Eun Chung, Nieun Seo, Jin-Young Choi, Mi-Suk Park, Myeong-Jin Kim, Isabelle Chemin
    PLOS ONE.2021; 16(9): e0257308.     CrossRef
  • Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1
    Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho
    International Journal of Molecular Sciences.2021; 22(18): 10027.     CrossRef
  • Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation
    Byung-Yoon Yun, Hye Won Lee, In Kyung Min, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2020; 12(9): 2527.     CrossRef
  • Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion


    Sojung Han, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Dai Hoon Han, Beom Kyung Kim
    Journal of Hepatocellular Carcinoma.2020; Volume 7: 403.     CrossRef
  • Intraindividual Comparison between Gadoxetate-Enhanced Magnetic Resonance Imaging and Dynamic Computed Tomography for Characterizing Focal Hepatic Lesions: A Multicenter, Multireader Study
    Chansik An, Chang Hee Lee, Jae Ho Byun, Min Hee Lee, Woo Kyoung Jeong, Sang Hyun Choi, Do Young Kim, Young-Suk Lim, Young Seok Kim, Ji Hoon Kim, Moon Seok Choi, Myeong-Jin Kim
    Korean Journal of Radiology.2019; 20(12): 1616.     CrossRef
  • 14,819 View
  • 442 Download
  • 35 Web of Science
  • Crossref

Hepatic neoplasm

Pathologic differential diagnosis of metastatic carcinoma in the liver
Jeong Hwan Park, Jung Ho Kim
Clin Mol Hepatol 2019;25(1):12-20.
Published online October 5, 2018
DOI: https://doi.org/10.3350/cmh.2018.0067
The liver is one of the most common sites to which malignancies preferentially metastasize. Although a substantial number of liver malignancies are primary tumors, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, the metastasis of carcinomas to the liver is relatively common and frequently encountered in clinical settings. Representative carcinomas that frequently metastasize to the liver include colorectal carcinoma, breast carcinoma, neuroendocrine tumors, lung carcinoma, and gastric carcinoma. The diagnostic confirmation of suspected metastatic lesions in the liver is generally achieved through a histopathologic examination of biopsy tissues. Although morphology is the most important feature for a pathologic differential diagnosis of metastatic carcinomas, immunohistochemical studies facilitate the differentiation of metastatic carcinoma origins and subtypes. Useful immunohistochemical markers for the differential diagnosis of metastatic carcinomas in the liver include cytokeratins (CK7, CK19, and CK20), neuroendocrine markers (CD56, synaptophysin, and chromogranin A), and tissue-specific markers (CDX2, SATB2, TTF-1, GCDFP-15, mammaglobin, etc.). Here, we provide a brief review about the pathologic differential diagnosis of major metastatic carcinomas in the liver.

Citations

Citations to this article as recorded by  Crossref logo
  • Pioneering efficient deep learning architectures for enhanced hepatocellular carcinoma prediction and clinical translation
    Sami Akbulut, Cemil Colak
    World Journal of Gastrointestinal Oncology.2026;[Epub]     CrossRef
  • RNA splicing dysregulation in hepatocellular carcinoma: Molecular mechanisms, therapeutic targets, and intervention strategies—A comprehensive review
    Shuai Xiong, Lei Hu, Yun-Yang Sun, Wei Huang, Xiao-Yu Hu
    Biomedicine & Pharmacotherapy.2026; 195: 119025.     CrossRef
  • Endoscopic ultrasound‐guided tissue acquisition for focal liver lesions in patients with a history of multiple primary malignant neoplasms
    Yuichi Takano, Naoki Tamai, Masataka Yamawaki, Jun Noda, Tetsushi Azami, Fumitaka Niiya, Fumiya Nishimoto, Naotaka Maruoka, Tatsuya Yamagami, Masatsugu Nagahama
    DEN Open.2025;[Epub]     CrossRef
  • Machine learning-assisted pattern recognition and imaging of multiplexed cancer cells via a porphyrin-embedded dendrimer array
    Jiabao Hu, Weiwei Ni, Mengting Han, Yunzhen Zhan, Fei Li, Hui Huang, Jinsong Han
    Journal of Materials Chemistry B.2025; 13(1): 207.     CrossRef
  • Molecular subtypes of intrahepatic cholangiocarcinoma
    Alessandro De Santis, Lei Zhu, Jianxin Tao, Christoph Reißfelder, Sebastian Schölch
    Trends in Molecular Medicine.2025; 31(8): 755.     CrossRef
  • Biliary Adenofibroma and the Threat of Malignant Transformation
    Mohamed A. Youssef, Joseph Gosnell, Heather L. Stevenson
    International Journal of Surgical Pathology.2025; 33(7): 1658.     CrossRef
  • Long-term SiNPs exposure induced genetic instability and malignant transformation via SQSTM1/p62-mediated autophagy dysfunction in lungs
    Kanglin Yan, Yuexiao Ma, Xuemin Shi, Chen Liang, Ruiyang Ding, Zhiwei Sun, Junchao Duan
    Materials Today Bio.2025; 33: 101972.     CrossRef
  • Metastatic hepatic carcinoma: Mechanisms, emerging therapeutics, and future perspectives
    Jianfeng Zhou, Yuan Sui, Zhihua Chen
    iScience.2025; 28(7): 112902.     CrossRef
  • Quantitative Assessment of Peritumoral Stiffness Using Shell Elastography Enhances the Differentiation of Hepatocellular Carcinoma From Metastatic Liver Carcinoma
    Yang Li, Zhaoyu Wu, Min Zhu, Banban Wu, Yibin Wang
    Journal of Ultrasound in Medicine.2025;[Epub]     CrossRef
  • Discovery of novel DNA methylation biomarker panels for the diagnosis and differentiation between common adenocarcinomas and their liver metastases
    Tina Draškovič, Nina Hauptman
    Scientific Reports.2024;[Epub]     CrossRef
  • Identifying primary tumor site of origin for liver metastases via a combination of handcrafted and deep learning features
    Chuheng Chen, Cheng Lu, Vidya Viswanathan, Brandon Maveal, Bhunesh Maheshwari, Joseph Willis, Anant Madabhushi
    The Journal of Pathology: Clinical Research.2024;[Epub]     CrossRef
  • Advancing Differentiation of Hepatic Metastases in Malignant Melanoma through Dual-Energy Computed Tomography Rho/Z Maps
    Ibrahim Yel, Vitali Koch, Leon D. Gruenewald, Scherwin Mahmoudi, Leona S. Alizadeh, Aynur Goekduman, Katrin Eichler, Thomas J. Vogl, Mirela Dimitrova, Christian Booz
    Diagnostics.2024; 14(7): 742.     CrossRef
  • Exploring the potential of drug repurposing for liver diseases: A comprehensive study
    Fares E.M. Ali, Mustafa Ahmed Abdel-Reheim, Emad H.M. Hassanein, Mostafa K. Abd El-Aziz, Hanan S. Althagafy, Khalid S.A. Badran
    Life Sciences.2024; 347: 122642.     CrossRef
  • Impact of immunotherapy on liver metastasis
    Zhuo Fu, Ming-Wei Wang, Ya-Hui Liu, Yan Jiao
    World Journal of Gastrointestinal Surgery.2024; 16(7): 1969.     CrossRef
  • An audit of metastatic tumors to the liver highlighting the spectrum of differential diagnosis: A retrospective study from a tertiary cancer center in North India
    Neha Singh, Ipsita Dhal, Kirti Rajput, Zachariah Chowdhury, Shashikant Patne, Parul Tripathi, Swapnil Patel, Mayank Tripathi, Durgatosh Pandey, Bipinesh Sansar
    Cancer Research, Statistics, and Treatment.2024; 7(2): 149.     CrossRef
  • Automated diagnosis and classification of liver cancers using deep learning techniques: a systematic review
    Sarthak Grover, Surbhi Gupta
    Discover Applied Sciences.2024;[Epub]     CrossRef
  • Benefits and drawbacks of radiofrequency ablation via percutaneous or minimally invasive surgery for treating hepatocellular carcinoma
    Ching-Lung Hsieh, Cheng-Ming Peng, Chun-Wen Chen, Chang-Hsien Liu, Chih-Tao Teng, Yi-Jui Liu
    World Journal of Gastrointestinal Surgery.2024; 16(11): 3400.     CrossRef
  • Albumin, filamin-A and cytokeratin 19 help distinguish intrahepatic cholangiocarcinoma from extrahepatic adenocarcinoma
    Yeon Seung Chung, Youngsic Jeon, Jeong Eun Yoo, Taek Chung, Hyang Joo Ryu, Hyunki Kim, Hyungjin Rhee, Young Nyun Park
    Hepatology International.2023; 17(1): 77.     CrossRef
  • Una causa inusual de fallo hepático fulminante: infiltración metastásica por carcinoma ductal infiltrante de mama
    Francisco Javier Pardilla Moraleda, Rosario Serrano Pardo, Lourdes del Campo del Val, Luisa García-Buey
    Gastroenterología y Hepatología.2023; 46(9): 710.     CrossRef
  • Laparoscopic Hepatectomy for Hepatocellular Carcinoma
    Qiyu Qiu
    Highlights in Science, Engineering and Technology.2023; 30: 12.     CrossRef
  • EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma
    Domenico Alvaro, Gregory J. Gores, Joël Walicki, Cesare Hassan, Gonzalo Sapisochin, Mina Komuta, Alejandro Forner, Juan W. Valle, Andrea Laghi, Sumera I. Ilyas, Joong-Won Park, Robin K. Kelley, Maria Reig, Bruno Sangro
    Journal of Hepatology.2023; 79(1): 181.     CrossRef
  • Breast mass as the first sign of metastasis from rectal carcinoma: a case report and review of the literature
    Jiawei Xu, Chao Liu, Chengdong Yu, Tenghua Yu, Fan Fan, Xiaofang Zhang, Chuansheng Huang, Wen Chen, Zhengkui Sun, Meng Zhou
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Carcinoma of unknown primary (CUP): an update for histopathologists
    Katie Beauchamp, Bruce Moran, Timothy O’Brien, Donal Brennan, John Crown, Kieran Sheahan, Maura Bríd Cotter
    Cancer and Metastasis Reviews.2023; 42(4): 1189.     CrossRef
  • Implementation of deep learning in liver pathology optimizes diagnosis of benign lesions and adenocarcinoma metastasis
    Mark Kriegsmann, Katharina Kriegsmann, Georg Steinbuss, Christiane Zgorzelski, Thomas Albrecht, Stefan Heinrich, Stefan Farkas, Wilfried Roth, Hien Dang, Anne Hausen, Matthias M. Gaida
    Clinical and Translational Medicine.2023;[Epub]     CrossRef
  • An unusual cause of fulminant hepatic failure: Metastatic infiltration by infiltrating ductal carcinoma of the breast
    Francisco Javier Pardilla Moraleda, Rosario Serrano Pardo, Lourdes del Campo del Val, Luisa García-Buey
    Gastroenterología y Hepatología (English Edition).2023; 46(9): 710.     CrossRef
  • Deep Learning for the Pathologic Diagnosis of Hepatocellular Carcinoma, Cholangiocarcinoma, and Metastatic Colorectal Cancer
    Hyun-Jong Jang, Jai-Hyang Go, Younghoon Kim, Sung Hak Lee
    Cancers.2023; 15(22): 5389.     CrossRef
  • Primäre und sekundäre Lebertumore
    Nabeel Mansour, Max Seidensticker, Maurice M. Heimer
    Angewandte Nuklearmedizin.2023; 46(04): 323.     CrossRef
  • Liver metastasis of breast carcinoma: An unusual presentation and growth pattern
    Mine Özşen, Nesrin Uğraş, Ömer Yerci, Adem Deligönül
    Indian Journal of Pathology and Microbiology.2023; 66(4): 877.     CrossRef
  • Metastatic Liver Tumors in Surgical Pathology: Impact of Contemporary Diagnostic and Therapeutic Paradigms in a Tertiary Care Center
    Ayşe Armutlu, Omer Saeed, Romil Saxena
    International Journal of Surgical Pathology.2022; 30(2): 138.     CrossRef
  • Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma
    Taek Chung, Young Nyun Park
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • The Impact of Pre-analytical Quality Initiatives on Cholangiocarcinoma Diagnostics in Thailand
    Supinda Koonmee, Sakkarn Sangkhamanon, Piyapharom Intarawichian, Chaiwat Aphivatanasiri, Waritta Kunprom, Prakasit Sa-ngiamwibool, Suwit Balthaisong, Chitsakul Phuyao, Piya Prajumwongs, Reza Alaghehbandan, Malinee Thanee
    Frontiers in Public Health.2022;[Epub]     CrossRef
  • Immunohistochemical Profile of Parathyroid Tumours: A Comprehensive Review
    Romans Uljanovs, Stanislavs Sinkarevs, Boriss Strumfs, Liga Vidusa, Kristine Merkurjeva, Ilze Strumfa
    International Journal of Molecular Sciences.2022; 23(13): 6981.     CrossRef
  • Oesophageal and gastric cancers: From epidemiology to modern treatment
    Nikola Milošević, Srđan Milanović
    Glasnik javnog zdravlja.2022; 96(2): 203.     CrossRef
  • Diagnosis of the Primary Tumor Site in the Case of Liver Metastatic Carcinoma
    Mercedes Malone, Christopher Bray, Xiaolong Sean Liu
    Cureus.2022;[Epub]     CrossRef
  • Probe electrospray ionization mass spectrometry‐based rapid diagnosis of liver tumors
    Hiroyuki Hakoda, Sho Kiritani, Takashi Kokudo, Kentaro Yoshimura, Tomohiko Iwano, Meguri Tanimoto, Takeaki Ishizawa, Junichi Arita, Nobuhisa Akamatsu, Junichi Kaneko, Sen Takeda, Kiyoshi Hasegawa
    Journal of Gastroenterology and Hepatology.2022; 37(11): 2182.     CrossRef
  • Case report: Rare isolated cystic hepatic metastasis of a patient with squamous cell lung carcinoma history and the prognosis
    Chunbao Liu, Xiaomin Chen, Hang Su, Liang Xia, Diyu Lu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Liver Metastases: Correlation between Imaging Features and Pathomolecular Environments
    Kumi Ozaki, Shohei Higuchi, Hirohiko Kimura, Toshifumi Gabata
    RadioGraphics.2022; 42(7): 1994.     CrossRef
  • Metastatic ovarian tumor from pancreatic cancer treated with combined immunotherapy: A case report
    Yiying Tao, Lei Tang, Li Zuo, Yue Ma, Fengchun Zhang, Yingchun Xu
    Oncology Letters.2022;[Epub]     CrossRef
  • Prognostic Significance of CDH1, FN1 and VIM for Early Recurrence in Patients with Colorectal Liver Metastasis After Liver Resection
    Aleksandar Bogdanovic, Jovana Despotovic, Danijel Galun, Nemanja Bidzic, Aleksandra Nikolic, Jovana Rosic, Zoran Krivokapic
    Cancer Management and Research.2021; Volume 13: 163.     CrossRef
  • Preoperative classification of primary and metastatic liver cancer via machine learning-based ultrasound radiomics
    Bing Mao, Jingdong Ma, Shaobo Duan, Yuwei Xia, Yaru Tao, Lianzhong Zhang
    European Radiology.2021; 31(7): 4576.     CrossRef
  • Real-time lipid patterns to classify viable and necrotic liver tumors
    Pierre-Maxence Vaysse, Heike I. Grabsch, Mari F.C.M. van den Hout, Marc H.A. Bemelmans, Ron M.A. Heeren, Steven W.M. Olde Damink, Tiffany Porta Siegel
    Laboratory Investigation.2021; 101(3): 381.     CrossRef
  • Self-organization in cancer: Implications for histopathology, cancer cell biology, and metastasis
    Senthil K. Muthuswamy
    Cancer Cell.2021; 39(4): 443.     CrossRef
  • Cervical lymph node enlargement as the initial manifestation of rectal cancer
    Tong-Hui Xie, Peng Su, Jian-Guo Hong, Hui Zhang
    BMC Gastroenterology.2021;[Epub]     CrossRef
  • Management of indeterminate hepatic nodules and evaluation of factors predicting their malignant potential in patients with colorectal cancer
    Mizelle D’Silva, Jai Young Cho, Ho-Seong Han, Taupyk Yerlan, Yoo-Seok Yoon, Hae Won Lee, Jun Suh Lee, Boram Lee, Moonhwan Kim
    Scientific Reports.2021;[Epub]     CrossRef
  • Evaluation of the Diagnostic Performance of Positron Emission Tomography/Magnetic Resonance for the Diagnosis of Liver Metastases
    Caiyuan Zhang, Aileen O'Shea, Chiara Anna Parente, Barbara Juarez Amorim, Peter Caravan, Christina R. Ferrone, Lawrence S. Blaszkowsky, Andrea Soricelli, Marco Salvatore, David Groshar, Hanna Bernstine, Liran Domachevsky, Lina Garcia Canamaque, Lale Umutl
    Investigative Radiology.2021; 56(10): 621.     CrossRef
  • Diagnostic and prognostic impact of cytokeratin 19 expression analysis in human tumors: a tissue microarray study of 13,172 tumors
    Anne Menz, Rifka Bauer, Martina Kluth, Clara Marie von Bargen, Natalia Gorbokon, Florian Viehweger, Maximilian Lennartz, Cosima Völkl, Christoph Fraune, Ria Uhlig, Claudia Hube-Magg, Noémi De Wispelaere, Sarah Minner, Guido Sauter, Simon Kind, Ronald Simo
    Human Pathology.2021; 115: 19.     CrossRef
  • Cholangiocarcinoma
    Samantha Sarcognato, Diana Sacchi, Matteo Fassan, Luca Fabris, Massimiliano Cadamuro, Giacomo Zanus, Ivana Cataldo, Paola Capelli, Francesca Baciorri, Matilde Cacciatore, Maria Guido
    Pathologica.2021; 113(3): 158.     CrossRef
  • Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing
    Jun-Kyu Kang, Sunghoon Heo, Hwang-Phill Kim, Sang-Hyun Song, Hongseok Yun, Sae-Won Han, Gyeong Hoon Kang, Duhee Bang, Tae-You Kim, Alvaro Galli
    PLOS ONE.2020; 15(5): e0232754.     CrossRef
  • Metastatic breast cancer presenting as acute liver injury: diagnostic dilemma in the setting of suspected hemochromatosis
    Raguraj Chandradevan, Hironobu Takeda, Benjamin Hayes, Kalli Faulkner, Matthew Darrow
    Oxford Medical Case Reports.2020;[Epub]     CrossRef
  • Critical steps to tumor metastasis: alterations of tumor microenvironment and extracellular matrix in the formation of pre-metastatic and metastatic niche
    Jianan Zhuyan, Mingyu Chen, Tianhao Zhu, Xunxia Bao, Timing Zhen, Kaichen Xing, Qiubo Wang, Sibo Zhu
    Cell & Bioscience.2020;[Epub]     CrossRef
  • Colorectal liver metastases: radiopathological correlation
    Luisa Paulatto, Marco Dioguardi Burgio, Riccardo Sartoris, Aurélie Beaufrère, François Cauchy, Valérie Paradis, Valérie Vilgrain, Maxime Ronot
    Insights into Imaging.2020;[Epub]     CrossRef
  • Italian Clinical Practice Guidelines on Cholangiocarcinoma – Part I: Classification, diagnosis and staging
    Domenico Alvaro, Cesare Hassan, Vincenzo Cardinale, Guido Carpino, Luca Fabris, Enrico Gringeri, Vincenza Granata, Massimiliano Mutignani, Helen Morement, Felice Giuliante, Alfredo Guglielmi, Lorenzo Ridola, Marco Marzioni, Gianluca Grazi, Maria Guido, Em
    Digestive and Liver Disease.2020; 52(11): 1282.     CrossRef
  • Hepatocellular carcinomas can be Special AT-rich sequence-binding protein 2 positive: an important diagnostic pitfall
    Whayoung Lee, Xiaodong Li, Vishal S. Chandan
    Human Pathology.2020; 105: 47.     CrossRef
  • Higher expression of SATB2 in hepatocellular carcinoma of African Americans determines more aggressive phenotypes than those of Caucasian Americans
    Wei Yu, Sanjit K. Roy, Yiming Ma, Thomas A. LaVeist, Sharmila Shankar, Rakesh K. Srivastava
    Journal of Cellular and Molecular Medicine.2019; 23(12): 7999.     CrossRef
  • 35,656 View
  • 1,181 Download
  • 51 Web of Science
  • Crossref

Case Report

Benign liver tumors and cystic disease of liver

Living-donor liver transplantation for giant hepatic hemangioma with diffuse hemangiomatosis in an adult: a case report
Ju Hyun Lee, Chang Jin Yoon, Young Hoon Kim, Ho-Seong Han, Jai Young Cho, Haeryoung Kim, Eun Sun Jang, Jin-Wook Kim, Sook-Hyang Jeong
Clin Mol Hepatol 2018;24(2):163-168.
Published online July 19, 2017
DOI: https://doi.org/10.3350/cmh.2017.0002
Hepatic hemangioma represents the most common benign primary hepatic neoplasm. Although most such tumors are small and asymptomatic, giant hepatic hemangioma is frequently symptomatic, and requires intervention. Moreover, diffuse multiple hepatic hemangiomatosis occupying almost the entire liver is extremely rare in adults, and the optimal management for this condition is unclear. We report a case of a rapidly growing, symptomatic giant hepatic hemangioma with diffuse hepatic hemangiomatosis in a 50-year-old female patient who was treated by living-donor liver transplantation. This case shows malignant behavior of a benign hemangioma that required liver transplantation. Although this case could not meet the criteria for transplantation according to the MELD (model for end-stage liver disease) score system, it should be considered as an exceptional indication for deceased-donor liver allocation. Further studies of the mechanism underlying hemangioma growth are warranted.

Citations

Citations to this article as recorded by  Crossref logo
  • Manejo quirúrgico de hemangiomas hepáticos gigantes
    Luis Manuel Barrera-Lozano, Jaime Alberto Ramírez Ramírez, Cristian Leonardo Muñoz, Sebastián Cerquera-Cajamarca, Jorge Iván Gutiérrez-Montoya
    Revista Colombiana de Cirugía.2025; 40(2): 245.     CrossRef
  • Laparoscopic microwave ablation for giant cavernous hemangioma coexistent with diffuse hepatic hemangiomatosis: Two case reports
    Fei Xu, Jian Kong, Shu-Ying Dong, Li Xu, Shao-Hong Wang, Wen-Bing Sun, Jun Gao
    World Journal of Gastrointestinal Surgery.2025;[Epub]     CrossRef
  • A case of portal hypertension due to an invasive hepatic hemangioma following a long-term disease course
    Naruhiro Kimura, Koutarou Yoshida, Yuuichi Kojima, Yuto Tanaka, Nao Nakajima, Hiroyuki Abe, Satoshi Ikarashi, Akira Sakamaki, Kenichi Mizuno, Shuji Terai
    Clinical Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Endovascular treatment of giant hepatic hemangiomas: a systematic review and meta-analysis
    Sofia Malosso Tronconi, João Felipe Federici de Almeida, Ana Terezinha Guillaumon
    Jornal Vascular Brasileiro.2025;[Epub]     CrossRef
  • Tratamento endovascular de hemangiomas hepáticos gigantes: uma revisão sistemática com metanálise
    Sofia Malosso Tronconi, João Felipe Federici de Almeida, Ana Terezinha Guillaumon
    Jornal Vascular Brasileiro.2025;[Epub]     CrossRef
  • Exceptional Liver Transplant Indications: Unveiling the Uncommon Landscape
    Teodor Cabel, Cristina Madalina Pascu, Catalin Stefan Ghenea, Bogdan Florin Dumbrava, Deniz Gunsahin, Andreea Andrunache, Livia-Marieta Negoita, Afrodita Panaitescu, Ecaterina Mihaela Rinja, Christopher Pavel, Oana-Mihaela Plotogea, Madalina Stan-Ilie, Va
    Diagnostics.2024; 14(2): 226.     CrossRef
  • Liver transplantation for liver hemangioma: The Paul Brousse Hospital experience and a systematic review of the literature
    Ainhoa Andres Imaz, Maria Conticchio, Chady Salloum, Daniel Cherqui, René Adam, Daniel Azoulay
    Journal of Liver Transplantation.2024; 13: 100193.     CrossRef
  • Surgery for a symptomatic massive liver haemangioma
    Sowmiya Velusamy, Souradeep Dutta, Debasis Naik, Vishnu Prasad Nelamangala Ramakrishnaiah
    BMJ Case Reports.2024; 17(3): e257370.     CrossRef
  • Adult diffuse hepatic hemangiomatosis lesion occupying the entire abdominal and pelvic cavities: a case report
    Ya-Nan Ge, Yan Shao, Shu-Chen Dong, Xing-Bin Ma, Wei Wang
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Hepatic hemangioma: proportion and predictor of surgical treatment with emphasis on its growth rate
    Young Cheol Shin, Eun Ju Cho, Hee Young Na, Jai Young Cho, Ho-Seong Han, Yoon Jin Lee, Haeryoung Kim, Sangmi Jang, Gwang Hyeon Choi, Eun Sun Jang, Jin-Wook Kim, Sook-Hyang Jeong
    The Korean Journal of Internal Medicine.2023; 38(6): 818.     CrossRef
  • Liver transplantation for giant hepatic hemangioma: A collective review
    Cheon-Soo Park, Yong-Kyu Chung
    Annals of Liver Transplantation.2023; 3(2): 69.     CrossRef
  • Adult diffuse hepatic hemangiomatosis: A case report and review of the literature
    Shihua He, Wenjing Chen, Ying Yang, Xiaoli Tang, Guangde Zhou, Jianhui Zhou, Chuanghong Wu
    Clinics and Research in Hepatology and Gastroenterology.2022; 46(2): 101789.     CrossRef
  • A Comprehensive Review of Hepatic Hemangioma Management
    Hassan Aziz, Zachary J. Brown, Azarakhsh Baghdadi, Ihab R. Kamel, Timothy M. Pawlik
    Journal of Gastrointestinal Surgery.2022; 26(9): 1998.     CrossRef
  • Liver transplantation for giant hemangioma of the liver: A case report and review of the literature
    Yun Zhao, Xiu-Ping Li, Yuan-Yuan Hu, Ji-Chang Jiang, Li-Jin Zhao
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Autologous Partial Liver Transplantation for a Symptomatic Giant Hepatic Hemangioma. A Case Report
    Ayato Obana, Yoshinobu Sato
    Transplantation Proceedings.2022; 54(10): 2787.     CrossRef
  • Liver Transplantation for Rapidly Progressive Giant Hepatic Hemangioma With Diffuse Hemangiomatosis
    Sadhana Shankar, Ashwin Rammohan, Venugopal H. Kulaseharan, Rathnavel Kanagavelu, Mettu S. Reddy, Mohamed Rela
    Experimental and Clinical Transplantation.2021; 19(10): 1106.     CrossRef
  • A case of diffuse hepatic hemangiomatosis coexistent with giant hemangioma: case report and literature review
    M. Isabel González-Nieto, Luz Adriana Escobar Hoyos
    Radiology Case Reports.2021; 16(6): 1518.     CrossRef
  • Liver transplantation for benign liver tumors
    Ana Ostojic, Anna Mrzljak, Danko Mikulic
    World Journal of Hepatology.2021; 13(9): 1098.     CrossRef
  • Orthotopic liver transplantation for Management of a Giant Liver Hemangioma: a case report and review of literature
    Hesameddin Eghlimi, Peyman Arasteh, Nazanin Azade
    BMC Surgery.2020;[Epub]     CrossRef
  • Invasive management of symptomatic hepatic hemangioma
    Wenfang Dong, Bin Qiu, Haifeng Xu, Leren He
    European Journal of Gastroenterology & Hepatology.2019; 31(9): 1079.     CrossRef
  • 24,023 View
  • 245 Download
  • 18 Web of Science
  • Crossref

Liver Pathology

Hepatic neoplasm

Epithelioid angiomyolipoma of the liver: a case report
Soo Yeon Lee, Baek-hui Kim
Clin Mol Hepatol 2017;23(1):91-94.
Published online March 17, 2017
DOI: https://doi.org/10.3350/cmh.2017.0011
Epithelioid angiomyolipoma (EAML) of liver is a rare neoplasm. Hepatic EAML is often misdiagnosed as other neoplasms such as hepatocellular carcinoma due to non-specific clinical and radiologic features. The morphologic features under microscope and immunohistochemistry staining profile are important in the diagnosis EAML. Here, we report a case of 52-year-old man who found 1.2 cm mass in liver by routine checkup. On the impression of hepatocellular carcinoma, lateral sectionectomy of the liver was done. Microscopically, the tumor is composed of predominant epithelioid cells with vascular component and foamy cells. These cells were positive for HMB45, MelanA, and smooth muscle actin and negative for epithelial membrane antigen. The final diagnosis was hepatic EAML.

Citations

Citations to this article as recorded by  Crossref logo
  • Hepatic epithelioid angiomyolipoma treated with laparoscopic resection and transcatheter arterial embolization first time: A case report and review of literature
    Fei Wang, Zhong-Xing Shi, Xin-Yu He, Xue-Jing Han, Jia-Hui Wang, Jia-Yi Yang, Li-Ming Cui
    World Journal of Gastrointestinal Surgery.2026;[Epub]     CrossRef
  • Epithelioid angiomyolipoma of the liver in a patient with Li-Fraumeni syndrome: a case report 
    Yaewon Yang, Jisun Lee, Chang Gok Woo, Ok-Jun Lee, Seung-Myoung Son
    Diagnostic Pathology.2024;[Epub]     CrossRef
  • The Difficulties of Diagnosis Giant Angiomyolipoma of the Liver: Clinical Case and Literature Review
    A. V. Arablinskii, O. P. Myasnyankina, A. A. Sedova, M. P. Onischenko
    Journal of oncology: diagnostic radiology and radiotherapy.2024; 7(1): 98.     CrossRef
  • Hepatic epithelioid angiomyolipoma: magnetic resonance imaging characteristics
    Li Junhao, Zhang Hongxia, Guo Jiajun, Ikram Ahmad, Gao Shanshan, Li Jianke, Chen Lingli, Ji Yuan, Zeng Mengsu, Wang Mingliang
    Abdominal Radiology.2023;[Epub]     CrossRef
  • Hepatic epithelioid angiomyolipoma is scattered and unsuitable for surgery: a case report
    Xiangreng Cai, Shuchuan Sun, Yuxin Deng, Jiangxin Liu, Siyuan Pan
    Journal of International Medical Research.2023;[Epub]     CrossRef
  • Epithelioid hepatic angiomyolipoma in pregnancy: A case report
    Abdullah Khalid, Bilal Ahmed Khan, Zubair Saeed, Usman Atique, Muhammad Yasir Khan, Ihsan -ul-Haq
    International Journal of Surgery Case Reports.2023; 111: 108902.     CrossRef
  • Hepatic angiomyolipoma
    Simone A. Günster, Mia Kim, Johan F. Lock, Katica Krajinovic
    International Journal of Surgery Case Reports.2020; 77(C): 345.     CrossRef
  • Angiomiolipoma epitelioide/PEComa hepático e hiperplasia nodular focal en una paciente con antecedentes de melanoma cutáneo
    Isidro Machado, Ana Marhuenda, Marta Trallero, María Caballero, Jesús Santos, Julia Cruz, Rafael Estevan
    Revista Española de Patología.2019; 52(4): 250.     CrossRef
  • Ultrasound‐guided fine needle aspiration cytology in the diagnosis of hepatic and pancreatic perivascular epithelioid cell tumors: A case series
    Valentina Sangiorgio, Lorenzo Daniele, Teresa Gallo, Rodolfo Rocca, Cristina Fava, Paola Campisi, Giovanni De Rosa
    Diagnostic Cytopathology.2019; 47(4): 315.     CrossRef
  • Two case reports and literature review for hepatic epithelioid angiomyolipoma: Pitfall of misdiagnosis
    Jia-Xi Mao, Fei Teng, Cong Liu, Hang Yuan, Ke-Yan Sun, You Zou, Jia-Yong Dong, Jun-Song Ji, Jun-Feng Dong, Hong Fu, Guo-Shan Ding, Wen-Yuan Guo
    World Journal of Clinical Cases.2019; 7(8): 972.     CrossRef
  • Hepatic epithelioid angiomyolipoma: contribution of a new case
    María Ángeles Valero González, Yolanda Núñez Delgado, Ana Milena Muñoz
    Revista Española de Enfermedades Digestivas.2019;[Epub]     CrossRef
  • Imaging appearance of renal epithelioid angiomyolipoma
    Jianguo Zhu, Haige Li, Liucheng Ding, Hongyong Cheng
    Medicine.2018; 97(1): e9563.     CrossRef
  • Hepatic Epithelioid Angiomyolipoma and 18F-FDG PET/CT
    Yiqiu Zhang, Beilei Li, Jun Hou, Haojun Yu, Hongcheng Shi
    Clinical Nuclear Medicine.2018; 43(6): 422.     CrossRef
  • Liver Angiomyolipoma Mimicking Malignancy in Liver
    Jeong-Ju Yoo, Min Jung Jung, Sang Gyune Kim, Young Seok Kim
    Clinical Ultrasound.2018; 3(1): 15.     CrossRef
  • Hepatic epithelioid angiomyolipoma with renal metastasis: radiologic-pathologic correlation
    Adrian Marcuzzi, Ehsan A. Haider, Ishaq S. Al Salmi
    Radiology Case Reports.2018; 13(4): 829.     CrossRef
  • Comparison of MRI Features of Epithelioid Hepatic Angiomyolipoma and Hepatocellular Carcinoma: Imaging Data From Two Centers
    Weihai Liu, Jiawei Wang, Qiang Huang, Qinyan Lu, Wenjie Liang
    Frontiers in Oncology.2018;[Epub]     CrossRef
  • 12,205 View
  • 157 Download
  • 16 Web of Science
  • Crossref

Liver Imaging

Vascular disorders of liver

Focal type of peliosis hepatis
Gil-Sun Hong, Kyoung Won Kim, Jihyun An, Ju Hyun Shim, Jihun Kim, Eun Sil Yu
Clin Mol Hepatol 2015;21(4):398-401.
Published online December 24, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.4.398

Citations

Citations to this article as recorded by  Crossref logo
  • Focal peliosis hepatis with undefined etiology:: Diagnostic elucidation via ultrasonography, CT, and MRI; case report with literature review
    Tingting Geng, Sumei Gao, Olena Kovalska, Zhijian Liu
    Medicine.2025; 104(51): e44151.     CrossRef
  • A unique presentation of peliosis hepatis: A case report and comprehensive review of the literature
    Alex Teshon, Crystal Walker, David P Schammel, Christine Marie-Gilligan Schammel, A Michael Devane
    International Journal of Hepatobiliary and Pancreatic Diseases.2023; 13(1): 16.     CrossRef
  • Histologic and microbiological findings of the defunctionalized loop in sleeve gastrectomy with jejunal bypass
    Matías Sepúlveda, Munir Alamo, Cristián Astorga, Yudith Preiss, Sebastián Saavedra
    Surgery for Obesity and Related Diseases.2021; 17(1): 131.     CrossRef
  • Hepatic disorders associated with exogenous sex steroids: MR imaging findings
    Cathryn L. Hui, Zhen Jiang Lee
    Abdominal Radiology.2019; 44(7): 2436.     CrossRef
  • Hepatic complications of oral contraceptive pills and estrogen on MRI: Controversies and update - Adenoma and beyond
    Janardhana Ponnatapura, Ania Kielar, Lauren M.B. Burke, Mark E. Lockhart, Abdul-Rahman Abualruz, Rafel Tappouni, Neeraj Lalwani
    Magnetic Resonance Imaging.2019; 60: 110.     CrossRef
  • Peliosis Hepatis Simulates Liver Metastases
    Bruna Migliavacca Zucchetti, Andrea Shimada, Luiz Tenorio Siqueira
    Journal of Global Oncology.2018; (4): 1.     CrossRef
  • A case of multiple spontaneous hepatic ruptures and literature review
    N. V. Tytarenko, O. V. Sergiychuk
    Perioperaciina Medicina.2018; 1(1): 60.     CrossRef
  • 12,573 View
  • 114 Download
  • 5 Web of Science
  • Crossref

Review

Hepatic neoplasm

Imaging findings of mimickers of hepatocellular carcinoma
Tae Kyoung Kim, Eunchae Lee, Hyun-Jung Jang
Clin Mol Hepatol 2015;21(4):326-343.
Published online December 24, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.4.326

Radiological imaging plays a crucial role in the diagnosis of hepatocellular carcinoma (HCC) as the noninvasive diagnosis of HCC in high-risk patients by typical imaging findings alone is widely adopted in major practice guidelines for HCC. While imaging techniques have markedly improved in detecting small liver lesions, they often detect incidental benign liver lesions and non-hepatocellular malignancy that can be misdiagnosed as HCC. The most common mimicker of HCC in cirrhotic liver is nontumorous arterioportal shunts that are seen as focal hypervascular liver lesions on dynamic contrast-enhanced cross-sectional imaging. Rapidly enhancing hemangiomas can be easily misdiagnosed as HCC especially on MR imaging with liver-specific contrast agent. Focal inflammatory liver lesions mimic HCC by demonstrating arterial-phase hypervascularity and subsequent washout on dynamic contrast-enhanced imaging. It is important to recognize the suggestive imaging findings for intrahepatic cholangiocarcinoma (CC) as the management of CC is largely different from that of HCC. There are other benign mimickers of HCC such as angiomyolipomas and focal nodular hyperplasia-like nodules. Recognition of their typical imaging findings can reduce false-positive HCC diagnosis.

Citations

Citations to this article as recorded by  Crossref logo
  • Updates in Abbreviated MRI‐Based HCC Surveillance
    Hyo Jung Park, So Yeon Kim, Young‐Suk Lim
    Journal of Gastroenterology and Hepatology.2026;[Epub]     CrossRef
  • Magnetic resonance imaging of hepatocellular carcinoma: a spectrum of uncommon morphologic subtypes, unusual imaging patterns and mimics
    Mindy X. Wang, M. Azfar Siddiqui, Alexandra Roudenko, Amita Kamath, Humaira Chaudhry, Roopa Ram, Amir A. Borhani, Venkateswar Surabhi, Khaled M. Elsayes, Robert M. Marks, Maxime Ronot
    Abdominal Radiology.2025; 50(7): 3020.     CrossRef
  • Utility of Corrected Effective Atomic Numbers in Differentiating Hepatocellular Carcinomas and Liver Metastases From Hepatic Hemangiomas
    Mitsunari Maruyama, Shota Hosogoshi, Minako Maruyama, Hisatoshi Araki, Rika Yoshida, Shinji Ando, Megumi Nakamura, Takeshi Yoshizako, Yasushi Kaji
    Cureus.2025;[Epub]     CrossRef
  • Abbreviated MRI-Based Surveillance Strategies for Early Hepatocellular Carcinoma Detection
    Hyo Jung Park, Dong Wook Kim, Won-Mook Choi, So Yeon Kim
    Journal of the Korean Society of Radiology.2025; 86(3): 335.     CrossRef
  • Differentiating between hepatocellular carcinoma and its mimickers using contrast-enhanced ultrasound with perflubutane microbubbles
    Yasunori Minami, Katsutoshi Sugimoto, Hidekatus Kuroda, Naohisa Kamiyama, Chikara Ogawa, Masatoshi Kudo
    Expert Review of Medical Devices.2025; 22(8): 817.     CrossRef
  • Mixed Plate Ductal Intrahepatic Cholangiocarcinoma Mimicking Hepatocellular Carcinoma
    Sania Ajmal, Srujan Edupuganti, Adiraj Singh
    Cureus.2024;[Epub]     CrossRef
  • Should Hypervascular Incidentalomas Detected on Per-Interventional Cone Beam Computed Tomography during Intra-Arterial Therapies for Hepatocellular Carcinoma Impact the Treatment Plan in Patients Waiting for Liver Transplantation?
    Haytham Derbel, Athena Galletto Pregliasco, Sébastien Mulé, Julien Calderaro, Youssef Zaarour, Laetitia Saccenti, Mario Ghosn, Edouard Reizine, Maxime Blain, Alexis Laurent, Raffaele Brustia, Vincent Leroy, Giuliana Amaddeo, Alain Luciani, Vania Tacher, H
    Cancers.2024; 16(13): 2333.     CrossRef
  • Inflammatory Pseudotumors after Liver Transplantation, a Rare Differential Diagnosis with Tumor Recurrence: a Case Report
    Cătălin Ştefan Ghenea, Mirela Boroş , Vanessa Dănăiaţă , Marc Cristian Cojocaru , Mariana Mihăilă
    Journal of Medical and Radiation Oncology.2024; 4(7): 51.     CrossRef
  • Prediction models for differentiating benign from malignant liver lesions based on multiparametric dual-energy non-contrast CT
    Takashi Ota, Hiromitsu Onishi, Hideyuki Fukui, Takahiro Tsuboyama, Atsushi Nakamoto, Toru Honda, Shohei Matsumoto, Mitsuaki Tatsumi, Noriyuki Tomiyama
    European Radiology.2024; 35(3): 1361.     CrossRef
  • Benign pericholecystic regeneration mimicking hepatocellular carcinoma: a potential pitfall in imaging of cirrhosis
    Amir A. Borhani, Naishal Patel, Vedang Patel, Maryam Haghshomar, Gregory Grimaldi, Frank H. Miller, Katrina McGinty
    Abdominal Radiology.2024; 50(4): 1547.     CrossRef
  • Magnetic Resonance Imaging-Based Surveillance of Hepatocellular Carcinoma: Current Status and Future Perspectives
    Hyo Jung Park, So Yeon Kim, Young-Suk Lim
    Current Hepatology Reports.2023; 22(3): 83.     CrossRef
  • Contrast-enhanced US Incorporating Kupffer-Phase Findings for the Diagnosis of Hepatocellular Carcinoma
    Tae Kyoung Kim
    Radiology.2023;[Epub]     CrossRef
  • Diagnosis of hepatocellular carcinoma using Sonazoid: a comprehensive review
    Woo Kyoung Jeong
    Journal of Liver Cancer.2023; 23(2): 272.     CrossRef
  • Cholangiocarcinoma – Part 2, Tumoral and Nontumoral Mimics and Imaging Features Helpful in Differentiation
    Sravanthi Mantripragada, Ashish Chawla
    Current Problems in Diagnostic Radiology.2022; 51(3): 362.     CrossRef
  • Differentiating infected focal liver lesions from malignant mimickers: value of ultrasound-based radiomics
    J.B. Peng, Y.T. Peng, P. Lin, D. Wan, H. Qin, X. Li, X.R. Wang, Y. He, H. Yang
    Clinical Radiology.2022; 77(2): 104.     CrossRef
  • Morphological, dynamic and functional characteristics of liver pseudolesions and benign lesions
    Matteo Renzulli, Nicolò Brandi, Giulia Argalia, Stefano Brocchi, Andrea Farolfi, Stefano Fanti, Rita Golfieri
    La radiologia medica.2022; 127(2): 129.     CrossRef
  • Current Landscape and Future Perspectives of Abbreviated MRI for Hepatocellular Carcinoma Surveillance
    Hyo Jung Park, Nieun Seo, So Yeon Kim
    Korean Journal of Radiology.2022; 23(6): 598.     CrossRef
  • Imaging features of hepatobiliary MRI and the risk of hepatocellular carcinoma development
    Jong-In Chang, Dong Hyun Sinn, Woo Kyoung Jeong, Jeong Ah Hwang, Ho Young Won, Kyunga Kim, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung-Woon Paik
    Scandinavian Journal of Gastroenterology.2022; 57(12): 1470.     CrossRef
  • Imaging-based diagnosis of benign lesions and pseudolesions in the cirrhotic liver
    Matteo Renzulli, Stefano Brocchi, Anna Maria Ierardi, Matteo Milandri, Irene Pettinari, Vincenzo Lucidi, Caterina Balacchi, Paolo Muratori, Giovanni Marasco, Giulio Vara, Francesco Tovoli, Alessandro Granito, Gianpaolo Carrafiello, Fabio Piscaglia, Rita G
    Magnetic Resonance Imaging.2021; 75: 9.     CrossRef
  • One stop shop approach for the diagnosis of liver hemangioma
    Larisa Daniela Sandulescu, Cristiana Marinela Urhut, Sarmis Marian Sandulescu, Ana-Maria Ciurea, Sergiu Marian Cazacu, Sevastita Iordache
    World Journal of Hepatology.2021; 13(12): 1892.     CrossRef
  • Small masses (≤3 cm) diagnosed as hepatocellular carcinoma on pre-treatment imaging: comparison of therapeutic outcomes between hepatic resection and radiofrequency ablation
    Dong Ik Cha, Kyoung Doo Song, Tae Wook Kang, Min Woo Lee, Hyunchul Rhim
    The British Journal of Radiology.2020;[Epub]     CrossRef
  • Spectrum of histological diagnoses among clinically suspected PLCC patients in a Nigerian teaching hospital
    MbwasIsaac Mashor, AbideenOlayiwola Oluwasola, SamuelOlawale Ola
    NIGERIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY.2020; 12(2): 50.     CrossRef
  • Diagnostic Value of CEUS Prompting Liver Biopsy: Histopathological Correlation of Hepatic Lesions with Ambiguous Imaging Characteristics
    Thomas Geyer, Dirk-André Clevert, Sonja Schwarz, Paul Reidler, Sebastian Gassenmaier, Thomas Knösel, Johannes Rübenthaler, Vincent Schwarze, Marco Armbruster
    Diagnostics.2020; 11(1): 35.     CrossRef
  • Common pitfalls when using the Liver Imaging Reporting and Data System (LI-RADS): lessons learned from a multi-year experience
    Roberto Cannella, Kathryn J. Fowler, Amir A. Borhani, Marta I. Minervini, Matthew Heller, Alessandro Furlan
    Abdominal Radiology.2019; 44(1): 43.     CrossRef
  • Diffusion Kurtosis MR Imaging versus Conventional Diffusion-Weighted Imaging for Distinguishing Hepatocellular Carcinoma from Benign Hepatic Nodules
    Yingmei Jia, Huasong Cai, Meng Wang, Yanji Luo, Ling Xu, Zhi Dong, Xu Yan, Zi-Ping Li, Shi-Ting Feng
    Contrast Media & Molecular Imaging.2019; 2019: 1.     CrossRef
  • Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System
    Sonal Krishan, Radha K. Dhiman, Navin Kalra, Raju Sharma, Sanjay S. Baijal, Anil Arora, Ajay Gulati, Anu Eapan, Ashish Verma, Shyam Keshava, Amar Mukund, S. Deva, Ravi Chaudhary, Karthick Ganesan, Sunil Taneja, Ujjwal Gorsi, Shivanand Gamanagatti, Kumble
    Journal of Clinical and Experimental Hepatology.2019; 9(5): 625.     CrossRef
  • Developing Quality Measures for Diagnostic Radiologists: Part 2
    Jason N. Itri, Kesav Raghavan, Samir B. Patel, Jennifer C. Broder, Samantha Tierney, Diedra Gray, Judy Burleson, Scott MacDonald, David J. Seidenwurm
    Journal of the American College of Radiology.2018; 15(10): 1366.     CrossRef
  • The essential of multiparametric magnetic resonance imaging in hepatocellular carcinoma diagnosis
    Ioana G. Lupescu
    Oncolog-Hematolog.ro.2018; 3(44): 16.     CrossRef
  • Development of Risk Prediction Model for Hepatocellular Carcinoma Progression of Indeterminate Nodules in Hepatitis B Virus-Related Cirrhotic Liver
    Hyo Jung Cho, Bohyun Kim, Jung-Dong Lee, Dae Ryong Kang, Jai Keun Kim, Jei Hee Lee, Sung Jae Shin, Kee Myung Lee, Byung Moo Yoo, Kwang Jae Lee, Soon Sun Kim, Jae Youn Cheong, Sung Won Cho
    American Journal of Gastroenterology.2017; 112(3): 460.     CrossRef
  • Microwave ablation of large HCC lesions: Added value of CEUS examinations for ablation success control
    B. Pregler, L.P. Beyer, I. Wiesinger, C. Nießen, E.M. Jung, C. Stroszczynski, P. Wiggermann, F. Jung, T. Gori
    Clinical Hemorheology and Microcirculation.2017; 64(3): 483.     CrossRef
  • MRI of Small Hepatocellular Carcinoma: Typical Features Are Less Frequent Below a Size Cutoff of 1.5 cm
    Moon Hyung Choi, Joon-Il Choi, Young Joon Lee, Michael Yong Park, Sung Eun Rha, Chandana Lall
    American Journal of Roentgenology.2017; 208(3): 544.     CrossRef
  • Performance of Gadoxetic Acid–Enhanced Liver Magnetic Resonance Imaging for Predicting Patient Eligibility for Liver Transplantation Based on the Milan Criteria
    Hwi Young Jang, Joon-Il Choi, Young Joon Lee, Michael Yong Park, Dong Myung Yeo, Sung Eun Rha, Eun Sun Jung, Young Kyoung You, Dong Goo Kim, Jae Young Byun
    Journal of Computer Assisted Tomography.2017; 41(1): 25.     CrossRef
  • Imaging characteristics of focal splenic and hepatic lesions in type 1 Gaucher disease
    Martine Regenboog, Anneloes E. Bohte, Inne Somers, Otto M. van Delden, Mario Maas, Carla E.M. Hollak
    Blood Cells, Molecules, and Diseases.2016; 60: 49.     CrossRef
  • 48,081 View
  • 1,009 Download
  • 29 Web of Science
  • Crossref

Case Report

Hepatic neoplasm

Imaging findings for intravascular large B-cell lymphoma of the liver
Jungmin Bae, Hyo Keun Lim, Ha Young Park
Clin Mol Hepatol 2015;21(3):295-299.
Published online September 30, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.3.295

Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of extranodal diffuse large B-cell lymphoma that most commonly involves the central nervous system and skin. To our knowledge, no state-of-the art imaging findings have been reported for hepatic IVLBCL in the English literature. We report the first case of hepatic involvement of IVLBCL along with a literature review.

Citations

Citations to this article as recorded by  Crossref logo
  • Intravascular Large B‐Cell Lymphoma Mimicking Intrahepatic Cholangiocarcinoma
    Seigi Oshima, Soichiro Sakamoto, Ken Takahashi, Toshiyuki Kitano
    Clinical Case Reports.2025;[Epub]     CrossRef
  • Case Report: Intravascular Large B-Cell Lymphoma: A Clinicopathologic Study of Four Cases With Review of Additional 331 Cases in the Literature
    Yingying Han, Qingjiao Li, Dan Wang, Lushan Peng, Tao Huang, Chunlin Ou, Keda Yang, Junpu Wang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Intravascular Cutaneous Disorders. A Clinicopathologic Review
    Pedro Vilas Boas, Lorenzo Cerroni, Luis Requena
    The American Journal of Dermatopathology.2021; 43(2): 119.     CrossRef
  • EBV-positive intravascular large B-cell lymphoma of the liver: a case report and literature review
    Qingjiao Li, Jinghe Li, Keda Yang, Ying Peng, Yao Xiang, Shuyuan Sun, Jian Zeng, Xin Zhang, Junpu Wang
    Diagnostic Pathology.2020;[Epub]     CrossRef
  • Intravascular Large B-cell Lymphoma Mimicking Hepatobiliary Infection: A Case Report and Literature Review
    Ryusaku Kusunoki, Hirofumi Fujishiro, Misaki Yoshimura, Kiyoka Sawada, Shinsuke Suemitsu, Masatoshi Kataoka, Aya Fujiwara, Kousuke Tsukano, Satoshi Kotani, Satoshi Yamanouchi, Masaki Tanaka, Youichi Miyaoka, Tatsuya Miyake, Naruaki Kohge, Tomonori Imaoka,
    Internal Medicine.2019; 58(13): 1885.     CrossRef
  • An unexpected finding of hepatic lymphoma after emergent cholecystectomy
    Shawn T. Steen, Evan D. Slater, Casey E. Barbaro, Emma R. Huebner
    Journal of Surgical Case Reports.2017;[Epub]     CrossRef
  • 12,380 View
  • 117 Download
  • 6 Web of Science
  • Crossref

Original Article

Hepatic neoplasm

Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease
Chansik An, Youn Ah Choi, Dongil Choi, Yong Han Paik, Sang Hoon Ahn, Myeong-Jin Kim, Seung Woon Paik, Kwang-Hyub Han, Mi-Suk Park
Clin Mol Hepatol 2015;21(3):279-286.
Published online September 30, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.3.279
Background/Aims

The goal of this study was to estimate the growth rate of hepatocellular carcinoma (HCC) and identify the host factors that significantly affect this rate.

Methods

Patients with early-stage HCC (n=175) who underwent two or more serial dynamic imaging studies without any anticancer treatment at two tertiary care hospitals in Korea were identified. For each patient, the tumor volume doubling time (TVDT) of HCC was calculated by comparing tumor volumes between serial imaging studies. Clinical and laboratory data were obtained from the medical records of the patients.

Results

The median TVDT was 85.7 days, with a range of 11 to 851.2 days. Multiple linear regression revealed that the initial tumor diameter (a tumor factor) and the etiology of chronic liver disease (a host factor) were significantly associated with the TVDT. The TVDT was shorter when the initial tumor diameter was smaller, and was shorter in HCC related to hepatitis B virus (HBV) infection than in HCC related to hepatitis C virus (HCV) infection (median, 76.8 days vs. 137.2 days; P=0.0234).

Conclusions

The etiology of chronic liver disease is a host factor that may significantly affect the growth rate of early-stage HCC, since HBV-associated HCC grows faster than HCV-associated HCC.

Citations

Citations to this article as recorded by  Crossref logo
  • Analyzing the interaction between time to surgery and tumor burden score in hepatocellular carcinoma
    Miho Akabane, Jun Kawashima, Selamawit Woldesenbet, Abdullah Altaf, François Cauchy, Federico Aucejo, Irinel Popescu, Minoru Kitago, Guillaume Martel, Francesca Ratti, Luca Aldrighetti, George A. Poultsides, Yuki Imaoka, Andrea Ruzzenente, Itaru Endo, Ana
    Journal of Gastrointestinal Surgery.2025; 29(2): 101903.     CrossRef
  • Evaluation of screening program for hepatocellular carcinoma at a single center
    Gasser Ibrahim El-Azab, Ghada Ahmed Ahmed El-Helw, Maha Mohamed Ahmed Elsabaawy, Mohamed Ahmed Samy Kohla, Yasmin Abdelrahman Muhammed Omar
    Egyptian Liver Journal.2025;[Epub]     CrossRef
  • Impact of the MELD Scale on Hospital Admissions for Hepatocarcinoma (2000 to 2018), Brazil
    Alexandro das Mercês Silva
    Journal of Community Medicine and Health Solutions.2025; 6(1): 027.     CrossRef
  • Analysis of factors influencing tumor volume doubling time in hepatocellular carcinoma and its predictive value for progression-free survival
    Ting Huang, Yong Chen
    Scientific Reports.2025;[Epub]     CrossRef
  • Cost-Effectiveness of Risk-Score-Based Surveillance Strategies for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B
    Ying Chen, Hao Feng, Yun Bao, Mengxia Yan, Kaijie Yao, Bin Wu
    Digestive Diseases and Sciences.2025;[Epub]     CrossRef
  • Hepatocellular Carcinoma Growth Kinetics and Outcomes After Transarterial Embolization: A Single-Center Analysis
    Ken Zhao, Harrison Blume, Elena N. Petre, Dimitrios Xenos, Zuzanna Kobus, Erica S. Alexander, Vlasios S. Sotirchos, Ruben Geevarghese, Anne Covey, Joseph P. Erinjeri, Etay Ziv, Constantinos T. Sofocleous, James J. Harding, Kevin Soares, Carlie Sigel, Efse
    Cancers.2025; 17(20): 3346.     CrossRef
  • Comparison of Annual Dynamic Abbreviated MRI and Biannual Ultrasound for HCC Surveillance in a High-Risk Group: Two-Center Cohort Study
    Jeong Hee Yoon, Joon-Il Choi, Jeongin Yoo, Sun Kyung Jeon, Jae Hyun Kim, Jae Seok Bae, Hyo-Jin Kang, Hokun Kim, Seo Yeon Youn, Dong Hwan Kim, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Jeong Won Jang, Pil Soo Sung, Myung-jin Jang, Jeong Min Lee
    Liver Cancer.2025; : 1.     CrossRef
  • Characterization of CAR-T cellular kinetics and efficacy in solid tumor patients with and without prior lymphodepletion chemotherapy using a PBPK-PD model
    Keyur R. Parmar, Agnish Dey, Angelia F. Wang, Ganesh M. Mugundu, Aman P. Singh
    Journal of Pharmacokinetics and Pharmacodynamics.2025;[Epub]     CrossRef
  • Survival Outcomes in Hepatocellular Carcinoma Patients Undergoing TARE: A Comparative Analysis Before and After Single Admission Order–Map–Treat Protocol Implementation
    Abdulmohsen Ahmed Alhussaini, Saleh AlShreadah, Mohamed Rajab Elzahrani, Abdulaziz AlTaweel, Mohammed AlAhmed, Omar Bashir, Shaker Al Shehri, Mohammad Arabi
    Cancers.2025; 17(24): 3930.     CrossRef
  • Hepatocellular Carcinoma Incidence Threshold for Surveillance in Virologically Cured Hepatitis C Individuals
    Jagpreet Chhatwal, Ali Hajjar, Peter P. Mueller, Gizem Nemutlu, Neeti Kulkarni, Mary Linton B. Peters, Fasiha Kanwal
    Clinical Gastroenterology and Hepatology.2024; 22(1): 91.     CrossRef
  • Radiographic and serologic response in patients with unresectable hepatocellular carcinoma receiving systemic antineoplastic treatments: A trial‐level analysis
    Giuseppe A. Colloca, Antonella Venturino
    Cancer.2024; 130(10): 1773.     CrossRef
  • The impact of waiting time and delayed treatment on the outcomes of patients with hepatocellular carcinoma: A systematic review and meta-analysis
    Feng Yi Cheo, Celeste Hong Fei Lim, Kai Siang Chan, Vishal Girishchandra Shelat
    Annals of Hepato-Biliary-Pancreatic Surgery.2024; 28(1): 1.     CrossRef
  • Based on Gadolinium Ethoxybenzyl DTPA–Enhanced MRI: Diagnostic Performance of the Category-Modified LR-5 Criteria in Patients At Risk for Hepatocellular Carcinoma
    Shaopeng Li, Kexue Deng, Jun Qiu, Peng Wang, Dawei Yin, Yiju Xie, Yongqiang Yu
    Technology in Cancer Research & Treatment.2024;[Epub]     CrossRef
  • Quantifying the natural growth rate of hepatocellular carcinoma: A real-world retrospective study in southwestern China
    Li Tu, Hong Xie, Qi Li, Ping-Gui Lei, Pei-Ling Zhao, Fan Yang, Chi Gong, Yuan-Lin Yao, Shi Zhou
    World Journal of Hepatology.2024; 16(5): 800.     CrossRef
  • Tumor Growth in Overdrive: Detailing an Aggressive Course of Hepatocellular Carcinoma
    Simardeep Singh, Thilini Delungahawatta, Marcos Wolff, Christopher J. Haas, Ned Snyder
    Case Reports in Hepatology.2024;[Epub]     CrossRef
  • CT- and MRI-based Factors Associated with Rapid Growth in Early-Stage Hepatocellular Carcinoma
    Hyeon Ji Jang, Sang Hyun Choi, Sungwoo Wee, Se Jin Choi, Jae Ho Byun, Hyung Jin Won, Yong Moon Shin, Claude B. Sirlin
    Radiology.2024;[Epub]     CrossRef
  • Physics-based tissue simulator to model multicellular systems: A study of liver regeneration and hepatocellular carcinoma recurrence
    Luciana Melina Luque, Carlos Manuel Carlevaro, Camilo Julio Llamoza Torres, Enrique Lomba, Roeland M.H. Merks
    PLOS Computational Biology.2023; 19(3): e1010920.     CrossRef
  • Current status of ultrasonography in national cancer surveillance program for hepatocellular carcinoma in South Korea: a large-scale multicenter study
    Sun Hong Yoo, Soon Sun Kim, Sang Gyune Kim, Jung Hyun Kwon, Han-Ah Lee, Yeon Seok Seo, Young Kul Jung, Hyung Joon Yim, Do Seon Song, Seong Hee Kang, Moon Young Kim, Young-Hwan Ahn, Jieun Han, Young Seok Kim, Young Chang, Soung Won Jeong, Jae Young Jang, J
    Journal of Liver Cancer.2023; 23(1): 189.     CrossRef
  • Performance and effectiveness of hepatocellular carcinoma screening in individuals with HBsAg seropositivity in China: a multicenter prospective study
    Hongmei Zeng, Maomao Cao, Changfa Xia, Dongmei Wang, Kun Chen, Zheng Zhu, Ruiying Fu, Shaokai Zhang, Jinyi Zhou, Huadong Wang, Xianyun Qi, Shuguang Dai, Yong Chen, Zhong Sun, Hao Ding, Qingwen Li, Hui Zhao, Xuehong Zhang, Jakub Morze, John S. Ji, Feng Sun
    Nature Cancer.2023; 4(9): 1382.     CrossRef
  • Threshold growth has a limited role in differentiating hepatocellular carcinoma from other focal hepatic lesions
    Rong Lyu, Di Wang, Weijuan Hu, Zhongsong Gao, Changlu Yu, Jiao Wang, Mingge Li, Kefeng Jia
    BMC Medical Imaging.2023;[Epub]     CrossRef
  • Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey
    Hong Zhao, Aiping Zhou, Jianguo Zhou, Xinyu Bi, Shida Yan, Jing Jin, Wenqiang Wei, Muxing Li, Caifeng Gong, Qichen Chen, Zhiwen Luo, Ning Li, Rui Mao, Xiao Chen, Bo Chen, Rongshou Zheng, Jianjun Zhao, Yue Han, Zhiyu Li, Xu Che, Yuan Tang, Yongkun Sun, Zhe
    HPB.2022; 24(3): 342.     CrossRef
  • Progression Rates of LR-2 and LR-3 Observations on MRI to Higher LI-RADS Categories in Patients at High Risk of Hepatocellular Carcinoma: A Retrospective Study
    Damithri Ranathunga, Heba Osman, Nayaar Islam, Matthew D. F. McInnes, Javeria Munir, Christian B. van der Pol, Mohamed Elfaal, Cynthia Walsh
    American Journal of Roentgenology.2022; 218(3): 462.     CrossRef
  • Focal liver lesions in cirrhosis: Role of contrast-enhanced ultrasonography
    Tommaso Vincenzo Bartolotta, Angelo Randazzo, Eleonora Bruno, Adele Taibbi
    World Journal of Radiology.2022; 14(4): 70.     CrossRef
  • Distinguishing excess mutations and increased cell death based on variant allele frequencies
    Gergely Tibély, Dominik Schrempf, Imre Derényi, Gergely J. Szöllősi, Teresa M. Przytycka
    PLOS Computational Biology.2022; 18(4): e1010048.     CrossRef
  • The impact of the COVID‐19 pandemic on patients with chronic liver disease: Results from the Global Liver Registry
    Zobair M. Younossi, Yusuf Yilmaz, Mohamed El‐Kassas, Ajay Duseja, Saeed Hamid, Gamal Esmat, Nahum Méndez‐Sánchez, Wah Kheong Chan, Ashwani K. Singal, Brian Lam, Sean Felix, Elena Younossi, Manisha Verma, Jillian K. Price, Fatema Nader, Issah Younossi, And
    Hepatology Communications.2022; 6(10): 2860.     CrossRef
  • Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma
    Maria Guarino, Valentina Cossiga, Mario Capasso, Chiara Mazzarelli, Filippo Pelizzaro, Rodolfo Sacco, Francesco Paolo Russo, Alessandro Vitale, Franco Trevisani, Giuseppe Cabibbo
    Journal of Clinical Medicine.2022; 11(15): 4475.     CrossRef
  • How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine?
    Islam H. Zaki, Erin Shropshire, Shuaiqi Zhang, Dong Xiao, Benjamin Wildman-Tobriner, Daniele Marin, Rajan T. Gupta, Alaattin Erkanli, Redon C. Nelson, Mustafa R. Bashir
    Abdominal Radiology.2021; 46(3): 969.     CrossRef
  • SBRT for HCC: Overview of technique and treatment response assessment
    Kimberly L. Shampain, Caitlin E. Hackett, Sohrab Towfighi, Anum Aslam, William R. Masch, Alison C. Harris, Silvia D. Chang, Kanika Khanna, Vivek Mendiratta, Ahmed M. Gabr, Dawn Owen, Mishal Mendiratta-Lala
    Abdominal Radiology.2021; 46(8): 3615.     CrossRef
  • Effect of cell microenvironment on the drug sensitivity of hepatocellular cancer cells
    Bhaskar Bhattacharya, Daniel Q. Huang, Sarah Hong Hui Low, Gim Hwa Tan, Min Ji Han, Sanamerjit Singh, Benny Tang, Sheng Chun Chang, Joey Sze Yun Lim, Mohd Feroz Mohd Omar, Yock Young Dan, Richie Soong
    Oncotarget.2021; 12(7): 674.     CrossRef
  • Exploration and time-serial validation of logistic regression models composed of multiple laboratory tests for early detection of HCV-associated hepatocellular carcinoma
    Toshihiko Kobayashi, Kiyoshi Ichihara, Shuhei Goda, Isao Hidaka, Takahiro Yamasaki, Haku Ishida
    Clinica Chimica Acta.2021; 521: 137.     CrossRef
  • Should Threshold Growth Be Considered a Major Feature in the Diagnosis of Hepatocellular Carcinoma Using LI-RADS?
    Jae Hyon Park, Yong Eun Chung, Nieun Seo, Jin-Young Choi, Mi-Suk Park, Myeong-Jin Kim
    Korean Journal of Radiology.2021; 22(10): 1628.     CrossRef
  • Recommendations of the BSSO for patients with hepatobiliary cancers in the context of COVID-19 epidemic 2020
    Victor Hugo Ribeiro Vieira, Alessandro Landskron Diniz, Alexandre Ferreira Oliveira, Heber Salvador de Castro Ribeiro, Luis Cesar Bredt, Paulo Henrique de Sousa Fernandes, Reitan Ribeiro, Mauro Monteiro Correia
    Brazilian Journal of Oncology.2021;[Epub]     CrossRef
  • Influence of pretreatment tumor growth rate on objective response of hepatocellular carcinoma treated with transarterial chemoembolization
    Yvonne Purcell, Riccardo Sartoris, Valérie Paradis, Valérie Vilgrain, Maxime Ronot
    Journal of Gastroenterology and Hepatology.2020; 35(2): 305.     CrossRef
  • Intra-procedural dual phase cone beam computed tomography has a better diagnostic accuracy over pre-procedural MRI and MDCT in detection and characterization of HCC in cirrhotic patients undergoing TACE procedure
    Pierleone Lucatelli, Gianluca De Rubeis, Luca Ginnani Corradini, Fabrizio Basilico, Michele Di Martino, Quirino Lai, Stefano Ginanni Corradini, Alessandro Cannavale, Pier Giorgio Nardis, Mario Corona, Luca Saba, Carlo Catalano, Mario Bezzi
    European Journal of Radiology.2020; 124: 108806.     CrossRef
  • Is delayed surgery justified for patients with hepatocellular carcinoma?
    Zheng-Liang Chen, Ying-Jian Liang, Hao Xing, Tian Yang
    Surgery.2020; 167(6): 1023.     CrossRef
  • Non‐invasive liver fibrosis scores are strongly associated with liver cancer mortality in general population without liver disease
    Ki‐Chul Sung, Michael P. Johnston, Mi Y. Lee, Christopher D. Byrne
    Liver International.2020; 40(6): 1303.     CrossRef
  • Strategy for the practice of digestive and oncological surgery during the Covid-19 epidemic
    J.-J. Tuech, A. Gangloff, F. Di Fiore, P. Michel, C. Brigand, K. Slim, M. Pocard, L. Schwarz
    Journal of Visceral Surgery.2020; 157(3): S7.     CrossRef
  • Stratégie pour la pratique de la chirurgie digestive et oncologique en situation d’épidémie de COVID-19
    J.-J. Tuech, A. Gangloff, F. Di Fiore, P. Michel, C. Brigand, K. Slim, M. Pocard, L. Schwarz
    Journal de Chirurgie Viscérale.2020; 157(3): S6.     CrossRef
  • Natural history of hepatocellular carcinoma after stereotactic body radiation therapy
    Mishal Mendiratta-Lala, William Masch, Dawn Owen, Anum Aslam, Chris Maurino, Theresa Devasia, Matthew J. Schipper, Neehar D. Parikh, Kyle Cuneo, Theodore S. Lawrence, Matthew S. Davenport
    Abdominal Radiology.2020; 45(11): 3698.     CrossRef
  • Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis
    Piyush Nathani, Purva Gopal, Nicole Rich, Adam Yopp, Takeshi Yokoo, Binu John, Jorge Marrero, Neehar Parikh, Amit G Singal
    Gut.2020; : gutjnl-2020-321040.     CrossRef
  • Gadoxetic acid-enhanced MRI for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: can hypointensity on the late portal venous phase be used as an alternative to washout?
    Kyoung A. Baek, Seung Soo Kim, Hyeong Cheol Shin, Jeong Ah Hwang, Seo-Youn Choi, Woong Hee Lee, Chan Ho Park, Hyoung Nam Lee, Nam Hun Heo
    Abdominal Radiology.2020; 45(9): 2705.     CrossRef
  • Diagnostic performance of Liver Imaging Reporting and Data System in patients at risk of both hepatocellular carcinoma and metastasis
    Min Jeong Cho, Chansik An, Khalid Suliman Aljoqiman, Jin-Young Choi, Joon Seok Lim, Mi-Suk Park, Hyungjin Rhee, Myeong-Jin Kim
    Abdominal Radiology.2020; 45(11): 3789.     CrossRef
  • Follow-up schedule for initial recurrent hepatocellular carcinoma after ablation based on risk classification
    Xuqi Sun, Lingling Li, Ning Lyu, Luwen Mu, Jinfa Lai, Ming Zhao
    Cancer Imaging.2020;[Epub]     CrossRef
  • Prevention and control strategies of general surgeons under COVID-19 pandemic
    Fenglin Liu, Weibin Wang, Hong Yu, Yong Wang, Wenming Wu, Xinyu Qin, Yupei Zhao
    Surgery in Practice and Science.2020; 1: 100008.     CrossRef
  • Liver Care and Surveillance: The Global Impact of the COVID‐19 Pandemic
    Hidenori Toyoda, Daniel Q. Huang, Michael H. Le, Mindie H. Nguyen
    Hepatology Communications.2020; 4(12): 1751.     CrossRef
  • Uncovering Biological Factors That Regulate Hepatocellular Carcinoma Growth Using Patient‐Derived Xenograft Assays
    Min Zhu, Lin Li, Tianshi Lu, Hyesun Yoo, Ji Zhu, Purva Gopal, Sam C. Wang, Matthew R. Porembka, Nicole E. Rich, Sofia Kagan, Mobolaji Odewole, Veronica Renteria, Akbar K. Waljee, Tao Wang, Amit G. Singal, Adam C. Yopp, Hao Zhu
    Hepatology.2020; 72(3): 1085.     CrossRef
  • Surveillance for HCC After Liver Transplantation: Increased Monitoring May Yield Aggressive Treatment Options and Improved Postrecurrence Survival
    David D. Lee, Gonzalo Sapisochin, Neil Mehta, Andre Gorgen, Kaitlyn R. Musto, Hana Hajda, Francis Y. Yao, David O. Hodge, Rickey E. Carter, Denise M. Harnois
    Transplantation.2020; 104(10): 2105.     CrossRef
  • Retrospective CT/MRI Texture Analysis of Rapidly Progressive Hepatocellular Carcinoma
    Charissa Kim, Natasha Cigarroa, Venkateswar Surabhi, Balaji Ganeshan, Anil K. Pillai
    Journal of Personalized Medicine.2020; 10(3): 136.     CrossRef
  • LI-RADS Imaging Criteria for HCC Diagnosis and Treatment: Emerging Evidence
    Anum Aslam, Richard Kinh Gian Do, Victoria Chernyak, Mishal Mendiratta-Lala
    Current Hepatology Reports.2020; 19(4): 437.     CrossRef
  • Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions
    Anum Aslam, Richard Kinh Gian Do, Avinash Kambadakone, Bradley Spieler, Frank H Miller, Ahmed M Gabr, Resmi A Charalel, Charles Y Kim, David C Madoff, Mishal Mendiratta-Lala
    World Journal of Hepatology.2020; 12(10): 738.     CrossRef
  • Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis
    Nicole E. Rich, Binu V. John, Neehar D. Parikh, Ian Rowe, Neil Mehta, Gaurav Khatri, Smitha M. Thomas, Munazza Anis, Mishal Mendiratta‐Lala, Christopher Hernandez, Mobolaji Odewole, Latha T. Sundaram, Venkata R. Konjeti, Shishir Shetty, Tahir Shah, Hao Zh
    Hepatology.2020; 72(5): 1654.     CrossRef
  • Can Immediately Treating Subcentimeter Hepatocellular Carcinoma Improve the Survival of Patients?


    Xuqi Sun, Dandan Hu, Yaojun Zhang, Ning Lyu, Li Xu, Qifeng Chen, Jinfa Lai, Minshan Chen, Ming Zhao
    Journal of Hepatocellular Carcinoma.2020; Volume 7: 377.     CrossRef
  • Impact of delayed time from diagnosis to treatment on the stage of hepatocellular carcinoma
    Bing Quan, Wen-Tao Yan, Wan Yee Lau, Meng-Chao Wu, Tian Yang
    Hepatobiliary & Pancreatic Diseases International.2019; 18(1): 100.     CrossRef
  • Magnetic Resonance Imaging Evaluation of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy: Long Term Imaging Follow-Up
    Mishal Mendiratta-Lala, William Masch, Prasad R. Shankar, Holly E. Hartman, Matthew S. Davenport, Matthew J. Schipper, Chris Maurino, Kyle C. Cuneo, Theodore S. Lawrence, Dawn Owen
    International Journal of Radiation Oncology*Biology*Physics.2019; 103(1): 169.     CrossRef
  • A continuous-time hidden Markov model for cancer surveillance using serum biomarkers with application to hepatocellular carcinoma
    Ruben Amoros, Ruth King, Hidenori Toyoda, Takashi Kumada, Philip J. Johnson, Thomas G. Bird
    METRON.2019; 77(2): 67.     CrossRef
  • Discrepancy between the Actual Clinical Status of Patients with Hepatocellular Carcinoma and Expectations from Hepatocellular Carcinoma Surveillance: a Single-Center Study
    Nak Min Kim, Young Seok Doh, Ji Woong Jang, Seok-Hwan Kim, Hyuk Soo Eun, Jae Hyuck Jun, Sae Hee Kim, Il Hyun Baek, Sung Hee Jung
    Journal of Liver Cancer.2019; 19(1): 30.     CrossRef
  • Optimal lexicon of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of hepatocellular carcinoma modified from LI-RADS
    Shin Hye Hwang, Sumi Park, Kyunghwa Han, Jin-young Choi, Young-Nyun Park, Mi-Suk Park
    Abdominal Radiology.2019; 44(9): 3078.     CrossRef
  • Combination Suicide Gene Delivery with an Adeno-Associated Virus Vector Encoding Inducible Caspase-9 and a Chemical Inducer of Dimerization Is Effective in a Xenotransplantation Model of Hepatocellular Carcinoma
    Nusrat Khan, Sridhar Bammidi, Sourav Chattopadhyay, Giridhara R. Jayandharan
    Bioconjugate Chemistry.2019; 30(6): 1754.     CrossRef
  • Pathologic complete response to chemoembolization improves survival outcomes after curative surgery for hepatocellular carcinoma: predictive factors of response
    Keungmo Yang, Pil S. Sung, Young K. You, Dong G. Kim, Jung S. Oh, Ho J. Chun, Jeong W. Jang, Si H. Bae, Jong Y. Choi, Seung K. Yoon
    HPB.2019; 21(12): 1718.     CrossRef
  • Historical Data Are Not Relevant to the Diagnostic Performance of Ultrasound in Surveillance for Hepatocellular Carcinoma
    Korosh Khalili
    Gastroenterology.2019; 157(3): 899.     CrossRef
  • Contrast-enhanced ultrasound of malignant liver lesions
    Isabelle Durot, Stephanie R. Wilson, Jürgen K. Willmann
    Abdominal Radiology.2018; 43(4): 819.     CrossRef
  • Extracellular contrast agent-enhanced MRI: 15-min delayed phase may improve the diagnostic performance for hepatocellular carcinoma in patients with chronic liver disease
    Si Eun Lee, Chansik An, Shin Hye Hwang, Jin-Young Choi, Kyunghwa Han, Myeong-Jin Kim
    European Radiology.2018; 28(4): 1551.     CrossRef
  • Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis
    Sally Ann Tran, An Le, Changqing Zhao, Joseph Hoang, Lee Ann Yasukawa, Susan Weber, Linda Henry, Mindie H Nguyen
    BMJ Open Gastroenterology.2018; 5(1): e000192.     CrossRef
  • Spontaneous Slowing and Regressing of Tumor Growth in Childhood/Adolescent Papillary Thyroid Carcinomas Suggested by the Postoperative Thyroglobulin-Doubling Time
    Toshihiko Kasahara, Akira Miyauchi, Takumi Kudo, Eijun Nishihara, Mitsuru Ito, Yasuhiro Ito, Minoru Kihara, Akihiro Miya
    Journal of Thyroid Research.2018; 2018: 1.     CrossRef
  • Chronic Hepatitis B Infection
    Lydia S. Y. Tang, Emily Covert, Eleanor Wilson, Shyam Kottilil
    JAMA.2018; 319(17): 1802.     CrossRef
  • Screening for hepatocellular carcinoma: What is missing?
    Neil J. Mehta, Aygul Dogan Celik, Marion G. Peters
    Hepatology Communications.2017; 1(1): 18.     CrossRef
  • Imaging of hepatocellular carcinoma and image guided therapies - how we do it
    Jonathon Willatt, Julie A. Ruma, Shadi F. Azar, Nara L. Dasika, F. Syed
    Cancer Imaging.2017;[Epub]     CrossRef
  • Men with biopsy‐confirmed hepatocellular adenoma have a high risk of progression to hepatocellular carcinoma: A nationwide population‐based study
    Lars Bossen, Henning Grønbæk, Peter Lykke Eriksen, Peter Jepsen
    Liver International.2017; 37(7): 1042.     CrossRef
  • Adding to the evidence base: Effectiveness of hepatocellular carcinoma surveillance in clinical practice
    Prashant Pandya, Fasiha Kanwal
    Hepatology Communications.2017; 1(8): 723.     CrossRef
  • Tumor Volume Doubling Time as a Dynamic Prognostic Marker for Patients with Hepatocellular Carcinoma
    Jong Kwan Kim, Hyung-Don Kim, Mi-Jung Jun, Sung-Cheol Yun, Ju Hyun Shim, Han Chu Lee, Danbi Lee, Jihyun An, Young-Suk Lim, Young-Hwa Chung, Yung Sang Lee, Kang Mo Kim
    Digestive Diseases and Sciences.2017; 62(10): 2923.     CrossRef
  • Liver Imaging Reporting and Data System: Review of Major Imaging Features
    Irene Cruite, An Tang, Adrija Mamidipalli, Amol Shah, Cynthia Santillan, Claude B. Sirlin
    Seminars in Roentgenology.2016; 51(4): 292.     CrossRef
  • Multiplication of Tumor Volume by Two Tumor Markers Is a Post-Resection Prognostic Predictor for Solitary Hepatocellular Carcinoma
    Shin Hwang, Gi-Won Song, Young-Joo Lee, Ki-Hun Kim, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Dong-Hwan Jung, Gil-Chun Park, Sung-Gyu Lee
    Journal of Gastrointestinal Surgery.2016; 20(11): 1807.     CrossRef
  • 17,329 View
  • 163 Download
  • 71 Web of Science
  • Crossref

Case Report

Benign liver tumors and cystic disease of liver

Caroli's disease misdiagnosed as intraductal papillary neoplasm of the bile duct
Dae Hoe Gu, Min Seon Park, Chang Ho Jung, Yang Jae Yoo, Jae Young Cho, Yun Ho Lee, Yeon Seok Seo, Hyung Joon Yim, Soon Ho Um, Ho Sang Ryu
Clin Mol Hepatol 2015;21(2):175-179.
Published online June 26, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.2.175

Caroli's disease is a rare autosomal-recessive disorder caused by malformation of the ductal plate during embryonic development. Although it is present at birth, Caroli's disease is typically not diagnosed until between the second and fourth decades of life, as it was in the present patient. Here we report a rare case of Caroli's disease limited to one liver segment, which was initially misdiagnosed as an intraductal papillary neoplasm of the bile duct. The asymptomatic patient was treated with liver segmentectomy.

Citations

Citations to this article as recorded by  Crossref logo
  • Surgical management of Caroli disease in a low-mid income country: a single-center study and review of literature
    Soukayna Bourabaa, Talha Laalou, Abderrahman Mansouri, Mohamed Hamid, Abdellatif Settaf
    BMC Surgery.2025;[Epub]     CrossRef
  • Caroli syndrome in children: a brief review and clinical observation
    R. A. Gudkov, A. V. Dmitriev, O. A. Slobodyanyuk
    Experimental and Clinical Gastroenterology.2023; (10): 169.     CrossRef
  • The Practical Multidisciplinary Management of the Indeterminate Biliary Stricture and/or Dilatation -Radiological Differential Diagnosis: Challenging but Essential-
    Hyun Seok Oh
    The Korean Journal of Pancreas and Biliary Tract.2023; 28(1): 15.     CrossRef
  • Findings of cholangitis in a kidney transplant patient with Caroli disease on FDG PET/CT and MRI
    Mustafa Natout, Madiha M. Hijazi, Mutaz Kassas, Samir Mallat, Mohamad Haidar
    Radiology Case Reports.2023; 18(5): 1700.     CrossRef
  • Pediatric segmental Caroli disease: A case report and review of the literature
    Donna C. Koo, P. Nina Scalise, Andrea Bakker, Sara O. Vargas, Raja Shaikh, Alex G. Cuenca, Heung Bae Kim, Eliza J. Lee
    Journal of Pediatric Surgery Case Reports.2023; 95: 102665.     CrossRef
  • Hepatic multiple hyperintense cystic lesions: a rare caroli disease.
    Mohammed H. Alsharif, Nagi.M Bakhit, Abdulaziz Alarifi, Elbagir M. Nassir, Abair A. Mahdi, Juman M. Almasaad, Abubaker.Y. Elamin, Khalid M. Taha
    THE NEW ARMENIAN MEDICAL JOURNAL.2023; (1, 17 (202): 41.     CrossRef
  • Hepatic multiple hyperintense cystic lesions: a rare caroli disease
    Mohammed H. Alsharif, Nagi M. Bakhit, Abdulaziz Alarifi, Elbagir M. Nassir, Abair A. Mahdi, Juman M. Almasaad, Abubaker Y. Elamin, Khalid M. Taha
    THE NEW ARMENIAN MEDICAL JOURNAL.2023; (1, 17 (202): 41.     CrossRef
  • Childhood-onset Caroli’s disease as a cause of recurrent fever: A case report
    Jing Sun, Sheng Wang, Biquan Chen
    Frontiers in Pediatrics.2022;[Epub]     CrossRef
  • Congenital Cystic Lesions of the Bile Ducts: Imaging-Based Diagnosis
    Roberto Cannella, Dario Giambelluca, Mariangela Diamarco, Giovanni Caruana, Giuseppe Cutaia, Massimo Midiri, Giuseppe Salvaggio
    Current Problems in Diagnostic Radiology.2020; 49(4): 285.     CrossRef
  • Endoscopic therapy for gastro-oesophageal varices of Caroli’s syndrome: a case report
    Song Wang, Mei Xiao, Liqun Hua, Yong Jia, Si Chen, Kaiguang Zhang
    Journal of International Medical Research.2020;[Epub]     CrossRef
  • Oberbauchschmerzen und Fieberschübe bei einer 44‑jährigen Philippinerin
    A. Deimel, J. Sturm, T. Vielfort, T. Zöpf
    Der Internist.2018; 59(3): 276.     CrossRef
  • Intraductal Papillary Neoplasm of the Bile Duct: Clinical, Imaging, and Pathologic Features
    Hyo Jung Park, So Yeon Kim, Hyoung Jung Kim, Seung Soo Lee, Gil Sun Hong, Jae Ho Byun, Seung-Mo Hong, Moon-Gyu Lee
    American Journal of Roentgenology.2018; 211(1): 67.     CrossRef
  • The role of next generation sequencing in the differential diagnosis of caroli’s syndrome
    B Smolović, D Muhović, A Hodžić, G Bergant, B Peterlin
    Balkan Journal of Medical Genetics.2018; 21(2): 49.     CrossRef
  • Diffuse-Type Caroli Disease with Characteristic Central Dot Sign Complicated by Multiple Intrahepatic and Common Bile Duct Stones
    Moon Joo Hwang, Tae Nyeun Kim
    Clinical Endoscopy.2017; 50(4): 400.     CrossRef
  • How to apply clinical cases and medical literature in the framework of a modified “failure mode and effects analysis” as a clinical reasoning tool – an illustration using the human biliary system
    Kam Cheong Wong
    Journal of Medical Case Reports.2016;[Epub]     CrossRef
  • Should Caroli’s disease be in the Todani classification?
    Özüm Tunçyürek, David J. Lomas
    Abdominal Radiology.2016; 41(9): 1873.     CrossRef
  • 12,695 View
  • 83 Download
  • 12 Web of Science
  • Crossref

Original Article

Socioeconomic costs of liver disease in Korea
Sunmi Lee, Woojin Chung, Kyung-Rae Hyun
Korean J Hepatol 2011;17(4):274-291.
Published online December 26, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.4.274
Background/Aims

This study analyzed the scale and trends of the social and economic costs of liver disease in Korea for the past 5 years.

Methods

The social aspects of socioeconomic costs were projected for viral hepatitis (B15-B19), liver cirrhosis, malignant neoplasm of the liver (C22) and other liver diseases (K70-K76), as representative diseases by dividing costs into direct and indirect from 2004 to 2008. Direct costs include hospitalization, outpatient, and pharmacy costs in the health-care sector, and transportation and caregiver costs. Indirect costs include the future income loss due to premature death and the loss of productivity resulting from absence from work.

Results

The social and economic costs of liver disease were projected to be KRW 5,858 billion in 2004, KRW 5,572 billion in 2005, KRW 8,104 billion in 2006, KRW 6,095 billion in 2007, and KRW 5,689 billion in 2008. The future income loss resulting from premature death is thus greatest, from 73.9% to 86.1%, followed by the direct medical costs, from 9.0% to 18.1%. The productivity loss resulting from absence from work accounts for 3.3-5.5%, followed by the direct nonmedical costs such as transportation and caregiver costs, at 1.5-2.5%.

Conclusions

Among the socioeconomic costs of liver disease in Korea, the future income loss resulting from premature death is showing a decreasing trend, whereas direct medical costs are increasing dramatically.

Citations

Citations to this article as recorded by  Crossref logo
  • eHealth Self-Management Interventions for Patients With Liver Cirrhosis: Scoping Review
    Seojin Lee, Youngshin Joo, Yeonsoo Jang
    Journal of Medical Internet Research.2025; 27: e68650.     CrossRef
  • Healthcare affordability and effects on mortality among adults with liver disease from 2004 to 2018 in the United States
    Divya Ayyala-Somayajula, Jennifer L. Dodge, Albert Farias, Norah Terrault, Brian P. Lee
    Journal of Hepatology.2023; 79(2): 329.     CrossRef
  • Cost of illness of liver diseases in Japan
    Kunichika Matsumoto, Yinghui Wu, Shigeru Fujita, Kanako Seto, Yosuke Hatakeyama, Ryo Onishi, Tomonori Hasegawa
    Annals of Hepatology.2021; 20: 100256.     CrossRef
  • Costs of viral hepatitis B in the Republic of Korea, 2002‐2015
    Dahye Baik, Byung‐Woo Kim, Jin‐Kyoung Oh, Kyung‐Ah Kim, Moran Ki
    Journal of Viral Hepatitis.2020; 27(2): 156.     CrossRef
  • Predictors of Emergency Room Admission in Patients With Liver Cirrhosis
    Eun Kyung Kim, Heeok Park
    Gastroenterology Nursing.2020; 43(1): 65.     CrossRef
  • Economic burden of alcohol-related cancers in the Republic of Korea
    Minji Han, Binh Thang Tran, Heeyoun Cho, Jin-Kyoung Oh
    Drug and Alcohol Dependence.2020; 217: 108295.     CrossRef
  • The Economic Burden of Cancers Attributable to Infection in the Republic of Korea: A Prevalence-Based Study
    Thi Xuan Trinh Nguyen, Minji Han, Moran Ki, Young Ae Kim, Jin-Kyoung Oh
    International Journal of Environmental Research and Public Health.2020; 17(20): 7592.     CrossRef
  • Comparison of the cost of illness of primary liver cancer between Japan and Taiwan
    Yinghui Wu, Kunichika Matsumoto, Ya-Mei Chen, Yu-Chi Tung, Tzu-Ying Chiu, Tomonori Hasegawa
    Health Economics Review.2020;[Epub]     CrossRef
  • The economic burden of cancers attributable to smoking in Korea, 2014
    Thi Nguyen, Minji Han, Jin-Kyoung Oh
    Tobacco Induced Diseases.2019;[Epub]     CrossRef
  • GWAS identifying HLA‐DPB1 gene variants associated with responsiveness to hepatitis B virus vaccination in Koreans: Independent association of HLA‐DPB1*04:02 possessing rs1042169 G ‐ rs9277355 C ‐ rs9277356 A
    Soie Chung, Eun Youn Roh, Boram Park, Yunhwan Lee, Sue Shin, Jong Hyun Yoon, Eun Young Song
    Journal of Viral Hepatitis.2019; 26(11): 1318.     CrossRef
  • Trends in socioeconomic costs of morbid obesity among Korean adults, 2009–2013: Data from National Health Insurance Service
    Jae-woo Lee, Young-Eun Choi, Dong-wook Kim, Sunmi Lee, Kyung-Hee Cho
    Obesity Research & Clinical Practice.2018; 12(4): 389.     CrossRef
  • Cost-effectiveness of antiviral prophylaxis during pregnancy for the prevention of perinatal hepatitis B infection in South Korea
    Donghoon Lee, Hyun-Young Shin, Sang Min Park
    Cost Effectiveness and Resource Allocation.2018;[Epub]     CrossRef
  • Cost of illness of hepatocellular carcinoma in Japan: A time trend and future projections
    Kunichika Matsumoto, Yinghui Wu, Takefumi Kitazawa, Shigeru Fujita, Kanako Seto, Tomonori Hasegawa, Isabelle Chemin
    PLOS ONE.2018; 13(6): e0199188.     CrossRef
  • Particulate Matter (PM10 and PM2.5) in Subway Systems: Health-Based Economic Assessment
    Thanh Nguyen, Duckshin Park, Yongil Lee, Young-Chul Lee
    Sustainability.2017; 9(11): 2135.     CrossRef
  • Effects of Interleukin-4 and Interleukin-12b Gene Polymorphisms on Hepatitis B Virus Vaccination
    Eun Youn Roh, Eun Young Song, Jong Hyun Yoon, Sohee Oh, Ju Young Chang, Hyunwoong Park, Soo Hyun Seo, Sue Shin
    Annals of Hepatology.2017; 16(1): 63.     CrossRef
  • An observational study of the direct costs related to hospital admissions, mortality and premature death associated with liver disease in Portugal
    Sofia Vitor, Rui Tato Marinho, José Gíria, José Velosa
    BMC Research Notes.2016;[Epub]     CrossRef
  • Readmission in Cirrhosis: a Growing Problem
    Sakkarin Chirapongsathorn, Jayant A. Talwalkar, Patrick S. Kamath
    Current Treatment Options in Gastroenterology.2016; 14(2): 236.     CrossRef
  • Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea
    Do Young Kim, Ki Tae Yoon, Won Kim, Jung Il Lee, Sung Hwi Hong, Danbi Lee, Jeong Won Jang, Jong Won Choi, Ilsu Kim, Yong Han Paik
    Medicine.2016; 95(30): e3896.     CrossRef
  • The cost of liver disease in Korea: methodology, data, and evidence
    Wankyo Chung
    Clinical and Molecular Hepatology.2015; 21(1): 14.     CrossRef
  • Cost-of-Illness Trends Associated with Thyroid Disease in Korea
    Kyung-Rae Hyun, Sungwook Kang, Sunmi Lee
    Endocrinology and Metabolism.2014; 29(3): 257.     CrossRef
  • Type and cause of liver disease in Korea: single-center experience, 2005-2010
    Sang Soo Lee, Young-Sang Byoun, Sook-Hyang Jeong, Yeo Myung Kim, Ho Gil, Bo-Young Min, Mun Hyuk Seong, Eun Sun Jang, Jin-Wook Kim
    Clinical and Molecular Hepatology.2012; 18(3): 309.     CrossRef
  • A tool for communication with decision-makers: limitations and utilization of studies on cost of illness
    Kun-Sei Lee
    The Korean Journal of Hepatology.2011; 17(4): 258.     CrossRef
  • 19,567 View
  • 56 Download
  • Crossref

Liver Pathology

Early hepatocellular carcinoma
So-Young Jin, In Ho Choi
Korean J Hepatol 2011;17(3):238-241.
Published online September 30, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.3.238

Citations

Citations to this article as recorded by  Crossref logo
  • Expansile invasive growth pattern is definite evidence for the diagnosis of small hepatocellular carcinomas: a comparative study of 37 cases
    Qiongrong Chen, Manxiang Wang, Mingwei Wang, Su Jin, Shu-yuan Xiao, Sufang Tian
    Human Pathology.2018; 80: 130.     CrossRef
  • 8,257 View
  • 42 Download
  • Crossref

Original Articles

Applicability of the BCLC staging system to patients with hepatocellular carcinoma in Korea: analysis at a single center with a liver transplant center
Sung Eun Kim, Han Chu Lee, Kang Mo Kim, Young-Suk Lim, Young-Hwa Chung, Yung Sang Lee, Dong Jin Suh
Korean J Hepatol 2011;17(2):113-119.
Published online June 23, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.2.113
Background/Aims

The Barcelona Clinic Liver Cancer (BCLC) staging system is logical for the staging and treatment of hepatocellular carcinoma (HCC) because it was based on survival data. This study evaluated the applicability of the BCLC staging system and reasons for divergence from BCLC-recommended treatments in Korean HCC patients.

Methods

One hundred and sixty consecutive HCC patients were prospectively enrolled. Treatments were generally recommended according to the guideline of the American Association for the Study of Liver Diseases, but patients were also informed about alternative treatments. The final decision was made with patient agreement, and was based on the doctor's preferences when a patient was unable to reach a decision.

Results

There were 2 (1%), 101 (64%), 20 (12.5%), 34 (21.5%), and 3 (1%) patients with very early-, early-, intermediate-, advanced-, and terminal-stage disease, respectively. Only 64 patients (40%) were treated according to BCLC recommendations. The treatment deviated from BCLC recommendations in 68% (69/101) and 79% (27/34) of patients with early and advanced stage, respectively. The main causes of deviation were refusal to undergo surgery, the presence of an indeterminate malignancy nodule, the absence of a suitable donor, or financial problems.

Conclusions

Donor shortage, financial problems, the relatively limited efficacy of molecular targeting agents, and the presence of an indeterminate nodule were the main causes of deviation from BCLC recommendations. Even after excluding cases in which decisions were made by patient preference, only 66% of the HCC patients were treated according to BCLC recommendations. Treatment guidelines that reflect the Korean situation are mandatory for HCC patients.

Citations

Citations to this article as recorded by  Crossref logo
  • Real-world 10-year retrospective study of the guidelines for diagnosis and treatment of primary liver cancer in China
    Yun-Wei Yan, Xin-Kui Liu, Shun-Xiang Zhang, Qing-Feng Tian
    World Journal of Gastrointestinal Oncology.2023; 15(5): 858.     CrossRef
  • Real-world 10-year retrospective study of the guidelines for diagnosis and treatment of primary liver cancer in China
    Yun-Wei Yan, Xin-Kui Liu, Shun-Xiang Zhang, Qing-Feng Tian
    World Journal of Gastrointestinal Oncology.2023; 15(5): 859.     CrossRef
  • The adherence to the American Association for the Study of Liver Diseases 2018 guidelines in the management of hepatocellular carcinoma and its impact on survival
    Ashish Manne, Madhuri Mulekar, Daisy Escobar, Pranitha Prodduturvar, Yazan Fahmawi, Phillip Henderson, Osama Abdul-Rahim, Zeiad Hussain, Spencer Liles, Annabelle Fonseca, John Harrison Howard, Wadad Mneimneh, Robert Gilbert, Omar Alkharabsheh, Sachin Pai,
    Journal of Cancer Research and Therapeutics.2023; 19(5): 1103.     CrossRef
  • Impact of guideline adherence on the prognosis of Barcelona clinic liver cancer stage B hepatocellular carcinoma
    Ji Eun Han, Hyo Jung Cho, Jae Youn Cheong, Sun Gyo Lim, Min Jae Yang, Choong-Kyun Noh, Gil Ho Lee, Soon Sun Kim
    World Journal of Gastroenterology.2023; 29(47): 6122.     CrossRef
  • Comparable effects of Jiedu Granule, a compound Chinese herbal medicine, and sorafenib for advanced hepatocellular carcinoma: A prospective multicenter cohort study
    He-tong Zhao, Yong-bin Meng, Xiao-feng Zhai, Bin-bin Cheng, Sha-sha Yu, Man Yao, Hui-xia Yin, Xu-ying Wan, Yun-ke Yang, Hui Liu, Feng Shen, Chang-quan Ling
    Journal of Integrative Medicine.2020; 18(4): 319.     CrossRef
  • Combined extensive liver resections in patients with locally advanced hepatocellular cancer – clinical cases
    D. V. Sidorov, M. V. Lozhkin, L. O. Petrov, A. G. Isaeva, M. S. Gusakova
    Research and Practical Medicine Journal.2020; 7(2): 154.     CrossRef
  • Selecting the first line treatment in non-metastatic hepatocellular carcinoma - comparing clinical practice guidelines
    Soumya Jogi, Radha Varanai, Sravani S. Bantu, Ashish Manne
    Oncology Reviews.2020;[Epub]     CrossRef
  • Efficacy and Safety of Combined Radiofrequency Ablation with Transarterial Chemoembolization in Patients with Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma Ineligible for Curative Treatment
    Ah Ran Kim, Eugene Park, So Young Kwon, Seong Jun Park, Young Jung Kim, Byung Chul Yoo, Won Hyeok Choe, Jeong Han Kim, Jin Ho Hwang, Sang Woo Park, Young Jun Kim, Hee Sun Park, Mi hye Yu, Hae jeong Jeon
    The Korean Journal of Gastroenterology.2019; 73(3): 167.     CrossRef
  • Adherence to Barcelona Clinic Liver Cancer therapeutic algorithm for hepatocellular carcinoma in the daily practice: a multicenter cohort study from Argentina
    Federico Piñero, Sebastián Marciano, Nora Fernández, Jorge Silva, Yanina Zambelo, Manuel Cobos, Alina Zerega, Ezequiel Ridruejo, Carlos Miguez, Beatriz Ameigeiras, Claudia D’Amico, Luis Gaite, Matías Coronel, Carla Bermúdez, Carlos Rosales, Gustavo Romero
    European Journal of Gastroenterology & Hepatology.2018; 30(4): 376.     CrossRef
  • Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence
    Ye Xin Koh, Hwee Leong Tan, Weng Kit Lye, Juinn Huar Kam, Adrian Kah Heng Chiow, Siong San Tan, Su Pin Choo, Alexander Yaw Fui Chung, Brian Kim Poh Goh
    World Journal of Hepatology.2018; 10(6): 433.     CrossRef
  • Adherence to BCLC recommendations for the treatment of hepatocellular carcinoma: impact on survival according to stage
    Luciana Kikuchi, Aline Lopes Chagas, Regiane S.S.M. Alencar, Claudia Tani, Marcio A. Diniz, Luiz A.C. D'Albuquerque, Flair José Carrilho
    Clinics.2017; 72(8): 454.     CrossRef
  • Hepatocellular carcinoma surgery outcomes in the developing world: A 20-year retrospective cohort study at the National Cancer Institute of Peru
    Eloy Ruiz, Teresa Rojas Rojas, Francisco Berrospi, Ivan Chávez, Carlos Luque, Luis Cano, Franco Doimi, Pascal Pineau, Eric Deharo, Stéphane Bertani
    Heliyon.2016; 2(1): e00052.     CrossRef
  • Radiofrequency ablation as an alternative to hepatic resection for single small hepatocellular carcinomas
    G-A Kim, J H Shim, M-J Kim, S Y Kim, H J Won, Y M Shin, P N Kim, K-H Kim, S-G Lee, H C Lee
    Journal of British Surgery.2016; 103(1): 126.     CrossRef
  • Health economic evaluation of Gd-EOB-DTPA MRI vs ECCM-MRI and multi-detector computed tomography in patients with suspected hepatocellular carcinoma in Thailand and South Korea
    Jeong-Min Lee, Myeong-Jin Kim, Sith Phongkitkarun, Abhasnee Sobhonslidsuk, Anke-Peggy Holtorf, Harald Rinde, Karsten Bergmann
    Journal of Medical Economics.2016; 19(8): 759.     CrossRef
  • Use of18F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization
    Min Jin Kim, Young Seok Kim, Youn Hee Cho, Hee Yoon Jang, Jeong-Yeop Song, Sae Hwan Lee, Soung Won Jeong, Sang Gyune Kim, Jae Young Jang, Hong Su Kim, Boo Sung Kim, Won Hyung Lee, Jung Mi Park, Jae Myung Lee, Min Hee Lee, Deuk Lin Choi
    The Korean Journal of Internal Medicine.2015; 30(3): 308.     CrossRef
  • Comparison of Chemoembolization with and without Radiation Therapy and Sorafenib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score Analysis
    Gi-Ae Kim, Ju Hyun Shim, Sang Min Yoon, Jinhong Jung, Jong Hoon Kim, Min-Hee Ryu, Baek-Yeol Ryoo, Yoon-Koo Kang, Danbi Lee, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee
    Journal of Vascular and Interventional Radiology.2015; 26(3): 320.     CrossRef
  • Real Life Treatment of Hepatocellular Carcinoma: Impact of Deviation from Guidelines for Recommended Therapy
    Alzhraa Alkhatib, Asmaa Gomaa, Naglaa Allam, Eman Rewisha, Imam Waked
    Asian Pacific Journal of Cancer Prevention.2015; 16(16): 6929.     CrossRef
  • Prognostic Impact of Telomere Maintenance Gene Polymorphisms on Hepatocellular Carcinoma Patients With Chronic Hepatitis B
    Seok Won Jung, Neung Hwa Park, Jung Woo Shin, Bo Ryung Park, Chang Jae Kim, Jong-Eun Lee, Eun-Soon Shin, Jeong A Kim, Young-Hwa Chung
    Hepatology.2014; 59(5): 1912.     CrossRef
  • Exposure to Ionizing Radiation During Liver Transplantation Evaluation, Waitlist Time, and in the Postoperative Period: A Cause for Concern
    Ser Yee Lee, Michael A. Mooney, Matthew L. Inra, Krishna Juluru, Alyson N. Fox, Sonja K. Olsen, Robert S. Brown, Jean C. Emond, Daniel Cherqui, Michael D. Kluger
    Hepatology.2014; 59(2): 496.     CrossRef
  • Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: Experience of the Bologna Liver Oncology Group
    Simona Leoni, Fabio Piscaglia, Ilaria Serio, Eleonora Terzi, Irene Pettinari, Luca Croci, Sara Marinelli, Francesca Benevento, Rita Golfieri, Luigi Bolondi
    Digestive and Liver Disease.2014; 46(6): 549.     CrossRef
  • Sorafenib Combined with Transarterial Chemoembolization versus Transarterial Chemoembolization Alone for Advanced-Stage Hepatocellular Carcinoma: A Propensity Score Matching Study
    Hao Hu, Zhenhua Duan, Xiaoran Long, Yancu Hertzanu, Haibin Shi, Sheng Liu, Zhengqiang Yang, Gayle E. Woloschak
    PLoS ONE.2014; 9(5): e96620.     CrossRef
  • Sorafenib Alone versus Sorafenib Combined with Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: Results of Propensity Score Analyses
    Gwang Hyeon Choi, Ju Hyun Shim, Min-Joo Kim, Min-Hee Ryu, Baek-Yeol Ryoo, Yoon-Koo Kang, Yong Moon Shin, Kang Mo Kim, Young-Suk Lim, Han Chu Lee
    Radiology.2013; 269(2): 603.     CrossRef
  • Comparison of Long-Term Survival of Patients with BCLC Stage B Hepatocellular Carcinoma after Liver Resection or Transarterial Chemoembolization
    Jian-Hong Zhong, Bang-De Xiang, Wen-Feng Gong, Yang Ke, Qin-Guo Mo, Liang Ma, Xing Liu, Le-Qun Li, Matias A. Avila
    PLoS ONE.2013; 8(7): e68193.     CrossRef
  • Sorafenib Alone versus Sorafenib Combined with Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: Results of Propensity Score Analyses
    Gwang Hyeon Choi, Ju Hyun Shim, Min-Joo Kim, Min-Hee Ryu, Baek-Yeol Ryoo, Yoon-Koo Kang, Yong Moon Shin, Kang Mo Kim, Young-Suk Lim, Han Chu Lee
    Radiology.2013; 269(2): 603.     CrossRef
  • Polymorphisms of DNA repair genes in Korean hepatocellular carcinoma patients with chronic hepatitis B: Possible implications on survival
    Seok Won Jung, Neung Hwa Park, Jung Woo Shin, Bo Ryung Park, Chang Jae Kim, Jong-Eun Lee, Eun-Soon Shin, Jeong A Kim, Young-Hwa Chung
    Journal of Hepatology.2012; 57(3): 621.     CrossRef
  • 11,774 View
  • 51 Download
  • Crossref
Treatment and clinical outcome of needle-track seeding from hepatocellular carcinoma
Dong-Won Ahn, Ju Hyun Shim, Jung-Hwan Yoon, Chung Yong Kim, Hyo-Suk Lee, Yeong Tae Kim, Yoon Jun Kim
Korean J Hepatol 2011;17(2):106-112.
Published online June 23, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.2.106
Background/Aims

Needle-track seeding is a rare but important complication of diagnostic and therapeutic ultrasound (US)-guided procedures in hepatocellular carcinoma (HCC). We examined the frequency of needle-track seeding after US-guided percutaneous ethanol injection (PEI), fine-needle aspiration biopsy (FNAB), and percutaneous transhepatic biliary drainage (PTBD) in order to determine the appropriate treatment for needle-track seeding and its clinical outcome.

Methods

We analyzed the clinical characteristics and treatment outcomes in eight patients who experienced needle-track seeding from HCC after an US-guided procedure (FNAB, PEI, or PTBD) between January 1990 and July 2004.

Results

Seven (0.14%) of 5,092 patients who experienced needle-track seeding (2 after PEI, 4 after FNAB, and 1 after PTBD) during the study period and 1 other patient who experienced needle-track seeding recently were recruited for this study. Two of the eight patients underwent mass excision and the other six patients underwent en-bloc wide excision for the needle-track seeding. Tumors recurred in the needle-tracks in both patients who underwent mass excision but not in the six patients who underwent en-bloc wide excision. Mortality occurred in three patients who experienced the recurrence and progression of intrahepatic HCC.

Conclusions

The incidence of needle-track seeding after US-guided procedures in HCC was 0.14%. En-bloc wide excision seems to be the optimal treatment for minimizing the probability of tumor recurrence due to needle-track seeding.

Citations

Citations to this article as recorded by  Crossref logo
  • Use of Albumin In Situ Hybridization to Diagnose Cutaneous Metastatic Hepatocellular Carcinoma With Poorly Differentiated Features: A Case Report and Review of the Literature
    Andrew J. Gauger, Aofei Li, Mike Fritz, Terrence M. Katona, Ahmed K. Alomari
    The American Journal of Dermatopathology.2025; 47(3): 211.     CrossRef
  • Combined Neuroendocrine Carcinoma and Hepatocellular Carcinoma of the Liver: Systematic Literature Review Suggests Implementing Biological Characterization to Optimize Therapeutic Strategy
    Daniela Sambataro, Sandro Bellavia, Paolo Di Mattia, Danilo Centonze, Carmela Emmanuele, Annalisa Bonasera, Giuseppe Caputo, Andrea Maria Onofrio Quattrocchi, Ernesto Vinci, Vittorio Gebbia, Maria Rosaria Valerio
    Cancers.2025; 17(7): 1074.     CrossRef
  • Fibrolamellar Hepatocellular Carcinoma (FLHCC) in a Young Patient Presenting With Nausea and Vomiting After a Greasy Meal
    Mohamed Ismail , Sahiba Singh, Menna-Allah Elaskandrany , David s Kim, Yazan Abboud, Michael Bebawy, Abena Oduro, Ritik mahaveer Goyal, Omar Mohamed , Weizheng Wang
    Cureus.2024;[Epub]     CrossRef
  • Tumor seeding across specialties: a systematic review
    Pavel Kipnis, Diya Ramanathan, Richard Hoehn, Ashok R. Jethwa, Daniel W. Karakla, Bethany Rohr, Christopher M. Sutter, Jonathan R. Mark, Sobia F. Khaja, Shawn Li, Jason Thuener, Bryan T. Carroll
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Safety of percutaneous, image-guided biopsy of hepatocellular carcinoma with and without concurrent ablation
    Justin R. Tse, Kevin Terashima, Luyao Shen, Justin P. McWilliams, David S. K. Lu, Steven S. Raman
    Abdominal Radiology.2022; 47(8): 2640.     CrossRef
  • Effect of Autotransfusion in HCC Surgery on Survival and Recurrence: A Systematic Review and Meta-Analysis
    Anastasia Murtha-Lemekhova, Juri Fuchs, Emil Ritscher, Katrin Hoffmann
    Cancers.2022; 14(19): 4837.     CrossRef
  • Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit
    Alexa Childs, Nekisa Zakeri, Yuk Ting Ma, Joanne O’Rourke, Paul Ross, Essam Hashem, Richard A. Hubner, Kimberley Hockenhull, Chinenye Iwuji, Sam Khan, Daniel H. Palmer, Joanna Connor, Daniel Swinson, Suzanne Darby, Chiara Braconi, Tom Roques, Dominic Yu,
    British Journal of Cancer.2021; 125(10): 1350.     CrossRef
  • S3538 Needle Track Seeding in a Patient With Hepatocellular Carcinoma
    Sara Goff, Bhishak Kamat, Alyssa Goldbach, Shqiponja Hajdinaj, Joseph Panaro
    American Journal of Gastroenterology.2020; 115(1): S16.     CrossRef
  • ACR Appropriateness Criteria® Liver Lesion-Initial Characterization
    Victoria Chernyak, Jeanne M. Horowitz, Ihab R. Kamel, Hina Arif-Tiwari, Mustafa R. Bashir, Brooks D. Cash, James Farrell, Alan Goldstein, Joseph R. Grajo, Samir Gupta, Nicole M. Hindman, Aya Kamaya, Michelle M. McNamara, Kristin K. Porter, Lilja Bjork. So
    Journal of the American College of Radiology.2020; 17(11): S429.     CrossRef
  • ЗАСТОСУВАННЯ ПЕРКУТАННОЇ ХІМІЧНОЇ АБЛЯЦІЇ В ЛІКУВАННІ ПАЦІЄНТІВ З ГЕПАТОЦЕЛЮЛЯРНОЮ КАРЦИНОМОЮ
    Lyudmila Levchenko, Yelyzaveta Kozachuk, Sergey Zemskov
    The Ukrainian Scientific Medical Youth Journal.2020; 116(2): 33.     CrossRef
  • Role of liver biopsy in hepatocellular carcinoma
    Luca Di Tommaso, Marco Spadaccini, Matteo Donadon, Nicola Personeni, Abubaker Elamin, Alessio Aghemo, Ana Lleo
    World Journal of Gastroenterology.2019; 25(40): 6041.     CrossRef
  • Rate of seeding with biopsies and ablations of hepatocellular carcinoma: A retrospective cohort study
    Jean‐Luc Szpakowski, Todd E. Drasin, Liisa L. Lyon
    Hepatology Communications.2017; 1(9): 841.     CrossRef
  • Response to transarterial chemoembolization may serve as selection criteria for hepatocellular carcinoma liver transplantation
    Jianyong Lei, Jinjing Zhong, Yefang Luo, Lunan Yan, Jinqiang Zhu, Wentao Wang, Bo Li, Tianfu Wen, Jiaying Yang
    Oncotarget.2017; 8(53): 91328.     CrossRef
  • Percutaneous Tumor Ablation
    Xiaofeng He, Yueyong Xiao, Xiao Zhang, Peng Du, Xin Zhang, Jie Li, Yunxia An, Patrick Le Pivert
    Technology in Cancer Research & Treatment.2016; 15(4): 597.     CrossRef
  • Metástasis cutánea de hepatocarcinoma tras procedimientos percutáneos
    F.J. de León, M.M. Blanes, M.P. Albares, L. Berbegal
    Actas Dermo-Sifiliográficas.2015; 106(5): 440.     CrossRef
  • Cutaneous Metastasis From Hepatocellular Carcinoma After a Percutaneous Interventional Procedure
    F.J. de León, M.M. Blanes, M.P. Albares, L. Berbegal
    Actas Dermo-Sifiliográficas (English Edition).2015; 106(5): 440.     CrossRef
  • Needle tract seeding: An avoidable complication
    Ruchita Tyagi, Pranab Dey
    Diagnostic Cytopathology.2014; 42(7): 636.     CrossRef
  • Parietal and peritoneal localizations of hepatocellular carcinoma: is there a place for a curative surgery?
    Nazario Portolani, Gian Luca Baiocchi, Federico Gheza, Sarah Molfino, Daniele Lomiento, Stefano Maria Giulini
    World Journal of Surgical Oncology.2014;[Epub]     CrossRef
  • Effectiveness and Complications of Ultrasound Guided Fine Needle Aspiration for Primary Liver Cancer in a Chinese Population with Serum α-Fetoprotein Levels ≤200 ng/ml - A Study Based on 4,312 Patients
    Qi-wen Chen, Chien-shan Cheng, Hao Chen, Zhou-yu Ning, Shi-feng Tang, Xun Zhang, Xiao-yan Zhu, Sonya Vargulick, Ye-hua Shen, Yong-qiang Hua, Jing Xie, Wei-dong Shi, Hui-feng Gao, Li-tao Xu, Lan-yun Feng, Jun-hua Lin, Zhen Chen, Lu-ming Liu, Bo Ping, Zhi-q
    PLoS ONE.2014; 9(8): e101536.     CrossRef
  • Consequences of needle tract seeding of hepatocellular cancer after liver transplant
    Kristi T. Lopez, Scott K. Kuwada, Linda L. Wong
    Clinical Transplantation.2013;[Epub]     CrossRef
  • Percutaneous interventional procedures in an era of liver transplantation
    Young Seok Kim
    The Korean Journal of Hepatology.2011; 17(2): 96.     CrossRef
  • 9,993 View
  • 57 Download
  • Crossref

Case Report

A case of pedunculated hepatic hemangioma mimicking submucosal tumor of the stomach
Han Kook Moon, Hyoung Su Kim, Gyeong Mi Heo, Woon Geon Shin, Kyung Ho Kim, Myoung Kuk Jang, Jin Heon Lee, Hak Yang Kim, Doo Jin Kim, Seong Jin Cho
Korean J Hepatol 2011;17(1):66-70.
Published online March 21, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.1.66

Hepatic hemangioma is the most common benign tumor of the liver. Most such hemangiomas are small, asymptomatic, and have an excellent prognosis. Giant hepatic hemangioma has been reported in the literature, but the exophytic and pedunculated forms of hepatic hemangioma are rare. A 56-year-old woman was referred to our hospital under the suspicion of having a gastric submucosal tumor. Abdominal computer tomography (CT) scans showed a pedunculated mass from the left lateral segment of the liver into the gastric fundus, exhibiting the atypical CT findings of hepatic hemangioma. We therefore decided to perform laparoscopic resection based on the symptoms, relatively large diameter, inability to exclude malignancy, and risk of rupture of the exophytic lesion. The pathology indicated it to be a cavernous hemangioma of the liver. Herein we report a case of pedunculated hepatic hemangioma mimicking a submucosal tumor of the stomach due to extrinsic compression of the gastric fundus.

Citations

Citations to this article as recorded by  Crossref logo
  • Gestieltes Hämangiom der Leber simuliert Dünndarm-GIST
    Wolfgang Schima, Edith Eisenhuber, Oskar Koperek, Brigitte Obermayer, Matthias Paireder
    Journal für Gastroenterologische und Hepatologische Erkrankungen.2025; 23(1): 33.     CrossRef
  • Gestieltes Hämangiom der Leber simuliert Dünndarm-GIST
    Wolfgang Schima, Edith Eisenhuber, Oskar Koperek, Brigitte Obermayer, Matthias Paireder
    Gastro-News.2025; 12(3): 6.     CrossRef
  • Exophytic Hepatic Hemangioma Mimicking a Right Adrenal Gland Mass: A Diagnostic Challenge
    Arun Arumugam, Abdul Rahman Abualruz, Intisar Ghleilib, Ravishankar Pillenahalli Maheshwarappa
    Cureus.2025;[Epub]     CrossRef
  • Giant pedunculated hepatic hemangioma accompanied by a 10‐year history of taking oral contraceptive: A case report and literature review
    Pirouz Samidoust, Maziar Moayerifar, Maede Mohammadian, Athar Zamani, Maryam Jafari, Mani Moayerifar, Fakhrieh Kalavari, Mahta Foroughifar
    Clinical Case Reports.2024;[Epub]     CrossRef
  • Case Report: Giant abdominal hemangioma originating from the liver
    Tianxiang Jiang, Zhou Zhao, Zhaolun Cai, Chaoyong Shen, Bo Zhang
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Giant pedunculated liver mass: primary hepatocellular carcinoma masquerading as hepatic haemangioma
    Olivia Cohen, Muhammad Aleem, Steven Wolberink, Miklos Attila Perenyei
    BMJ Case Reports.2021; 14(9): e242625.     CrossRef
  • Two hepatic cavernous hemangiomas mimicking colorectal liver metastasis
    Tlal Matouq Alsofyani, Mohammed Yousef Aldossary, Faisal Fahd AlQahtani, Mahmoud Tabbal, Ameera Balhareth
    International Journal of Surgery Case Reports.2021; 81(C): 105817.     CrossRef
  • Torsion of a giant pedunculated liver hemangioma
    Llenner Castañeda Puicón, Yeray Trujillo Loli, Stefanie Campos Medina
    International Journal of Surgery Case Reports.2020; 75(C): 207.     CrossRef
  • Atypical exophytic liver mass: Giant pedunculated hepatic haemangioma masquerading as a gastrointestinal stromal tumour of the gastric wall
    Venkatram Krishnan, Sunil K. Bajaj, Abhilash Sethy, Neetika Gupta
    South African Journal of Radiology.2019;[Epub]     CrossRef
  • Uncommon evolutions and complications of common benign liver lesions
    Federica Vernuccio, Maxime Ronot, Marco Dioguardi Burgio, Jérôme Lebigot, Wassim Allaham, Christophe Aubé, Giuseppe Brancatelli, Valérie Vilgrain
    Abdominal Radiology.2018; 43(8): 2075.     CrossRef
  • Ein klarer Fall von GIST des Magens und eine überraschende intraoperative Diagnose
    Wolfgang Schima, Ehrenfried Schmaranzer, Eva Achter, Hermann Nehoda
    Journal für Gastroenterologische und Hepatologische Erkrankungen.2018; 16(2): 63.     CrossRef
  • Giant Pedunculated Hepatic Hemangioma: A Case Report and Literature Review
    Abdallah  Al Farai, Lénaïg Mescam, Valeria De Luca, Audrey Monneur, Delphine Perrot, Jerome Guiramand, Jean-Robert Delpero, François Bertucci
    Case Reports in Oncology.2018; 11(2): 476.     CrossRef
  • Pedunculated liver hemangioma mimicking stomach neoplasm
    Sonay Aydın, Erdem Fatihoğlu, Elif Ergün, Pınar Nercis Koşar
    The European Research Journal.2017;[Epub]     CrossRef
  • Treatment of atypically-localized cavernous hemangioma in abdomen with atypical pain
    Mehmet Ilhan, Gizem Oner, Ali Fuat Kaan Gök, Mesut Bulakçı, Gülçin Yeğen
    International Journal of Surgery Case Reports.2016; 25: 24.     CrossRef
  • Torsion of a Giant Pedunculated Hemangioma of the Liver Presenting With Acute Abdomen: A Case Report
    Aliasghar Darzi, Hassan Taheri, Sekineh Kamali Ahangar, Alameh Mirzapour Shafiei, Yasser Asghari
    Iranian Red Crescent Medical Journal.2016;[Epub]     CrossRef
  • Giant pedunculated hemangioma of the liver
    Paula de Castro Menezes Candido, Izabela Machado Flores Pereira, Breno Assunção Matos, Mario Henrique Giordano Fontes, Teófilo Eduardo de Abreu Pires, Petrônio Rabelo Costa
    Radiologia Brasileira.2016; 49(1): 57.     CrossRef
  • Hepatic hemangioma masquerading as a tumor originating from the stomach
    XINGMAO ZHANG, ZHIXIANG ZHOU
    Oncology Letters.2015; 9(3): 1406.     CrossRef
  • Collagenous nodule mixed simple cyst and hemangioma coexistence in the liver
    Zhen-Jiang Zheng
    World Journal of Gastroenterology.2015; 21(14): 4419.     CrossRef
  • Bilateral Lower Limb Edema Caused by Compression of the Retrohepatic Inferior Vena Cava by a Giant Hepatic Hemangioma
    Sami Akbulut, Mehmet Yilmaz, Aysegul Kahraman, Sezai Yilmaz
    International Surgery.2013; 98(3): 229.     CrossRef
  • Giant Hepatic Hemangioma Presenting as Gastric Outlet Obstruction
    Cemalettin Aydin, Sami Akbulut, Koray Kutluturk, Aysegul Kahraman, Cuneyt Kayaalp, Sezai Yilmaz
    International Surgery.2013; 98(1): 19.     CrossRef
  • 10,221 View
  • 54 Download
  • Crossref

Liver Imaging

Hepatic adrenal rest tumor mimicking hepatocellular carcinoma
Yong Moon Shin
Korean J Hepatol 2010;16(3):338-341.
Published online September 30, 2010
DOI: https://doi.org/10.3350/kjhep.2010.16.3.338

Citations

Citations to this article as recorded by  Crossref logo
  • Hepatic Ectopic Adrenal Gland in a Patient with Hepatitis C Virus Who Achieved a Sustained Virological Response
    Mariya Kawanishi, Akitoshi Douhara, Koji Ishida, Masato Nakatsuji, Noriyuki Hamato, Daisuke Hokuto, Masahiro Tsutsumi, Toshiya Nakatani
    Internal Medicine.2026; 65(3): 420.     CrossRef
  • Ectopic adrenocortical adenoma in liver disguising as hepatocellular carcinoma: A case report and literature review
    Jixuan Duan, Chong Peng, Ting Sun, Heng Wen, Fangyan Lu, Yan Zheng, Wenjin Zhang
    Human Pathology Reports.2025; 41: 300780.     CrossRef
  • Hepatic adrenal rest tumor presenting as a giant cystic lesion with regular wall nodule
    Yu Liu, Donghua Sun, Heng Liu
    iRADIOLOGY.2024; 2(2): 220.     CrossRef
  • Ectopic adrenocortical adenoma characterized by hypogonadism: a case report and review of the literature
    Zhihua Wang, Xueyu Zhong, Jiayu Yu, Huiqing Li, Juan Zheng
    Journal of Medical Case Reports.2024;[Epub]     CrossRef
  • Laparoscopic resection for a case preoperatively diagnosed as adrenal rest tumor in the liver: A case report
    Masataka Nakagawa, Tomoyuki Abe, Tsuyoshi Kobayashi, Hideki Ohdan, Kazuhiro Toyota
    International Journal of Surgery Case Reports.2024; 124: 110408.     CrossRef
  • Adrenocortical carcinoma mimicking hepatocellular carcinoma: A case report
    Takahiro Ikeda, Amane Kitasato, Tatsuya Okamoto, Momoko Soeda, Shiro Miura, Tamotsu Kuroki
    International Journal of Surgery Case Reports.2023; 105: 108122.     CrossRef
  • Duplicated adrenal veins in primary aldosteronism misdiagnosed with ectopic aldosteronoma due to apparent bilateral aldosterone suppression
    Jingwen Yu, Cunxia Fan, Weiping Wei, Haiwei Liu, Tuanyu Fang, Huibiao Quan, Kaining Chen, Yuhai Zhang
    Blood Pressure.2023;[Epub]     CrossRef
  • A case of hepatic adrenal rest tumor diagnosed by various clinical examination findings
    Shunsuke Nakamura, Tatsuya Kakegawa, Hirohito Takeuchi, Hiroshi Takahashi, Yusuke Tomita, Masakazu Abe, Yu Yoshimasu, Yoshitaka Kasai, Katsutoshi Sugimoto, Yoshihiro Furuichi, Takao Itoi
    Kanzo.2022; 63(2): 69.     CrossRef
  • Hepatic Adrenal Rest Tumors Mimicking Hepatocellular Carcinoma: A Case Report and Review of the Literature
    Ahmad Al-Taee, Danielle Capenter, Robert Garrett, Mustafa Nazzal, Brent Tetri
    Cureus.2022;[Epub]     CrossRef
  • Hepatic isolated ectopic adrenocortical adenoma mimicking metastatic liver tumor
    Jing-Yi Zhang, Yan Luo, Fei Liu, Bo Li
    Hepatobiliary & Pancreatic Diseases International.2021; 20(1): 83.     CrossRef
  • An ectopic adrenocortical oncocytic adenoma in the liver highly mimicking hepatocellular carcinoma: case report and literature review
    Jingci Chen, Xueshuai Wan, Yao Lu, Wenze Wang, Dachun Zhao, Zhaohui Lu, Yilei Mao, Jie Chen
    Diagnostic Pathology.2021;[Epub]     CrossRef
  • Large adrenal tumours mimicking hepatic malignancy: the role of concurrent adrenalectomy and anterior approach hepatectomy
    Nitin Agarwal, Nihar Mohapatra, Nilesh S. Patil, Piyush K. Sinha, Gattu Tharun, Viniyendra Pamecha
    ANZ Journal of Surgery.2021; 91(4): 730.     CrossRef
  • Hepatic adrenal rest tumor in a patient with multifactorial liver cirrhosis: a case report with CT and MRI findings and pathologic correlation
    Piero Boraschi, Francesca Turini, Francescamaria Donati, Francesca Peruzzi, Annamaria Bartolucci, Niccolò Roffi, Piero Colombatto, Lucio Urbani
    Egyptian Journal of Radiology and Nuclear Medicine.2021;[Epub]     CrossRef
  • Intrahepatic adrenocortical adenoma arising from adrenohepatic fusion mimicking hepatic malignancy
    Yong Soo Cho, Jin Woong Kim, Hyun Ju Seon, Ju-Yeon Cho, Jun-Hee Park, Hyung Joong Kim, Yoo Duk Choi, Young Hoe Hur
    Medicine.2019; 98(23): e15901.     CrossRef
  • State-of-the-art MR Imaging of Fat-containing Focal Lesions of the Liver
    Joanna Podgorska, Agnieszka Anysz-Grodzicka, Andrzej Cieszanowski
    Current Medical Imaging Formerly Current Medical Imaging Reviews.2019; 15(5): 435.     CrossRef
  • Uncommon liver lesions with multimodality imaging and pathology correlation
    A.K. Ho, S. Girgis, G. Low
    Clinical Radiology.2018; 73(2): 191.     CrossRef
  • Fat-Containing Liver Lesions on Imaging: Detection and Differential Diagnosis
    Andreu F. Costa, Seng Thipphavong, Thomas Arnason, Ashleigh E. Stueck, Sharon E. Clarke
    American Journal of Roentgenology.2018; 210(1): 68.     CrossRef
  • Adrenocortical carcinoma co-occurrence with a hepatocellular carcinoma within an adrenohepatic fusion: a case report
    Faisal A. Alfaqeeh, Ghadeer Algehani, Mazin Hassanain, Abdulsalam Alsharaabi, Mohammad Alsohaibani
    Journal of Surgical Case Reports.2017;[Epub]     CrossRef
  • Adrenal Rest Tumor of the Liver Preoperatively Diagnosed as Hepatocellular Carcinoma
    Megumu Enjoji, Katsuya Sanada, Ryota Seki, Takashi Ito, Masato Maeda
    Case Reports in Surgery.2017; 2017: 1.     CrossRef
  • Chemical Shift MR Imaging of the Adrenal Gland: Principles, Pitfalls, and Applications
    Sharon Z. Adam, Paul Nikolaidis, Jeanne M. Horowitz, Helena Gabriel, Nancy A. Hammond, Tanvi Patel, Vahid Yaghmai, Frank H. Miller
    RadioGraphics.2016; 36(2): 414.     CrossRef
  • Adrenal ectopy of adult groin region: a systematic review of an unexpected anatomopathologic diagnosis
    L. Senescende, P. L. Bitolog, E. Auberger, A. Zarzavadjian Le Bian, M. Cesaretti
    Hernia.2016; 20(6): 879.     CrossRef
  • Sonographic Detection of Accessory Adrenal Tissue in Neonates
    Daniel Ben-Mordechay, Aviva Ben-Shlush, Lisa Raviv-Zilka, Jeffrey M. Jacobson, Michalle Soudack
    Journal of Ultrasound in Medicine.2016; 35(5): 959.     CrossRef
  • Hepatic adrenal rest tumor: Diagnostic pitfall and proposed algorithms to prevent misdiagnosis as lipid‐rich hepatocellular carcinoma
    Tomoko Sugiyama, Takuma Tajiri, Shinichiro Hiraiwa, Chie Inomoto, Hiroshi Kajiwara, Seiichiro Kojima, Kouske Tobita, Naoya Nakamura
    Pathology International.2015; 65(2): 95.     CrossRef
  • Hepatic Adrenal Rest Tumour (HART): A Case Report
    Kai Ling Soo, Rafay Azhar, London Lucien PJ Ooi
    Annals of the Academy of Medicine, Singapore.2014; 43(2): 120.     CrossRef
  • Possible Origin of Aldosteronoma from Adrenohepatic Fusion Resulting in Intrahepatic Tumor
    Takumi Takeuchi, Takashi Inoue, Keiko Kanemoto, Kazuchika Hagiwara, Koji Mikami, Mami Hattori, Masayoshi Zaitsu, Akiko Tonooka, Toshimasa Uekusa, Susumu Uda
    Open Journal of Urology.2013; 03(06): 223.     CrossRef
  • Growth Patterns of Placental and Paraovarian Adrenocortical Heterotopias Are Different
    Hua Zhong, Bo Xu, Dorota A. Popiolek
    Case Reports in Pathology.2013; 2013: 1.     CrossRef
  • 11,835 View
  • 71 Download
  • Crossref

Liver Pathology

Sarcomatoid hepatocellular carcinoma
Jae Yeon Seok , Young Bae Kim
Korean J Hepatol 2010;16(1):89-94.
Published online March 26, 2010
DOI: https://doi.org/10.3350/kjhep.2010.16.1.89

Citations

Citations to this article as recorded by  Crossref logo
  • Sarcomatoid carcinoma of the pancreas (Review)
    Yijie Ma, Yiwen Yang, Huizhi Zhang, Joseph Mugaanyi, Yangke Hu, Shengdong Wu, Caide Lu, Shuqi Mao, Ke Wang
    Oncology Letters.2024;[Epub]     CrossRef
  • Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma
    Chubin Luo, Haoyang Xin, Dan Yin, Tongyi Zhao, Zhiqiang Hu, Zhengjun Zhou, Rongqi Sun, Na Yao, Qiman Sun, Jia Fan, Xiaowu Huang, Jian Zhou, Shaolai Zhou
    Aging.2021; 13(11): 15126.     CrossRef
  • Sarcomatoid carcinoma of the gallbladder: a case report
    Yunfu Shi, Jiabin Chen, Hua Chen, Xiufang Hong
    Journal of International Medical Research.2020;[Epub]     CrossRef
  • Paraneoplastic leukemoid reaction in a patient with sarcomatoid hepatocellular carcinoma: A case report
    Bo Hu, Xin-Ting Sang, Xiao-Bo Yang
    World Journal of Clinical Cases.2019; 7(11): 1330.     CrossRef
  • Sarcomatoid hepatocellular carcinoma (SHC): a case report
    Yingying Yu, Yanping Zhong, Jingyu Wang, Di Wu
    World Journal of Surgical Oncology.2017;[Epub]     CrossRef
  • Multiple Colonic Metastases from Hepatocellular Carcinoma
    Gwi Hong Jeong, Byong Duk Ye, Seung Jae Myung
    The Korean Journal of Gastroenterology.2011; 58(5): 288.     CrossRef
  • 6,538 View
  • 88 Download
  • Crossref

Liver Imagings

Neuroendocrine tumors of the Liver
Won Jae Lee
Korean J Hepatol 2009;15(4):528-532.
Published online December 31, 2009
DOI: https://doi.org/10.3350/kjhep.2009.15.4.528
.

Citations

Citations to this article as recorded by  Crossref logo
  • References

    Journal of the International Commission on Radiation Units and Measurements.2014; 14(2): 123.     CrossRef
  • References

    Journal of the ICRU.2014; 14(2): 123.     CrossRef
  • 5,352 View
  • 27 Download
  • Crossref
Peliosis hepatis
Won Jae Lee
Korean J Hepatol 2009;15(3):379-382.
Published online September 30, 2009
DOI: https://doi.org/10.3350/kjhep.2009.15.3.379
.

Citations

Citations to this article as recorded by  Crossref logo
  • Two Cases of Hepatic Sinusoidal Dilatation Mimicking Hepatic Metastases
    Jong-Hoon Hyun, Yoo-Kyung Cho, Hyun-Joo Song, Eun-Kwang Choi, Chang-Lim Hyun, Jung-Mi Kwon, Bong-Soo Kim, Byung-Cheol Song
    The Korean Journal of Gastroenterology.2014; 64(4): 239.     CrossRef
  • A Case of Peliosis Hepatis Mimicking Metastatic Lesions of Increasing Size
    Min Jeong Kim, Hyun Jung Kim, Boem-Ha Yi, Hee Kyoung Kim, Jina Yun, Se Hyung Kim, Chan Kyu Kim, Sung Kyu Park, Dae Sik Hong
    Soonchunhyang Medical Science.2012; 18(2): 141.     CrossRef
  • 6,197 View
  • 33 Download
  • Crossref
Epithelioid hemangioendothelioma
Won Jae Lee
Korean J Hepatol 2009;15(2):222-226.
Published online June 30, 2009
DOI: https://doi.org/10.3350/kjhep.2009.15.2.222
  • 5,524 View
  • 27 Download

Case Report

A case of hepatocellular carcinoma invading the gallbladder misdiagnosed as a primary gallbladder carcinoma
Han Seung Ryu, M.D., Eui Tae Hwang, M.D., Chang Soo Choi, M.D., Tae Hyeon Kim, M.D., Haak Cheoul Kim, M.D., Ki Jung Yun, M.D.1, Dong Eun Park, M.D.2
Korean J Hepatol 2009;15(1):80-84.
Published online March 31, 2009
DOI: https://doi.org/10.3350/kjhep.2009.15.1.80
Extrahepatic metastasis of hepatocellular carcinoma (HCC) is occasionally seen in the lung, bone, adrenal gland, and lymph nodes. It is well known that HCC sometimes invades the biliary system. Since there is no peritoneum between the gallbladder and the liver fossa, a gallbladder cancer easily invades the liver; however, HCC seldom invades the gallbladder because it rarely destroys the muscle layer or the collagen fibers of the gallbladder wall. Routes of gallbladder metastasis of HCC include direct invasion, extension to the biliary system, and invasion of the adjacent hepatic vascular system. Some cases of gallbladder metastasis of HCC without direct invasion have been reported. We report here a case of HCC that directly invaded the gallbladder, and that resembled gallbladder carcinoma invading the liver. (Korean J Hepatol 2008;15:80-84)

Citations

Citations to this article as recorded by  Crossref logo
  • Transarterial Embolization for Cystic Artery Pseudoaneurysm Caused by Hepatocellular Carcinoma Rupture in the Gallbladder: A Case Report
    Soichiro Okamoto, Yusuke Matsui, Shoichi Komoto, Takao Hiraki
    Cureus.2024;[Epub]     CrossRef
  • Gallbladder carcinoma: causes of misdiagnosis at CT
    S.W. Kim, H.C. Kim, D.M. Yang, J.K. Ryu, K.Y. Won
    Clinical Radiology.2016; 71(1): e96.     CrossRef
  • Pathologic Evaluation of Gallbladder in Patients Who Underwent Cholecystectomy Hepatic Resection for Hepatocellular Carcinoma
    Shih-Wei Lai
    The American Journal of the Medical Sciences.2011; 341(4): 305.     CrossRef
  • 6,367 View
  • 96 Download
  • Crossref

Liver Imagings

Angiosarcoma
Won Jae Lee
Korean J Hepatol 2009;15(1):101-105.
Published online March 31, 2009
DOI: https://doi.org/10.3350/kjhep.2009.15.1.101
  • 4,671 View
  • 26 Download
Focal nodular hyperplasia-Like nodule
Won Jae Lee
Korean J Hepatol 2008;14(4):537-540.
Published online December 31, 2008
DOI: https://doi.org/10.3350/kjhep.2008.14.4.537

Citations

Citations to this article as recorded by  Crossref logo
  • A Case of Multiple Hypervascular Hyperplastic Liver Nodules in a Patient with No History of Alcohol Abuse or Chronic Liver Diseases
    Byoung Joo Do, In Young Park, So Yon Rhee, Jin Kyung Song, Myoung Kuk Jang, Seong Jin Cho, Eun Sook Nam, Eun Joo Yun
    The Korean Journal of Gastroenterology.2015; 65(5): 321.     CrossRef
  • 5,569 View
  • 27 Download
  • Crossref
Imaging findings of hepatic adenoma
Joon Koo Han , Hyo Won Eun , Se Hyung Kim
Korean J Hepatol 2008;14(3):405-410.
Published online September 30, 2008
DOI: https://doi.org/10.3350/kjhep.2008.14.3.405

Citations

Citations to this article as recorded by  Crossref logo
  • Inflammatory Hepatic Adenoma
    Jae Seung Lee, Eun Kyo Jeong, Eun Kyung Kim, Chansik An, Hyun Gi Kim, Seung Up Kim, Kwang-Hyub Han
    The Korean Journal of Gastroenterology.2015; 66(1): 59.     CrossRef
  • 5,658 View
  • 24 Download
  • Crossref
Radiologic findings of dysplastic nodule
Joon Koo Han , Hyo Won Eun , Se Hyung Kim
Korean J Hepatol 2008;14(2):231-234.
Published online June 20, 2008
DOI: https://doi.org/10.3350/kjhep.2008.14.2.231

Citations

Citations to this article as recorded by  Crossref logo
  • Pathology-MRI Correlation of Hepatocarcinogenesis: Recent Update
    Jimi Huh, Kyung Won Kim, Jihun Kim, Eunsil Yu
    Journal of Pathology and Translational Medicine.2015; 49(3): 218.     CrossRef
  • 5,252 View
  • 36 Download
  • Crossref
Angiomyolipoma
Won Jae Lee
Korean J Hepatol 2008;14(1):113-115.
Published online March 20, 2008
DOI: https://doi.org/10.3350/kjhep.2008.14.1.113

Citations

Citations to this article as recorded by  Crossref logo
  • OPTIMIZATION OF EXTRACTION CONDITION FOR ALISOL B AND ALISOL B ACETATE IN ALISMATIS RHIZOMA USING RESPONSE SURFACE METHODOLOGY
    A Yeong Lee, Jun Yeon Park, Jin Mi Chun, Byeong Cheol Moon, Byoung Kab Kang, Young Bae Seo, Hyeun-Kyoo Shin, Ho Kyoung Kim
    Journal of Liquid Chromatography & Related Technologies.2013; 36(4): 513.     CrossRef
  • Hepatic Angiomyolipoma with Variable Histologic Features: 8 Cases Resembling Hepatocellular Carcinoma or Inflammatory Pseudotumor
    Ilseon Hwang, Eunsil Yu, Kyung-Ja Cho
    The Korean Journal of Gastroenterology.2012; 60(4): 242.     CrossRef
  • 4,866 View
  • 15 Download
  • Crossref
Original Articles
Spiral CT of Hepatic Masses ; Usefulness of Additional Findings Except Enhancement Patterns
Keun Young Kong , Dong Ho Lee , Young Tae Ko , Ju Won Lim , Joung Il Lee , Byung Ho Kim
Korean J Hepatol 1998;4(1):23-32.
Backgound/Aims - We compared the accuracy in the diagnosis of hepatic masses such as hepatocellular carcinoma (HCC), metastasis and hemangioma using enhancing pattern alone with using additional findings, and determined whether the additional findings could improve the diagnostic accuracy. M ethods/Materials Triphasic spiral CT images were retro- spectively analyzed in 83 cases of hepatic lesions,' 40 HCC, 21 metastases, and 22 hemangiomas. Three observers made the diagnosis first by the enhancement pattern of the mass alone, and then, by the whole information. The diagnosis of a lesion was considered correct if the lesion was correctly categorized by at least two observers. Diagnostic accuracies of two sessions were compared with McNemar test. Results - Using enhancing patterns alone, 31/40 HCC (78%), 8/21 metastases (38%), 21/22 hemangiomas (95%) were correctly diagnosed. The frequency of correct diagnosis was significantly improved when all images with additional findings were used: 36/40 (90%) HCC, 20/21 (95%) metastases, 22/22 (100%) hemangiomas (P=0.00006). Metastasis showed most prominent and statistically significant improvement in the diagnostic accuracy (P=0.0004). The number of correct diagnoses for HCC increased without statistical significance (P=0.17). However, the images with additional findings did not significantly contribute to the diagnosis of hemangiomas. The additional finidngs those led to correct diagnosis of metastases were multiple mass (7 cases), coexistence of primary malignancy (6 cases), and metastasis to other organ (1 case). The findings of liver cirrhosis were helpful to diagnose HCC correctly in 5 cases. Conclusion- The enhancing pattems of tumors were important in the diagnosis of hepatic masses in spiral CT. However, the additional finidngs were also helpful for the diagnosis of hepatic masses especially for the masses with atypical enhancement pattern. In metastases, the additional findings such as multiple masses or detection of primary malignant focus were useful to diagnose correctly. (Korean J Hepatol 1998;8:23 - 32)
  • 3,049 View
  • 14 Download
Expression of Transforming Growth Factor Alpha mRNA in Livers of Patients with Chronic Viral Hepatitis and Hepatocellular Carcinoma
Young-Hwa Chung, M.D. Jung A Kim, M.S., Byung-Cheol Song, M.D., Geun Chan Lee, M.D., Moon Soo Koh, M.D., Yung Sang Lee, M.D., Seung Gyu Lee, M.D.,* Dong Jin Suh, M.D.
Korean J Hepatol 2000;6(1):33-40.
Background/Aims
: Transforming growth factor alpha (TGFα) is an important autocrine growth factor of hepatocytes. We were to evaluate the roles of TGF α in chronic viral hepatitis (CVH) and hepatocellular carcinoma (HCC). Me thods : We measured the amounts of TGFα mRNA in liver tissues from 18 patients with HCC, 31 with CVH and 7 normal controls. ‘Hot start’ reverse transcription polymerase chain reaction (RT - PCR) us ing oligo- dT and specific primers detected TGFα mRNA in total cellular RNA extracted from liver tissues. T he levels of TGFα mRNA were determined by the end point titers of serial two- fold dilutions of cDNA. T he amounts of HBV- RNA in livers of patients with chronic hepatitis B were also measured by Northern blot hybridization. Re s ults : TGFα mRNA levels were significantly higher in HCC than CVH and normal controls ; those of CVH were also elevated compared to normal controls . They were overexpressed in the nontumorous livers surrounding HCC compared to CVH, although lower than HCC tissues. T hey were higher in chronic hepatitis B than in chronic hepatitis C. T hey were not correlated with serum alanine aminotransferase (ALT ) or HBV- RNA levels in liver tissues (in cases of chronic hepatitis B). However, the expression of TGFα mRNA tended to be higher in the livers of patients with serum AFP levels raised. Conclus ion: Overexpress ion of TGFα mRNA in liver seems to be associated with the regeneration of hepatocytes rather than hepatic necrosis or viral replication. Also, it may be closely related to the development or growth of HCC, especially in the livers of chronic hepatitis B.
  • 2,976 View
  • 13 Download
Efficacy of Chronic Oral Etoposide and Tamoxifen in the Far-Advanced Hepatocellular Carcinoma
Ho Young Kim, M.D., Chong In Lee, M.D., Kwang Yong Shim, M.D., Yong Tai Kim, M.D. Jae Gwon Kim, M.D., Min Soo Kim, M.D., Soon Ku Baik, M.D., Dong Ki Lee, M.D. Sang Ok Kwon, M.D., Young Hak Shim, M.D., and Woo Ick Jang, M.D.*
Korean J Hepatol 2000;6(1):41-51.
Aim
s :. This study evaluated the use and efficacy of chronic oral etoposide plus tamoxifen as a palliative treatment in 30 patients with far-advanced HCC in whom surgical resection, percutaneous ethanol injection or transarterial chemoembolization(TACE) was not possible. Methods : To be eligible for the study, patients had to have objectively measurable or evaluable tumors, adequate hematologic profiles and hepatorenal functions, had to be between 20 and 75 years of age, and had to have an ECOG performance status of less than or equal to 2. The treatment included etoposide, 50 mg/m2/day, taken orally for 21 days, and tamoxifen, 40 mg/day, taken orally for 21 days. Each cycle was repeated every 5 weeks. Results : Two patients(7%) achieved a partial response(PR) and 16 patients(53%) achieved a stable disease(SD) with a median time-to-progression of 5 months(range: 2-24). Median of patients survival with the response of PR or SD and those patients with the response of progressive disease(PD) was 10 months and 7 months, respectively(p=0.0004). Of the 20 patients with initial elevated serum alpha-fetoprotein(≥500 ng/ml), 9 patients(45%) experienced a significant(≥50%) decrease in their values after chemotherapy and all 9 patients achieved objective tumor response of more than or equal to SD. Among the 30 patients in the study, 10 patients(33%) achieved performance status improvements of grade according to the ECOG criteria and 6 patients(20%) experienced improvements of subjective symptoms, such as abdominal pain, abdominal fullness and anorexia. Conclusion : Based on our results, the use of chronic oral etoposide plus tamoxifen as a palliative treatment for the far-advanced hepatocellular carcinoma are beneficial. A randomized two-arm study may be warranted to validate the results of this study.(Korean J Hepatol 2000;6:41-51)
  • 2,982 View
  • 15 Download
Mutations of the Pre-S Region in HBV-Associated Liver Cirrhosis and Hepatocellular Carcinoma
Sang Ook Lee, M.D., Youn Jae Lee, M.D., Yeun Sik Jang, M.D., Sang Hyuk Lee, M.D., Sang Young Seol,, M.D., Young Hong Park*, M.D. Jung Myung Chung, M.D.
Korean J Hepatol 2000;6(1):91-101.
Background/Aims
: According to the recent research, mutations in the HBV pre-S region may have an impact on the progression of hepatitis B virus(HBV)-related liver disease. The aim of this study was to clarify the frequency and location of naturally occurring mutations in the pre-S region of HBV, and their possible effects on the clinical course of HBV-associated chronic liver diseases. Methods : HBV DNA was extracted from the sera of 15 patients (8 with liver cirrhosis and 7 with hepatocellular carcinoma). The pre-S sequence was amplified via polymerase chain reaction, subcloning and sequenced. Results : All patients had point mutations in the pre-S region. Nine of 10 mutation sites (90%) in the pre-S1 region, and 4 of 5 mutation sites (80%) in the pre-S2 region were identical in both liver cirrhosis and hepatocellular carcinoma. Deletions were detected in seven patients (4 with liver cirrhosis and 3 with hepatocellular carcinoma). Among the 4 patients with liver cirrhosis, three had deletion in 5'-end of the pre-S2 region and one spanning the 3'-end of the pre-S1 to 5'-end of the pre-S2 region. All 3 patients with hepatocellular carcinoma had deletions in 5'-end of the pre-S1 region, and two patients had simultaneous deletion spanning the 3'-end of the pre-S1 to the 5'-end of the pre-S2. Conclusion : The pre-S mutants were frequently detected in HBV-associated liver cirrhosis or hepatocellular carcinoma and the point mutations or deletions in the pre-S gene were clustered in specific regions. (Korean J Hepatol 2000;6:91-101)
  • 3,014 View
  • 14 Download
Analysis of Recurrence and Prognostic Factors after Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma
Min Su Geum, M.D.*, Dae Hyun Kim, M.D., Won Young Tak, M.D. Young Oh Kweon, M.D., Sung Kook Kim, M.D., Yong Hwan Choi, M.D. and Joon Mo Chung, M.D.
Korean J Hepatol 2000;6(1):111-123.
Background/Aims
: Hepatocellular carcinoma (HCC) is a malignant tumor with very poor prognosis if left untreated after diagnosis. However, recent advances in digital subtraction imaging techniques and superselective catheterization seem to have somewhat increased the survival rate in patients with HCC after transarterial chemoembolization (TACE). This study analyzed the relationship between prognostic factors and recurrence after TACE, an aspect which has not attracted much attention. Methods : This investigation included 258 cases of HCC with 100% lipiodol uptake who received TACE for a duration of 13 years from 1985 to 1997. Clinical characteristics, biochemical factors, tumoral factors, angiographic characteristics, embolization technique, degree of lipiodol uptake, response, and recurrence factors were analyzed retrospectively. Results : Significant differences in survival were noted among 3 groups according to cancer-free interval (p<0.01). The different factors between early recurrence group (within 6 months) and late recurrence group (after 18 months) were initial tumor size (8.8±4.1/6.1±3.7cm, p<0.01), tumor type (multinodular,massive/single nodule, p<0.01), ill-defined margin (51.4/22.0%, p<0.01), response after TACE (NC/CR,PR, p<0.01), ALP level (196.1±124.5/144.4±72.0 IU/L, p<0.05), absence of encapsulation (42.3/25.0%, p<0.05), portal vein thrombosis (64.3/14.3%, p<0.05), nonsegmental embolization (46.6/25.0%, p<0.05), post-TACE AFP level (180.5±252.1/76.6±329.8 ng/mL, p<0.05), and recurrence pattern (revascularization of initial lesion/single nodule, p<0.05). Conclusions : Recurrence factors were significant in the survival of patients with HCC after TACE. Therefore, an understanding of the relationship between prognostic factors and recurrence is very important for early detection of recurrence and the timely provision of further TACE treatment. (Korean J Hepatol 2000;6:111-123)
  • 2,906 View
  • 15 Download
Clinical Usefulness of PIVKA-II and Lens Culinaris Agglutinin-A Reactive Alpha-fetoprotein(AFP-L3) for the Diagnosis of Hepatocellular Carcinoma
B.H. Byun, Y.M. Park, S.H. Bae, J.Y. Choi, K.Y. Sung, S.H. Cho, N.I. Hahn, J.M. Yang, S.O. Choi, S.B. Cha, K.W. Chung, H.S. Sun, D.H. Park, B.S. Kim
Korean J Hepatol 2000;6(2):205-214.
Background/Aims
Des-γ-carboxy prothrombin(DCP), a protein induced by vitamin K absence or antagonist-II(PIVKA-II), and Lens culinaris agglutinin-A reactive AFP-L3 have been reported to be useful markers for the diagnosis of hepatocellular carcinoma (HCC). In the present study, both the PIVKA-II and AFP-L3 were analyzed and compared with a conventional AFP to determine its usefulness, specificity and sensitivity in the diagnosis of HCC. Methods: Sera were collected from 108 patients consisting of 17 patients with chronic hepatitis, 22 patients with liver cirrhosis and 69 patients with HCC. The AFP-L3 was determined by an lectin affinity electrophoresis coupled with an antibody-affinity blotting. Level of DCP was measured by an enzyme immunoassay with an anti-DCP monoclonal antibody. Results: The sensitivity and specificity of PIVKA-II and AFP L3 were 49.3% and 89.5%, and 32.5% and 85.7%, respectively. No significant correlation was found between the PIVKA-II or AFP L3 and serum AFP. No correlation was found between the PIVKA-II or AFP L3 and the characteristics of HCC. Conclusion: The determination of plasma DCP and AFP L3 levels combined with AFP levels may be useful especially for the differential diagnosis between HCC and chronic liver diseases without HCC.(Korean J Hepatol 2000;6:205-214)
  • 3,331 View
  • 38 Download
Long - term Outcome of Chronic Hepatitis B According to the New Histological Classification
Byung Kyu Park M.D., Young Nyun Park M.D.1, Kwang-Hyub Han M.D., Sang Hoon Ahn M.D., Kwan Sik Lee M.D., Chae Yoon Chon M.D., Young Myoung Moon M.D., and Chanil Park M.D.1
Korean J Hepatol 2000;6(3):287-300.
Background/Aims
Chronic hepatitis has been divided into chronic persistent hepatitis, chronic lobular hepatitis and chronic active hepatitis. These terms should be discontinued in favor of etiologic terminology. The activity of necro-inflammation and the degree of fibrosis should be evaluated for grading the severity and the stage of the disease. In this study, we sought to evaluate the long-term outcome and prognostic factors of chronic hepatitis B according to the new histological classification of chronic hepatitis proposed by the Korean Study Group for the Pathology of Digestive Diseases. Method: One hundred and eighty-eight patients (mean age, 35.0 years; male/female 3.9:1) with biopsy-proven chronic hepatitis B were retrospectively assessed with a mean follow-up of 80.6 months. The patients were divided into a biochemically-active group and a biochemically-inactive group according to serum alanine aminotransferase (ALT) changes during follow-up periods. The development of compensated cirrhosis and hepatocellular carcinoma were investigated during follow-up periods. As well, the liver biopsy specimens of the patients were reviewed according to the new histological classification of chronic hepatitis (grade of lobular activity and porto-periportal activity, stage of fibrosis). Results: Lobular activity and porto-periportal activity correlated with the serum ALT level at the time of biopsy (p<0.05). The development of compensated cirrhosis correlated with porto-periportal activity and stage of fibrosis (p<0.05). The probability of the development of compensated cirrhosis, decompensated cirrhosis and hepatocellular carcinoma increased significantly in the older age group (≥40 years) and the biochemically-active hepatitis group (p<0.01). The risk factors for the development of compensated cirrhosis and decompensated cirrhosis were old age (≥40 years) and biochemically-active hepatitis during follow-up periods. For hepatocellular carcinoma they were old age (≥40 years), male gender and biochemically-active hepatitis during follow up periods by multivariate analysis. Conclusions: The present study suggests that the new histological classification of chronic hepatitis indicates hepatitis activity and the prospect for progression to cirrhosis in chronic hepatitis B. The biochemical hepatitis activity during follow-up periods is the independent prognostic factor for the development of cirrhosis and hepatocellular carcinoma in chronic hepatitis B. Therefore, effective treatment to decrease hepatitis activity may reduce the develoment of cirrhosis and hepatocellular carcinoma.
  • 2,896 View
  • 20 Download
Prognostic Factors Affecting Survival Rate in Patients with Hepatocellular Carcinoma Treated by Transcatheter Chemoembolization
Sung Woo Kim,Soong hwan Lee,Byung Joo Roh,Jong Cheol Kim,Sung Soo Park,Dong Hoo Lee
Korean J Hepatol 2000;6(3):311-320.
Purpose
There have been studies concerning prognostic factors in patients with hepatocellular carcinoma (HCC) undergoing transcatheter arterial chemoembolization (TACE) but they reported different prognostic factors from each other. The aim of this study is to determine which prognostic factors contribute to long-term survival after TACE of hepatocellular carcinoma. Material and Method: Two hundred and forty-one patients with HCC who had been treated by TACE were analyzed retrospectively. TACE was accomplished by hepatic arterial infusion of a suspension of lipodol and anticancer drugs (Mitomycin-C and Adriamycin), either alone or followed by gelfoam embolization. Results: Male to female ratio was 4.7:1. Mean survival was 13.98 months. Maximum survival was 101 months. The overall cumulative survival rates at the end of the first and second years were, respectively, 41.54% and 20.06%. According to univariate analysis (log-rank scale test), variables significantly associated with survival were: sex, liver cirrhosis, Child-Pugh classification, gross type of the tumor, location of the tumor, size of the tumor, TNM stage, metastasis, portal vein thrombosis, arterioportal shunt, ascites, AFP, protein, albumin, alkaline phosphatase, AST, AST/ALT ratio, total bilirubin, and sodium. Multivariate analysis (Cox proportional hazard model) for the significant variables in a univarariate analysis revealed that the gross type of the tumor, portal vein thrombosis, and Child-Pugh classification were statistically significant independent prognostic factors. Conclusion: The prognosis of patients with HCC treated with TACE was affected favorably by the nodular type tumor, the patent main and the first-order portal vein, and the good liver function (Child-Pugh class A).
  • 3,372 View
  • 25 Download